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Abstract 
A library of eight novel gymnastatin analogues has been prepared. The compounds 
consist of an unsaturated side chain linked to a tyrosine unit using an amide bond. The 
compounds have various chain lengths and degrees of conjugation. Additional 
functionality was added to the tyrosine unit by methylation of the acid side group to 
prepare methyl ester derivatives. While gymnastatins have shown promising cytotoxic 
activity, their mode of action is not fully understood. The prepared compounds were 
evaluated against the A549 cancer cell line. A selection of the compounds were further 
evaluated for inhibition against POLO like kinase (Plk1). 
The methyl ester derivatives showed more activity than compounds containing the acid 
side group.  It was also observed that increasing the chain length resulted in increased 
activity against the cancer cells. The presence of an additional alkene did not significantly 
improve the activity. Furthermore, preliminary results of the activity of compounds using 
an ELISA assay showed that the compounds containing the methyl ester side group 
inhibited Plk1, while compounds with the acid side group showed no inhibition. 
An introduction to gymnastatins is presented in Chapter 1 of this thesis. Chapter 2 
contains a review of iron oxide nanoparticles, their synthesis and applications in targeted 
delivery. Due to time constraints, this part of the proposed study was not carried out 
synthetically. The synthesis and biological evaluation of gymnastatin analogues are 
presented in Chapter 3 and 4 respectively. The conclusions and future work are presented 
in Chapter 5. Finally, Chapter 6 details the experimental procedures employed in this 
work. 
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1 Gymnastatins as anticancer agents 
1.1 Marine-Derived fungi as a source of bioactive natural products  
Marine derived fungi are an ecological group divided into two subgroups, indigenous and 
non-indigenous species. Indigenous species can be further divided into obligate 
(exclusively grow and sporulate in the marine environment) and facultative fungi (retain 
their ability to grow and/or sporulate in the marine environment). Non-indigenous species 
stay dormant and are unable to grow and multiply in the marine environment.1 
The investigation of marine-derived fungi as sources of natural products has been a 
promising and growing field since the discovery of unusual nucleoside derivatives in the 
sponge Tethya crypta in the 1950s by Bergmann and Feeney. The nucleosides provided 
the basis for antiviral and anticancer drugs, most notably Ara-C (cytarabine), an 
anticancer agent, and Ara-A (vidarabine), the first antiviral drug (Figure 1.1). 2-3 
 
Figure 1.1: Structures of Vidarabine (1) and Cytarabine (2) 
Vidarabine 1 inhibits viral DNA polymerase and DNA synthesis of herpes, vaccinica and 
varicella zoster viruses. Cytarabine 2 is one of the most effective drugs for the treatment 
of acute myeloid leukemia.4-5 
There have been several reports on the use of natural products derived from fungi as anti-
viral, anti-microbial, anti-tumour, anti-inflammatory, anti-protozoal, 
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2 
 
immunosuppressive, anti-fouling agents, and they also display a range of other 
bioactivities. 6-8  
1.1.1 Marine Sponges (Porifera) 
Among all marine organisms investigated, sponges are the richest sources of new marine 
natural products, with over 4000 compounds to date, contributing to nearly 30% of all 
marine natural products discovered so far. Sponges are aquatic animals that dominate in 
benthic habitats. They produce secondary metabolites which protect them from microbial 
infections, biofouling and overgrowth by other organisms. This property makes them 
attractive as natural products.  
Gymnascella dankaliensis OUPS- N134 is derived from one such sponge, Halichondria 
Japonica. Several strains have been isolated from Halichondria Japonica e.g. Phoma sp. 
Q60596 which gave rise to the antibiotic YM-202204 which exhibits potential antifungal 
activity (Fig 1.2).  Other products with antibacterial, antileukemic, antimalarial and 
anticancer activity have also been reported. 7-9  
 
Figure 1.2: Chemical structure of antibiotic YM-202204 (3) 
Gymnastatins are produced by a strain of Gymnascella dankaliensis OUPS-N134 which 
was initially isolated from the sponge Halichondria japonica (Figure 1.3), collected from 
Osaka bay in Japan in April 1994. 
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Figure 1.3: Image of H. Japonica  
Several gymnastatins have shown potent cytotoxicity and growth inhibition against 
cultured human cancer cell lines.10 Gymnastatins and their derivatives studied to date are 
discussed below.  
1.2 Gymnastatins A-E 
Gymnastatins were first isolated and their stereostructures established by Numata and co-
workers in 1998.10 They reported the isolation and establishment of stereostructures of 
gymnastatins A-E (Figure 1.4) which exhibited significant cytotoxicity against tumour 
cells.  
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Figure 1.4: Structures of Gymnastatin A (4, 5), Gymnastatin B (6), Gymnastatin C (7), 
Gymnastatin D (8-9), Gymnastatin E (10-11) 
Upon evaluation, NMR data suggested that gymnastatin A existed in a 2:1 mixture of 
stereoisomers (4a and 4b) which could not be separated by column chromatography; 
however, acetylation afforded two separable acetates (5a and 5b). Gymnastatins B-C 
existed as single isomers.  Gymnastatins D-E both contain epoxy rings and are isomeric 
with each other. Like gymnastatin A they also exist in a 2:1 mixture of stereoisomers (8a 
and 8b; 10a and 10b). Acetylation of the two stereoisomers gave diacetates which could 
be separated by column chromatography (9a and 9b; 11a and 11b). 
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Cytotoxicity activities of compounds A-C were examined in the P388 lymphocytic 
leukemia test system according to a method reported by Numata et al.11 This study 
showed that all three compounds exhibited significant potency against the cancer cell line. 
Gymnastatin A was the most potent with an ED50 of 0.018 µg.cm
-3 compared to 
gymnastatins B and C (0.108 and 0.106 µg.cm-3). The strong cytotoxicity in gymnastatin 
A was attributed to the conjugated ketone. 10,11  
Ogamino et al reported the synthesis of Gymnastatin A with oxidative cyclisation, amide 
coupling and Evans asymmetric alkylation as key steps.12 (Scheme 1.1). 
 
Scheme 1.1: Retrosynthetic analysis of Gymnastatin A (4) reported by Ogamino et al. 
1.3 Gymnastatin F, G, H and gymnamide 
Amagata reported the isolation and structure elucidation of gymnastatins F-H and 
gymnamide. (Fig 1.5).13 All compounds featured the same side chain as the gymnastatins 
previously reported. However, gymnastatins F, G and H possessed different ring systems. 
Gymnastatin F and G feature a unique bicyclo[3.3.1]nonane ring system whereas 
gymnastatin H has a tyrosine methyl ester moiety.  
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Figure 1.5: Structures of Gymnastatin F (12), Gymnastatin G (13), Gymnastatin H (14) 
and Gymnamide (15) 
The structure elucidation as well as the relative stereochemistry were determined by 1D 
and 2D NMR. Gymnastatin G 13 was acetylated due to instability during NMR 
measurements. It has the molecular formula C24H35NO4 established by HREIMS (High-
Resolution Electron Ionisation Mass Spectrometry). The total synthesis of gymnastatin H 
allowed for its stereoconfiguration to be determined. (Scheme 1.2) 
 
Scheme 1.2: Synthesis of Gymnastatin H (14) from Gymnamide (15) - (i) KOH, (ii) L-
tyrosine methyl ester, WSC.  
Gymnamide (15) which was also isolated from Halichondria sponge derived from 
Gymnascella dankaliensis was hydrolysed to give an acid which was subsequently treated 
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with L-tyrosine methyl ester in the presence of water soluble carbodiimide to furnish the 
desired molecule 14.11  
Gymnastatins F-H and gymnamide were evaluated for cancer cell growth inhibition 
against the P388 lymphocytic leukemia cell line. Upon evaluation, gymnastatins F and G 
showed significant growth inhibition (ED50 0.13, 0.03 µg.cm
-3, respectively). 
Gymnastatin H and gymnamide were inactive.13,14 
Raffier et al used diastereoselective photodeconjugation of an α, β-unsaturated ester to 
synthesise gymnastatin H starting with aldehydes. (Scheme 1.3)15 The synthesis was 
achieved in 14 synthetic steps. 
 
Scheme 1.3: Gymnastatin H synthesis reported by Raffier et al. 
1.4 Gymnastatins Q and R 
Gymnastatins Q and R were isolated in 2008 and their structures elucidated (Fig 1.6).11 
 
Figure 1.6: Structures of Gymnastatin Q (16) and Gymnastatin R (17) 
The cancer cell growth inhibition properties of gymnastatin Q and R were examined 
against P388 lymphocytic leukemia cell line (ED50 1.7, 2.8 µg.cm
-3, respectively). 
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Furthermore, gymnastatin Q showed growth inhibition against BSY-1 (breast) and 
MKN7 (stomach) cell lines (IC50 = 0.7, 0.71 µg.cm
-3, respectively) 14  
1.5 Gymnastatins I-K, S-Y and 11’-carboxygymnastatin N 
More recently, gymnastatins I-K and T-Y (Figure 1.7) were isolated from a soil fungus 
collected near the Giza pyramids in Egypt and assessed for biological activity. 16-18 
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Figure 1.7: Structures of Gymnastatins I-K (18-20), 11’-carboxygymnastatin N (21), 
Gymnastatin S-Y (22-27) 
Gymnastatins I-K, T-Y are brominated tyrosine derived alkaloids. Gymnastatins T, V, Y, 
I, J and K can be considered derivatives of gymnastatins G, D, A, B and C whose chlorines 
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have been replaced by bromine. Halichondria is known to produce mainly chlorinated 
alkaloids. Halogenating enzymes including halogenases and haloperoxidases have been 
discovered and are used to halogenate natural products. Hammerschmidt and Wang et al. 
fermented fungal cultures isolated from Halichondria in the presence of NaCl or KBr to 
produce chlorinated or brominated metabolites respectively. The fungal controls were not 
chlorinated or brominated as indicated by LCMS. 17 
Gymnastatins I-K, T-Y (18-27b) were evaluated for their cytotoxicity against murine 
lymphoma L5178Y cell line.18 They showed moderate to significant activity against the 
cancer cell line (IC50 0.078 to 14.1 μM). Gymnastatin K was the most potent (0.078 μM). 
A comparison between 25 vs 27 and 19 vs 20 suggested the conjugated ketone system to 
be important for the cytotoxic activity (Table 1.1). Gymnastatins I (18) and J (19) were 
compared to their chlorinated analogues, gymnastatins A (1) and B (2). Gymnastatin I 
showed similar activity to gymnastatin A, whereas gymnastatin I exhibited much stronger 
activity than gymnastatin B17,18 
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Entry Compound IC50 (μM) 
18 Gymnastatin I 0.55 
19 Gymnastatin J 0.078 
20 Gymnastatin K 9.6 
23a Gymnastatin T 1.3 
23b Gymnastatin U 3.0 
24 Gymnastatin V 3.6 
25 Gymnastatin W 0.99 
26 Gymnastatin X 14.1 
27a Gymnastatin Y 6.2 
27b Gymnastatin Y 3.0 
4 Gymnastatin A 0.64 
6 Gymnastatin B 5.8 
Table 1.1: Cytotoxicity of gymnastatins against L5178Y mouse lymphoma cells 
1.6 Gymnastatin N 
It has been suggested that gymnastatin N 28 (Figure 1.8) is an important intermediate in 
the biosynthetic pathway of tyrosine derived amides isolated from Gymnascella derived 
alkaloids.  
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Figure 1.8: Structure of Gymnastatin N (28) 
Gymnastatin N has an intact tyrosine unit. Cytotoxic evaluation of gymnastatins has 
shown no cytotoxic activity of compounds with an intact tyrosine unit. However, an 
examination of the biological properties of gymnastatin N 28 and a range of analogues 
showed that gymnastatin N and its analogues inhibited the protein kinase POLO-like 
kinase (Plk 1).17-19  It was proposed that the conjugated diene and free acid on the tyrosine 
unit functionalities were responsible for bioactivity against Plk1.19 
1.6.1 Plk1 and protein kinases 
Protein kinases are enzymes that phosphorylate specific amino acids in protein substrates. 
They are involved in a wide variety of growth hormones and growth factors which trigger 
cell growth and cell division. In most cancers, there is an overexpression or excess of a 
growth hormone. In other cases, there is an excess of a protein kinase receptor. Due to 
their role in processes that drive cell growth and division, there has been keen interest in 
developing and using protein kinase inhibitors as anti-cancer agents.20 
Plk1 is a protein kinase belonging to a family of serine-threonine kinases. Plk1 plays a 
key role in regulating the cell cycle and ensuring proper cell cycle progression. Other 
proteins called cyclins, and enzymes, including cycline-dependent kinases (Cdk), also 
play various roles in different stages of the cell cycle. Cdk 1 functions as a serine-
threonine kinase and is sequentially activated and deactivated during the cell cycle as 
required. Excessive and insufficient production of these enzymes has been associated 
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with imbalances and errors in the cell cycle which lead to tumourigenesis, birth defects 
and spontaneous abortions.21-23 
1.6.2 The Cell Cycle 
The cell cycle is divided into four phases, the G1, S, G2 and the M phase. During the S 
phase, the cell replicates its nuclear DNA. The M-phase is the most important part of the 
entire cell cycle and it consists of six stages followed by cytokinesis (Figure 1.9). It is 
accompanied by major reorganization of the entire cell. Events in the M-phase vary in 
different organisms; however, the fundamental and basic events are conserved in 
eukaryotic cells. These events include chromosome condensation, formation of the 
mitotic spindle, attachment of the chromosomes to the spindle microtubules and finally 
the formation of daughter nuclei. During the gap phases (G1 and G2) the cell monitors its 
environment to ensure the conditions are suitable before moving on to the S or M phases. 
The gap phases also give the cell time to grow. Plk1 as well as cycline-dependent kinases 
(Cdks) are prominent in the M-phase.22, 24,25 
 
Figure 1.9: Schematic view of the cell cycle in eukaryotic cells.26 
1.6.3 Plk1 and cancer 
Excessive, insufficient and/or deregulation of Plk1 has been associated with imbalances 
and errors in the cell cycle which lead to tumourigenesis, birth defects and spontaneous 
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abortions. Several studies have linked overexpression of Plk1 with numerous types of 
cancer and their aggressiveness, e.g. lung, oesophageal, gastric, melanoma, and breast 
cancers. If Plk1 can enhance tumour formation, then selective inhibition of Plk1 can be 
used to achieve tumour regression.  Hence Plk1 has been proposed as a prognostic marker 
for malignancies and as a potential target for cancer therapy.27-30 
Efforts are ongoing to identify molecular inhibitors of Plk1. These inhibitors would 
deplete Plk1 activity at various stages of the cell cycle where Plk1 is prominent, thereby 
suppressing tumour growth.  In several studies, inhibitors have induced apoptosis and 
caused mitotic spindle abnormalities thereby inhibiting tumour cell proliferation. One 
such molecule is ON01910 (Figure 1.10) which was found to be a potent inhibitor and 
exhibits very little or no toxicity21, 27, 31  
 
Figure 1.10: Structure of ON01910 
ON01910, trade name Estybon inhibits Plk1 and is currently on Phase III clinical trials 
for the treatment of chronic myelomonocytic leukaemia.32 
1.7 Conclusion 
This chapter introduces gymnastatins beginning with their first discovery and details the 
gymnastatins that have been reported to date. The cytotoxicity of these compounds 
against various cell lines are also discussed. Moreover, an overview of protein kinases 
and Plk1, the role they play in the cell cycle, and their relevance to cancer is presented. 
Although gymnastatins have shown promising cytotoxic activity, their mode of action of 
gymnastatins is not fully understood. Literature reports to date focus primarily on the 
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natural product chemistry and there is little detail on the mechanism of action of these 
and other related compounds. 
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2.  Magnetically tagged drugs for cancer treatment 
2.1. Introduction  
Cancer is a leading cause of death worldwide. There were an estimated 14.1 million 
cancer cases around the world in 2012, of these 7.4 million cases were in men and 6.7 
million in women. Europe carries a significant load of the global burden, with one quarter 
of the global burden of cancer observed in Europe despite a total population that 
comprises one-ninth of the world’s population. Cancer is the second most common cause 
of death in Ireland. According to the Irish cancer society, one in three people in Ireland 
will develop cancer during their lifetime. An average of 30,000 new cases of cancer are 
diagnosed each year. The number is expected to rise to over 40,000 per year by 2020. 
Table 2.1 shows cancer incidences and deaths in Europe.1,2 
Region Incidences in 2012 Deaths in 2012 
Central and Eastern Europe 1,036,900 638,200 
Northern Europe 525,900 245,100 
Southern Europe 769,200 390,500 
Western Europe 1,110,300 482,600 
Ireland 20,515 8,544 
Table 2.1: Cancer incidences in 2012 
Chemotherapy, radiation therapy and surgery are the most common methods of treatment 
with the first accounting for 50% of all procedures.  Chemotherapeutics suffer from 
several barriers that limit their delivery to specific targets. Only 0.1-1% of administered 
therapeutic agents reach the tumour and the rest enter healthy tissue resulting in 
undesirable side effects. Toxic effects are thus significant, and desired therapeutic effects 
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are suboptimal. Targeted drug delivery aims to increase the bioavailability of a drug at a 
specific part of the body for a defined duration of time. Current efforts are focused on 
developing drug delivery systems that are target specific, i.e., have the ability to target 
the tumour cells, thereby leaving healthy cells unharmed. The advantages of this approach 
are the reduction in quantity and frequency of dosage, reduced costs and fewer side 
effects. 3, 4,5,6,7 
Over the last two decades, nanotechnology has evolved into a multidisciplinary topic. It 
has revolutionized fields such as catalysis, robotics, design, imaging, data storage and 
medicine. Advances in nanotechnology are enabling the development of nanoparticles 
with specific functional properties to address current limitations in a range of chemical 
and biological applications. 8 
A number of nanomedicines have been approved for clinical use in cancer therapy. These 
include liposomal doxorubicin used to treat breast cancer;9 polymer based PEG-L-
Asparaginase (Oncaspar®) for leukemia; 10 micellar paclitaxel for breast, lung and 
ovarian cancer; albumin based nanoparticle containing paclitaxel for breast cancer.11 
There are several other drugs still undergoing clinical trials.  (Table 2.2) 
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Nanocarrier Nanodrug Indication Phase in clinical 
trials 
Micelles Paclitaxel (Genexol-PM) Breast cancer IV 
il Ovarian  Approved 
Paclitaxel Non-Small Cell Lung 
Cancer 
III 
Docetaxel-PM Head and Neck 
Squamous Cell 
Carcinoma 
II 
Polymer-
drug 
conjugate 
Pegylated Irinotecan Small Cell Lung 
Carcinoma 
II 
NC-6004 Head and Neck Cancer I 
Docetaxel-PNP Advanced Solid 
Malignancies 
I 
Liposome Myocet (Non-pegylated 
liposomal doxorubicin) 
Metastatic breast 
cancer 
Approved 
LipoDox (liposomal 
doxorubicin) 
Kaposi's sarcoma, 
breast and ovarian 
cancer 
Approved 
Doxil (liposomal 
doxorubicin) 
AIDS-related Kaposi's 
sarcoma, recurrent 
ovarian cancer, 
metastatic breast cancer 
and multiple myeloma 
Approved 
Table 2.2: Examples of tumour-targeted nano-carriers in cancer therapy. Extracted 
from https://clinicaltrials.gov/ct2/home 2016 
In the first part of this review, the use of targeted drug delivery for cancer treatment will 
be discussed. In the second part the unique properties of superparamagnetic iron oxide 
nanoparticles (SPIONPs), their synthesis and subsequent protective coatings will be 
discussed. Finally, advances in magnetically tagged drugs for cancer treatment, 
limitations, tagging of SPIONPS to chemotherapeutics and their release in vivo will be 
presented. 
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2.1.1. Targeted Drug Delivery 
Chemotherapy is the most common form of cancer treatment and has considerable impact 
on the patient. To overcome the drawbacks with chemotherapy, it is important to improve 
the pharmacokinetics and target site accumulation of drugs through sufficient 
bioavailability. Even intravenous drug delivery does not guarantee that the drug is freely 
available at the target site due to competing particles such as red blood cells, leukocytes 
and proteins such as albumin.  Over the last number of years, several drug delivery 
systems have been designed to overcome this low efficiency. Liposomes, antibodies, 
micelles, polymers and nanoparticles have demonstrated clinical relevance for cancer 
therapy. The advantage of using these drug delivery systems includes improved selective 
delivery of chemotherapeutics to target sites and their guidance away from healthy tissue. 
14, 15, 16 
Cancerous cells have different biological characteristics from healthy cells and targeted 
therapies take advantage of these differences. Cancerous cells replicate faster than tumour 
cells and therapies like doxorubicin capitalise on this by intercalating DNA and disrupting 
its replication. This is termed circumstantial targeting, but has limited efficacy due to sub 
optimal drug concentrations that must be used to avoid cytotoxic effects on healthy cells. 
Therefore, there is urgent need to develop more efficient systems for targeted delivery of 
cancer treatments.  14, 17 
2.1.2. Magnetic Drug Targeting  
In 1960, Freeman et al established the concept of magnetic drug targeting (MDT) using 
iron oxide nanoparticles (IONPs). Subsequently there has been significant interest in 
using IONPs and other magnetic nanoparticles for targeted delivery in cancer treatment. 
(Figure 2.1) Biocompatible magnetic nanoparticles (MNPs), conjugated with drugs have 
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been injected into the bloodstream and accumulated at a tumour site with the help of an 
external magnetic field. 14, 16, 18 
 
Figure 2.1: Principle of magnetic drug targeting 8 
IONPs typically have two structural configurations, namely magnetite and maghemite.  
Magnetite is the most commonly used IONP because of its biocompatibility. It possesses 
a cubic inverse spinel with oxygen forming a face centred cubic (fcc) close packing and 
Fe occupying the octahedral sites. (Figure 2.2) 6, 7 
 
Figure 2.2: Structure of inverse spinel magnetite (Fe3O4)  
For magnetisable nanoparticles to be introduced into a biological system, they should 
only display magnetic behaviour under the influence of an external magnetic field and 
lose the behaviour when the field is withdrawn. This can be achieved by restricting their 
size to  be a specific range. Superparamagnetism arises when such nanoparticles have a 
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diameter in the region of 10-20 nm, and are at a temperature above the so-called “blocking 
temperature”. To be used in vivo, the blocking temperature has to be below room 
temperature to guarantee disappearance of residual magnetism when the magnetic field 
is removed. In this review, such nanoparticles will be referred to as superparamagnetic 
nanoparticles (SPIONPs). 15, 16, 19 
Much research has focused on numerous innovative targeting strategies to increase 
selectivity of chemotherapeutics and minimize their accumulation in healthy tissues. 
Nanomedicines can be passively or actively targeted to the tumour tissue. Passive and 
active targeting have been used together with MDT to improve efficacy of 
chemotherapeutics. 
2.1.3. Passive targeting 
Passive targeting relies on the preferential delivery of nanomedicines to solid tumours 
due to the enhanced permeability and retention (EPR) effect.20 Tumour tissues lack an 
effective lymphatic drainage and are leaky due to abnormality in form and architecture. 
Nanoparticles, due to their size, easily diffuse passively through the leaky vasculature to 
reach the tumour. This enables high local drug concentration at the tumour site instead of 
normal tissue. In order to achieve sufficient targeting at the tumour site, the circulation 
time of the therapeutic agent must be sufficiently long.21 The size and surface chemistry 
of nanoparticles influence circulation time and therefore can be manipulated to avoid 
premature clearance. Surface modification of nanoparticles has been used to prolong the 
circulation time. Nanoparticles with a size range of 10-100 nm are big enough to avoid 
renal filtration but are small enough to slow down activation of the reticuloendothelial 
system (RES). RES is part of the immune system that is responsible for clearance of 
foreign material from the body.22 Upon administration, nanoparticles are quickly 
recognised as foreign particles and are opsonized by blood opsonins (protein markers). 
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The opsonized nanoparticles interact with receptors on macrophages in the spleen and are 
rapidly eliminated via RES. Larger IONPs are more visible to RES and are cleared faster.  
RES is the main barrier in nanoparticle systemic circulation. In order to evade RES and 
opsonisation IONPs have to be modified and thereby increasing their circulation time.23 
Passive targeting also uses charges on nanoparticles to induce targeting towards the 
tumour. Myocet, Doxil and Abraxane are amongst passively targeted nanomedicines. 14 
2.1.4. Active Targeting 
In active targeting, the delivery systems are designed to interact with specific 
biomolecules usually by the attachment of a ligand/linker on the outer surface of a 
nanocarrier.  Active targeting relies on disease-selective molecular markers. The 
molecular recognition of a ligand coupled to a nanodrug surface promotes cellular entry 
via receptor-mediated endocytosis thereby enhancing cellular uptake of the 
nanomedicine. 24 In active targeting long circulation time is important to allow effective 
transport of nanoparticles to the tumour site; moreover, the targeting molecule enhances 
endocytosis. 11 
Active targeting can also be used to target cell proliferation receptors that are expressed 
in certain tumour cells. Most of the research regarding actively targeting nanoparticle 
systems have been directly associated with a type of cancer.11 
2.1.5. Tumour cell targeting 
Tumour cell targeting is specific to a type of cancer. The most established cell 
proliferation targets used by actively targeting nanoparticles include human endothelial 
transferrin, HER-2 and folate receptors. (See section 2.2.) 
Prostate, breast, lung and bowel are the most common non-melanoma cancers in Ireland. 
These four account for 53% of new cancer cases per year (2008-2010). 25 Current 
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treatment methods include surgery, radiation therapy, chemotherapy and hormone 
therapy. Table 2.3 shows the most common types of cancer in Ireland, their prevalence 
and receptors that are usually targeted in treatment methods.  
Cancer % of all cancer 
deaths Ireland 
(2008-2010) 
Receptor 
targets 
Clinically 
approved drugs 
targeting receptor 
References 
Prostate 12.2 PSMA Prostascint 26, 27 
sigma -- 28, 29 
folate -- 30, 31 
Breast 7.9 HER-2 Trastuzumab 
lapatinib 
32, 33 
LHRH -- 34 
sigma -- 35 
Bowel/Colorectal 11 EGFR Panitumab,   
Cetuximab 
36 
VEGF Avastin,  
ramucirumab 
37 
guanylyl 
cyclase C 
-- 38, 39 
Lung 20.4 aptamers -- 40 
VEGF -- 41 
Table 2.3: Most common cancers in Ireland 2, 12 
The overexpression of certain receptors in cancer cells has provided important tools for 
exploitation in the active targeting of drugs to cancer cells. SPIONs can achieve specific 
targeting of tumours with high accuracy when conjugated with targeting ligands. Ligands 
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can be designed to be specific to receptors that are over- expressed on cancerous cells, 
but are normally expressed on healthy cells. In the next section, the most common 
receptor molecules and their mode of operation are evaluated.2 
2.2. Tagging 
2.2.1. Folate 
Folate receptors stand out as one of the most promising and most investigated cell 
markers. Folate based targeting systems have shown great potential for therapeutic 
applications. 38 The folate receptor, also known as the high affinity membrane folate 
binding protein, is often overexpressed in many human carcinomas including 
malignancies of the ovary, brain, kidney, breast, colon, myeloid cells and lung. In normal 
tissue however, folate is either absent or inaccessible to circulating drugs. 42 Two general 
strategies are used for targeted delivery of drugs to folate receptor positive cells (a) 
coupling to a monoclonal antibody against folate receptor (b) coupling to a high affinity 
ligand of folate receptor- folic acid.  
 
Scheme 2.1: Structures of folate and folic acid 
Folic acid (FA), the conjugate acid of folate (Scheme 2.1), is required for essential cell 
function. It has a high binding affinity to the folate receptor that is overexpressed in 
tumours and therefore provides a distinguishable marker from normal cells. Moreover, 
FA is cheap, non-immunogenic, highly stable and gets internalized quickly through cell 
membranes. FA is usually conjugated to nanoparticles via the carboxylic acid or the 
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amine moiety. Socaci et al. developed folic acid di-ester functionalized MNPs and used 
1° and 2° amine sites as the anchoring reaction sites instead of the carboxylic acid. 43 
Pourjavadi et al developed PEGylated dendritic nano-carriers functionalized with folic 
acid as tumour targeting agents. FA conjugated agents showed enhanced cytotoxicity 
against carcinoma cell line A431 and improved cellular uptake of cancerous cells 
compared to free nano-carriers.44 Huang et al reported modified IONPs with poly 
(glycidyl methacrylate) (PGMA) followed by conjugation with different amounts of FA 
to form SPIONs–PGMA–FA. These folate modified nano-carriers achieved a 
significantly higher uptake by cancer cells than those by macrophages and 3T3 
fibroblasts. 45 
Cis-platin is one of the most effective therapeutic agents for the treatment of head and 
neck cancer. However, it has many disadvantages including rapid clearance, binding to 
plasma proteins and toxicity.46 Chen et al recently developed a pH sensitive therapeutic 
agent release system using folic acid modified cis-platin loaded MNPs to overcome 
problems associated with cis-platin and to improve its efficacy. The resulting moiety 
exhibited superparamagnetic properties andhigh stability and released cis-platin in a low 
pH environment which is ideal for targeted delivery to acidic tumour environment. 46 
Ma et al developed a magnetic polymer nano-carrier with folate receptor-targeting and 
pH sensitive functionalities loaded with doxorubicin (DOX) (F-PDOX) for the treatment 
of advanced gastric cancer. F-PDOX displayed FR-targeting specificity and pH 
sensitivity that were hoped to improve uptake. Encouragingly the cytotoxicity studies in 
vitro and in vivo showed tumour suppression and tumour accumulation, demonstrating 
that F−PDOX were indeed effective on gastric cancer treatment, importantly without 
significant side effects. 47 
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Li et al developed nanosized folate-conjugated PEGylated PLGA nanoparticles co-
encapsulated with anticancer drug (sorafenib). The folic acid-conjugated NP exhibited 
sustained drug release and enhanced cellular uptake in BEL7402, liver cancer cells. 48 
Maeng et al synthesized multifunctional polymeric IONPs, carrying the anticancer drug 
doxorubicin (DOX), for treatment of liver cancer. The formation of nanoparticles was 
mediated by poly (ethylene oxide)-trimellitic anhydride chloride-folate (PEOTMA-FA) 
(Figure 2.3) containing folate as the targeting moiety. 49 
 
Figure 2.3: Structure of PEO-TMA-FA polymer  
The presence of the folate significantly facilitated the specific delivery of DOX to folate 
receptor-positive liver tumour cells and inhibited tumour growth without causing any 
toxic effects such as body weight loss or cardiac toxicity that are usually associated with 
the use of DOX. 49 
2.2.2. Integrins  
Linkage of the cell to the extracellular matrix requires adhesion proteins that act as matrix 
receptors. Integrins are the principal receptors used by animal cells to bind to 
the extracellular matrix. Integrins, unlike other cell surface receptors, bind their ligand 
with lower affinity to stop them being irreversibly glued to the cellular matrix.50 In 
addition to this, integrins function as signal transducers, activating various intracellular 
signalling pathways when activated by cellular binding. Integrin receptors are highly 
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expressed in tumour cells but not in normal cells. They are heterodimers and there are at 
least 24 distinct integrin heterodimers formed by the combination of 18 α subunits and 8 
β subunits. Studies have shown that integrins can influence tumour survival both 
positively or negatively by either enhancing cell survival or initiating apoptosis. 
Expression of integrins αvβ3, αvβ5, α5β1, α6β4, α4β1and αvβ6 has been associated with 
tumour progression in various tumour types and therefore these integrins are the most 
widely studied. 50, 51 Table 2.4 shows the most studied integrins and tumours associated 
with them. The advances in integrin facilitated drug delivery in cancer treatment are 
reviewed elsewhere. 52 
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Tumour type  Integrins expressed Associated phenotypes 
Melanoma  αvb3 and α5b1 Vertical growth phase and lymph node metastasis 
Breast α6b4 and αvb3 Increased tumour size and grade, and decreased 
survival (α6b4). Increased bone metastasis (αvb3) 
Prostate αvb3 Increased bone metastasis 
Pancreatic αvb3 Lymph node metastasis 
Ovarian α4b1 and αvb3 Increased peritoneal metastasis (α4b1) and tumour 
proliferation (αvb3) 
Cervical αvb3 and αvb6  Decreased patient survival 
Glioblastoma αvb3 and αvb5  Both are expressed at the tumour–normal tissue margin 
and have a possible role in invasion 
Non-small-cell 
lung 
carcinoma 
α5b1  Decreased survival in patients with lymph node-
negative tumours 
Colon αvb6  Reduced patient survival 
Table 2.4:  Integrins in cancer progression, adapted from Desgrosellier 53 
IONPs have been used in combination with integrin targeting receptors for enhanced drug 
delivery. Nazli et al developed DOX loaded nano-carriers designed for integrin receptor 
specific uptake. 54 
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2.2.3. Prostate specific antigen (PSA) 
There are several treatment methods for prostate cancer, however chemotherapy is the 
primary clinical treatment to prolong overall patient survival. Prostate specific antigen 
(PSA) is overexpressed in prostate cancer cells and is the most studied target for cancer 
treatment. PSA specific ligands are good candidates for prostate cancer targeting.  
Yang et al developed a dual targeting nanomedicine, PTX-HMNC-EPEG-APSMA and 
combined it with magnetic targeting to increase local accumulation of paclitaxel. 
Paclitaxel (PTX) was conjugated to non-toxic high magnetization nano-carriers. The 
surface was functionalized with long, carboxylated EPEG linkers to prolong the 
circulation time. Antiprostate PSA (APSA) were then conjugated to the carrier to 
recognize PSA and bind to cancer cells using active targeting. The treatment was 
significantly more effective in low doses against cancer cells, compared to free paclitaxel. 
Moreover, functionalizing the surface increased the circulation time from 6 minutes to 
120 minutes before being cleared by the RES. 42 
Docetaxel is one of the commonly used therapeutic options for prostate cancer. Nagesh 
et al developed PSA targeted IONPs loaded with Docataxel to improve its efficacy. The 
resulting moiety showed potent anti-cancer effect in prostate cancer cells and 
immunofluorescence data confirmed that only PSA positive cancer cells were targeted. 55 
2.3. IONPs Synthesis  
To be used in vivo, nanoparticles must be biocompatible and studies have shown that this 
behaviour is highly dependent on their morphology and physical properties. The size and 
shape of IONPs affects their magnetic and biological properties, toxicity, stability, bio-
distribution and elimination. The choice of synthetic route is important as it influences 
the size and morphological properties of IONPs. 56-57 
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Several studies have linked high surface area on IONPs to toxicity in vivo. Changes in the 
shape and size of nanoparticles are accompanied by alterations on the surface that 
influences cytotoxicity. A study by Han-Lee et al revealed that rod shaped IONPs had a 
high surface area compared to spherical IONPs. The high surface area in the rod shaped 
IONPs resulted in increased cytotoxicity towards mouse macrophage cells. 58 
The size of IONPs also influences the circulation time of IONPs in vivo. Lin Yang et al 
studied the effect of size on the bio-distribution, toxicokinetics and toxicity of various 
size carboxyl coated IONPs ranging from 10-40 nm (Figure 2.4. The smallest IONPs 
showed highest uptake by the liver and were cleared fast from the liver and kidneys. 59 
 
Figure 2.4: TEM and DLS images of carboxyl coated IONPs (a) 10 nm, (b) 20 nm (c) 
30 nm (d) 40 nm 59 
The particles also entered the uterus more readily and penetrated the blood brain barrier. 
On the other hand, larger IONPs (over 40 nm) were mostly taken up and eliminated by 
the spleen. In a study by Gil et al, the large IONPs changed expression levels of genes 
associated with oxidative stress and metabolic processes in mice. 18, 59 
Roohi et al carried out a study on the effect of size of IONPs on blood half-life and 
systemic clearance. This study demonstrated a decrease in the blood half-life from 50 to 
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3 minutes when the hydrodynamic size of nanoparticles was increased from 19 to 86 nm. 
60 
Ideally, IONPs should be in the range of 10-100 nm. At this range, they are small enough 
to delay the mononuclear phagocyte system but big enough to avoid renal filtration. Due 
to the importance of size and shape on IONPs, it is vital to use the appropriate synthetic 
method to obtain the desirable nanoparticles for use in vivo. Over the last number of years, 
different synthetic routes have been developed including co-precipitation, thermal 
decomposition, hydrothermal synthesis, wet grinding, micro emulsion and laser 
pyrolysis, amongst others. These routes allow the size range, shape and stability of the 
nanoparticles to be manipulated and tailored to enable interaction with specific 
biomolecules. 61, 62, 63 
2.3.1 Co-Precipitation 
Co-precipitation is the most common, simplest and convenient way to synthesise IONPs. 
It involves the use of readily available starting materials under mild reaction conditions, 
resulting in naked magnetite in high concentrations. Massart et al first reported the 
synthesis of IONPs using the co-precipitation method in 1981.64 In this synthesis, the 
particles were roughly spherical and had a diameter of 8 nm. Since then, a number of 
modified synthetic methods have been reported where parameters are varied to achieve 
certain properties suited for their application.  
Addition of a base to an aqueous solution of Fe2+/Fe3+ ions in a ratio of 1:2 produces a 
black precipitate of magnetite in uniform sizes under alkaline conditions and an oxygen 
free environment. The chemical reaction of dissolved iron salts to magnetite can be 
summarized according to the equation below.64 
Fe2+ +  2Fe3+ 8OH−  →  Fe3O4 ↓ + 4H2O 
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In co-precipitation, the chemical, physical, structural and magnetic properties of 
nanoparticles can be manipulated by varying certain reaction conditions. The size and 
shape of nanoparticles is dependent on the type of salt used, pH value and ionic strength 
of the aqueous media, reaction temperature and ratio of Fe3+ /Fe2+ ions. 65 
Berensmeier et al recently studied the effects of process parameters on particle size and 
saturation magnetization. Nanoparticles with diameters of 3 – 17 nm and saturation 
magnetization of 29 – 89 Am2/kg were obtained by varying the following (1) iron salt 
concentration (2) reaction temperature (3) ratio of hydroxide ions to iron ions (4) ratio of 
Fe3+ /Fe2+ ions.  High saturation magnetization was reported at high synthesis 
temperatures, high iron salt concentrations and lowest ratios of Fe3+ /Fe2+. Furthermore, 
the particle size of magnetite was increased by using a higher iron salt concentration and 
a higher ratio of hydroxide ions to iron ions. The particles also showed superparamagnetic 
behaviour. 66 
Despite being the most widely used method for the synthesis of IONPs, co-precipitation 
has several disadvantages. Naked NPs synthesised by this method need to be coated in 
situ or in a subsequent step to prevent oxidation and agglomeration at ambient 
temperature. The use of alkaline solution for the synthesis represents environmental 
issues, and as a subsequent treatment step is required before disposal of waste. 65 
2.3.2 Hydrothermal 
Hydrothermal synthesis of nanoparticles involves the synthesis in water, of crystals at 
high temperature and high pressure using materials that would otherwise be insoluble at 
normal conditions. In this technique, nanoparticles are synthesised by other methods and 
then treated under hydrothermal conditions where the pressure can be higher than 2000 
psi and the temperature can be above 200 °C. Techniques like microemulsion, co-
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precipitation and microwave have been utilised in combination with hydrothermal 
methods to form SPIONPs.66, 67, 68, 69 Kockar et al and Wang et al reported that increasing 
hydrothermal treatment temperatures, up to 200 °C, resulted in high crystallinity and 
increased saturation magnetization. 67, 70 It has also been reported that increasing reaction 
time results in an increase in nanoparticle size. More recently, Fester et al reported a 
detailed study on the influence of process parameters on nanoparticle characteristics using 
a continuous hydrothermal system (CHS) synthesis. This study revealed that an increase 
in temperature and flow rate of CHS resulted in a major increase in nanoparticle 
crystallinity. 71Varying other process parameters like concentration, pressure, residence 
time etc. had minimal effect on nanoparticle crystallinity. 71, 72 
2.3.3. Thermal Decomposition 
Thermal decomposition involves the decomposition of an organometallic precursor in a 
high boiling organic solvent in the presence of a surfactant. It is a recognised method for 
the synthesis of monodisperse SPIONPS with a narrow size distribution. The synthesis of 
monodisperse SPIONPs through the thermal decomposition method involves two stages. 
Firstly, tiny crystal nuclei are formed at around 200°C, and this is called nucleation. The 
second stage involves the growth of the nuclei at the boiling point of the organic solvent 
used.  It is at this stage that the size, shape and magnetic properties of the nanoparticles 
can be manipulated by varying the reaction time and temperature. The use of high 
temperatures makes this process expensive and limited to small batch reactions because 
of difficulties in maintaining a uniform temperature in large scale reactions.73 Continuous 
flow and microwave assisted thermal decomposition methods have been proposed to 
overcome this limitation. 74, 75, 76 The prepared nanoparticles are water insoluble due to 
their hydrophobic surfaces and thus cannot be used in a biological system. This can be 
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overcome by employing a ligand exchange strategy to substitute the hydrophobic layer 
with a hydrophilic one.  
Other considerations for this method include long reaction times, use of organic solvents, 
and the safety issues associated with use of high temperatures. 66, 77, 78, 79 
2.3.4 Other methods 
Other methods for the synthesis of IONPs include laser pyrolysis, sol gel synthesis and 
microemulsion. 80-87 
2.4. Surface modification of Iron Oxide Nanoparticles 
Their application in biology and therapy require IONPs to be stable in water at neutral 
pH and at physiological salinity. Naked IONPs are very unstable and tend to aggregate at 
ambient conditions leading to rapid clearance from the system before their intended use. 
To address this, IONPs are coated with a surface layer during or after synthesis. This layer 
provides an interface between the surrounding environment and the core. The presence 
of a surface layer reduces opsonisation, inhibits corrosion/oxidation of the magnetic core, 
ensures colloidal stability under physiological conditions and enhances circulation time. 
Moreover, the coating layer can also be functionalized by attaching carboxyl groups, 
carbodiimide and other molecules that can be augmented to drug molecules by covalent 
attachment, adsorption or entrapment to the nanoparticles. 88, 89 Coating systems can also 
be made stimuli sensitive, e.g. to pH and temperature, to favour release at a specific site.  
However, coatings affect the magnetic properties of IONPs. The extent to which magnetic 
properties are affected depends on the molecular weight, composition and thickness of 
coating. Conjugation to other molecules also deteriorates the magnetic properties. 7 
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Several organic and inorganic coatings have been reported to date and include dextran, 
silica, lipids, polyethylene glycol (PEG), and chitosan (Figure 2.5) amongst others and 
these are discussed in more detail in this section.  
 
Figure 2.5: Chemical structures of selected coating materials  
 Like nanoparticles, the coatings should be biocompatible, nontoxic and hydrophilic. 
Their size should be less than 100 nm so they can avoid elimination via the RES. 90, 91 
2.4.1. Organic Coatings 
2.4.1.1. Polyethylene glycol (PEG) and its derivatives 
One way of increasing the circulation time and the blood half-life of nanoparticles in vivo 
is by using hydrophilic polymers. PEG can be integrated onto IONPs surface to form a 
hydrophilic, uncharged, biocompatible and non-immunogenic layer. IONPs are coated 
during synthesis in situ or post synthesis via adsorption or end grafting resulting in 
uniform encapsulation.92 Studies have shown that PEG provides the nanoparticles with 
functionality, stability and compatibility in the biological environment and improves their 
hydrophilicity.90, 91 At sizes below 100,000 dalton, PEG polymers are amphiphilic and 
soluble in water as well as many organic solvents. This property makes them compatible 
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with a range of chemistries in aqueous or organic phases. Bio distribution studies have 
also shown that PEGylated IONPs preferentially accumulate in the tumour region via 
enhanced permeability and the retention effect. 92, 94 Cytotoxicity studies by Pisciotti et al 
revealed that IONPs coated with PEG were nontoxic up to concentrations as high as 100 
µg/mL. In the same study, an increased tumour uptake (160%) in vivo was observed when 
PEG coated SPIONPS were used in the presence of a magnetic field. 95 
Several reports have been published on the use of so-called PEGylated IONPs with a 
commercially available drug, Doxorubicin (DOX) (Figure 2.6), to increase its efficacy. 93 
DOX is an anti-cancer chemotherapy drug used for several cancers including breast, 
gastric, liver and ovarian cancer. Its clinical use is limited due to its adverse side effects, 
resistance developed by cancer cells to it, dose dependent cardiotoxicity and 
hematotoxicity.94, 96 
 
Figure 2.6: Structure of Doxorubicin (DOX) 
As well as making nanoparticles stealth, PEGylation can also have an important influence 
on drug loading, drug release, use with other therapies and nanoparticle distribution into 
the cell. 
Quinto et al synthesized PEG coated IONPs loaded with DOX for chemotherapy-
hyperthermia combinatorial treatment.97 It was also found that the presence of PEG not 
only gave protection to IONPs but also has the potential to concurrently deliver DOX and 
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generate heat for an enhanced multimodal cancer treatment. The synergy between 
chemotherapy and hyperthermia has a potential for a more effective treatment of cancer. 
97 
Gautier et al developed DOX loaded IONPs and investigated the release of DOX in vitro 
in order to observe how PEGylation modifies the release.89 The study showed a pH 
dependent release of DOX from the polymer coating. A sustained, gradual release with 
no burst effect was observed at pH 7.4. Release was accelerated when the pH was lowered 
to 4. 89 
There are also several reports on using PEG derivatives for surface modification to 
improve stealthiness of IONPs. Orlando et al reported the synthesis of IONPs coated with 
an amphiphilic polymer (PMA) followed by PEGylation in order to form PEG-IONP-
PMA.94, 98 The PMA polymer coating not only gives the IONP extra protection but also 
bears several carboxylate groups for further functionalization. IONP-PMA were 
synthesized according to a previously reported procedure99 and PEGylated using PEG-
NH2 and an amide-coupling agent to form PEG-IONP-PMA.  The nanoparticles did not 
exhibit cytotoxicity and were less internalized by macrophages or human endothelial cells 
(HUVEC). Moreover, these nanoparticles crossed the blood brain barrier, which makes 
them potentially useful as therapeutic agents for brain diseases. 98 
There has been several reports by Nagasaki et al on the use of PEG based hydrophilic 
block copolymers demonstrating their stability even in harsh conditions (e.g. high salt 
concentrations and broad range of pHs).94  Block copolymers are commonly used for the 
encapsulation of SPIONs for direct use in cancer therapy and imaging. Block copolymers 
are prepared by controlled polymerization of one monomer (A), followed by chain 
extension with a different monomer (B) and in some case a third monomer (C) to form 
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AB or ABC block copolymers. In one of their reports, IONPs were synthesized by co-
precipitation in the presence of PEG-poly (4-vinylbenzylphosphonate) (PEG-b-PVBP) 
(Figure 2.7) as a surface coating to form PEG-PION4 block co polymer.64 The 
nanoparticles were strongly bound to the polymer through multi point anchoring via the 
phosphate group.  
 
Figure 2.7: Structure of PEG-b-PVBP 
Following in vivo administration to mice, these modified nanoparticles showed prolonged 
blood circulation time and significant EPR-mediated tumour accumulation. PEG-PION4 
also showed excellent dispersion stability, remaining intact after one week in serum 
containing solution due to the strong phosphate anchoring. More recently, the same group 
synthesized DOX loaded IONPs coated with PVBP to study their encapsulation 
efficiency and stability in tumour bearing mice.62 They showed high drug loading 
efficiency and excellent dispersion stability under physiological conditions. Furthermore, 
the IONPs had a crystalline structure, superparamagnetic properties and exhibited 
sufficient saturation magnetization to be used in MDT. 62, 94, 100 
Yang et al developed PEG modified, cross-linked starch coated magnetic nanoparticles 
using N-hydroxysuccinimide chemistry to produce nanoparticles with long circulation 
time.20 Recently, Prabha et al developed β-cyclodextrin (Figure 2.8) (β-CD)-PEG–PEI 
coated iron oxide nanoparticles as drug delivery agents.102 β-CD is an oligosacharride 
with a hydrophilic surface layer used to improve solubility, stability and bioavailability 
thereby enhancing drug delivery. 
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Figure 2.8: (a) chemical structure and (b) toroidal shape β-cyclodextrin molecule101 
The resulting coated NPs exhibited superparamagnetic behaviour and were used as a 
carrier vehicle for the hydrophobic anti-cancer drug 5-fluorouracil.102 
Schleich et al reported paclitaxel loaded PEGylated PLGA (poly (lactide-co-glycolide)-
based IONPs with excellent magnetic properties for theranostic purposes. They had high 
cellular uptake and showed growth inhibition against colon carcinoma (CT26) tumour 
cells at a range of PTX concentrations (2–20 μg/ml). This concentration corresponds to 
plasma levels of the drug achievable in humans. 103 
Polyethylene oxide (PEO), like PEG, is a polymer of ethylene oxide. However, polymers 
of PEO have a molecular weight above 20000 g/mol compared to a molecular weight of 
lower 20000 g/mol in PEG.104 PEO chains present a steric barrier against the adsorption 
of proteins on the nanoparticle surface. This reduces opsonisation and hence increase the 
blood circulation of NPs.105 
Aqil et al prepared poly (acrylicacid)-b-poly (ethyleneoxide), PAA–PEO, and poly 
(acrylicacid)-b-poly (acrylate methoxy poly (ethyleneoxide)), PAA–PAMPEO, by 
reversible addition fragmentation chain transfer (RAFT) polymerization. RAFT is an 
organic process of controlled radical polymerization technique, applicable for a wide 
range of monomers under mild reaction conditions. The stealthiness of PAA–PAMPEO 
Chapter 2 Magnetically tagged drugs for cancer treatment 
42 
 
and PAA–PEO (Scheme 2.2) was investigated in vitro by assessing the amount of proteins 
adsorbed to NP surface. The block copolymers demonstrated stealthiness and stability.106 
 
Scheme 2.2: Strategy for synthesis of PAA-PEO and PAA-PAMPEO by Aqil et al 107 
 Hafeli et al investigated the toxic properties of polyethylene oxide (PEO) triblock 
copolymers and found that the PEO tail length was inversely correlated to toxicity. The 
study concluded that magnetite nanoparticles coated with triblock copolymers containing 
PEO tail lengths of above 2 kDa were biocompatible and appropriate for in vivo 
application. 108 
PEI is a polycation (highly positive polymer), also used as a capping agent to stabilize 
IONPs. It is a branched biopolymer with amine groups on it with potential to bind to other 
molecules. PEI has been used together with PEG to form hydrophilic, biocompatible 
SPIONPS, resulting in increased blood circulation. 102, 109 
The use of PEG and other organic coatings does not render sufficient protection of 
SPIONPS against physiological conditions.  Drug loading efficiency and specific bio 
distribution in vivo remains a challenge. There is still need to improve the surface 
immobilization density of the PEG chains as well as their binding stability to the 
nanoparticle surface. 
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2.4.2. Inorganic Coatings 
2.4.2.1. Silica 
Silica is one of the most abundant minerals and the most widely used inorganic coating 
for IONPs in MDT for cancer therapy. (Figure 2.9) Philipse et al. 110 first reported the use 
of silica for coating magnetite. Since then, the stability and biocompatibility of silica 
coated IONPs have been studied extensively. The toxicity of silica nanoparticles has also 
received significant attention because of their use in food111, food packaging112, 
sunscreen113, clothing114 and detergents115 to improve texture, kill microbes, or enhance 
shelf life, among other uses. Surface modifications using silica are easy due to the 
presence of silanol groups on the silica layer that are compatible with a variety of 
functional groups. The free silanol groups (Si-OH) can be used as scaffolds for attaching 
other molecules such as drugs and enzymes for use in biological applications. The 
hydroxyl groups present on the surface of silica coated NPs also gives them a hydrophilic 
character, which enhances their biocompatibility. More importantly, silica provides a 
chemically inert surface on IONPs giving them high stability against aggregation and 
oxidation.116, 117 
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Figure 2.9: TEM images of IONPs whose surface has been coated with silica at various 
thicknesses, depending on the amount of precursor added to the solution. (A) 10 mg (B) 
60 mg (C) 1000 mg of TEOS added to solution. (D) HRTEM image of the iron oxide 
nanoparticle uniformly coated with a 6 nm thin amorphous silica shell. Reproduced 
with kind permission from ref.173 
Several methods have been reported for coating IONPs with silica; these include the sol-
gel process, Stöber methods, non-transferred arc plasma and reverse micelle method.118 
Since its discovery in 1968 by Werner Stöber and co-workers, the Stöber process has been 
researched extensively and various modifications of the method published. The Stöber 
process permits controlled growth of silica particles. The Stöber method involves 
hydrolysis followed by condensation of tetraethoxy silicates in alcohol under alkaline 
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conditions resulting in a coreshell structure. Naked NPs are mixed together with an 
aqueous solution and an alkoxysilane in alcohol. Ammonia was used as a morphological 
catalyst. Scheme 2.3 shows a summary of the reactions. 
(a) Hydrolysis Si- [OC2H5] 4 + 4 H2O → Si - (OH) 4 + 4 C2H5OH 
(b) Alcohol condensation Si-(OH) 4 + Si-[OC2H5] 4 → ≡Si-O-Si ≡ + 4 C2H5OH 
(c) Water condensation Si-(OH) 4 + Si-(OH) 4 → ≡Si-O-Si ≡ + 4 H2O 
Scheme 2.3: Summary of reactions in Stöber process for the synthesis of silica 
nanoparticles 
The coating thickness, which can be 5 – 200 nm, is controlled by varying the reaction 
conditions. The main disadvantage of this method is that it results in polydisperse 
particles that limit its use in vivo.65, 118, 119, 120, 121 
The reverse micelle method (inverse microemulsion) represents a more convenient and 
versatile method to coat IONPs with silica. It allows for the control of coating thickness 
and roughness by manipulating process parameters.122, 123 
Jang et al completed a study which compared the stability and toxicity of silica coated 
IONPs vs uncoated IONPs. The silica-coated nanoparticles were stable and demonstrated 
enhanced resistance to acidity compared to uncoated nanoparticles. A study on the 
cytotoxicity indicated that at concentrations of up to 250 µg/mL, both silica coated and 
uncoated nanoparticle IONPs did not significantly decrease cell viability. 124 
Magnetite can be stabilized prior to coating. Zare et al. reported the coating of NPs with 
polyvinylpyrrolidone (PVP) prior to silica coating.125 
Arpanaeia et al studied the effect of using sodium citrate as a stabilizer on silica coated 
NPs. Sodium citrate-modified and non-modified magnetite nanoparticles synthesized at 
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pH 9 were coated with amorphous silica via the Stöber method. Results indicated that the 
stabilised silica coated NPs were more homogenous and had a narrower size distribution. 
This is because the presence of the citrate groups prevents the NPs from aggregating. On 
the other hand unmodified NPs showed stronger magnetic properties. This was attributed 
to the presence of the nonmagnetic layer on the surface of magnetite. 126 
2.4.3. Natural Coatings 
2.4.3.1. Chitosan 
Chitosan is a natural polymer available from various sea species. It is cationic, 
biocompatible, hydrophilic, biodegradable, non-immunogenic, non-toxic and non-
antigenic. Chitosan has limited solubility under basic conditions; however, it contains 
several free amino groups that are protonated under acidic conditions, making it cationic; 
this increases solubility and is responsible for the biocompatibility of chitosan. Chitosan 
nanoparticles have been developed and several studies on their use for intracellular drug 
delivery reported.127, 128 Chitosan-coated IONPs have demonstrated superparamagnetic 
properties and promising drug release profiles by the use of an external magnet, and 
therefore could be an effective coating for use in targeted therapy.129 The limited 
solubility of chitosan at basic pH makes it difficult to coat IONPs in situ because of the 
basic conditions required to precipitate IONPs.130 
Y. Ding et al recently reported the synthesis of chitosan polymerised IONPs loaded with 
the anticancer drug 5-fluorouracil via emulsion chemical cross-linking.131 In this study, 
the chitosan swelling effect (degradation of the chitosan matrix) was investigated at 
different pH. The drug release rate was rapid in acidic buffer solution as opposed to 
neutral and basic buffer solution. The study also demonstrated how the thicker polymer 
diameters slowed down the release of the drug.131 
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2.4.3.2. Dextran 
Dextran, a branched polysaccharide, comprising of glucose sub units up to 150 kDa has 
been used successfully for many applications in vivo and in vitro. It is non-toxic, 
biocompatible, biodegradable and inexpensive. Dextran-coated SPIONPs (DSPIONPs) 
are a well-established platform for the synthesis of imaging agents for applications in 
diagnostic imaging by MRI, positron emission tomography and photodynamic therapy. 
Superparamagnetic iron oxide ferumoxtran-10 (Combidex) is approved for clinical use as 
an MRI contrast agent.132, 133, 134 
In a recent study, Peng et al developed DSPIONPs loaded with Dox (Dox-DSPIONPs) 
and evaluated cytotoxicity of free Dox, DSPIONPS and Dox-DSPIONPs. The 
DSPIONPS (up to 2000 μl/mL) showed no cytotoxicity. The IC50 values for free Dox and 
Dox-DSPIONPs were 1.36 μg/mL and 0.533 μg/mL respectively, indicating that Dox-
DSPIONPs had reduced cytotoxicity compared to free Dox. In the same study, it was 
found that Dox was released from Dox-DSPIONPs conjugate after being taken up by 
cells, released in the cytoplasm, entered the nuclei and eventually intercalated DNA base 
pairs. Further evaluation in vitro showed pH dependency of release of DOX. 133 
Lima et al synthesized SPIONPs via thermal decomposition in the presence of oleic acid 
to yield crystalline, monodisperse NPs with a mean diameter of 18 nm. Functionalisation 
with Dextran or PEG resulted in particles with a hydrodynamic diameter of 170 ± 70 nm 
and 120 ± 40 nm respectively. Cytotoxicity studies revealed that SPIONPS coated with 
PEG were non-toxic up to 100 µg/mL, Dextran coated NPs presented low toxicity at 
concentrations as high as 400 µg/mL. In vivo experiments determined the amount of PEG 
coated and Dextran coated SPIONPS accumulating in the liver, lung, tumour and skin. 
The majority of nanoparticles accumulated in the lungs and liver. This suggests that when 
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adsorbed, IONP distribution takes place mainly via RES leading to high concentrations 
in the liver, lungs and the spleen.135 
Several researchers have reported treating IONPs with epichlohydrin to promote Dextran 
to form cross-linked iron oxide nanoparticles (CLIOs). Dextran molecules have weak 
interactions with IONPS, which are prone to detachment after administration in vivo. The 
CLIOs prevent Dextran dissociation and reduce opsonisation thereby increasing the 
circulation time and blood half-life. Moreover, cross-linking introduces functional groups 
e.g. amine and acid groups these can be used for conjugation with targeting ligands or 
therapeutics.20, 128, 136, 136  
2.4.3.3. Surfactants 
SPIONPS may be coated with surfactants. Surfactants usually have a hydrophobic and 
hydrophilic segment. The hydrophilic segment is adsorbed onto the surface of the 
nanoparticles, while the hydrophobic segment faces outwards to the solvent to produce a 
steric effect, thus improving the dispersion state of nanoparticles. The hydrophilic end 
groups can be –OH, -COOH, -PO (OH)2, -S(=O)2OH.7 
Various surfactants have been investigated to date and these include sodium oelate, 
modified polyacrylic acid, sodium hyaluronan, sodium citrate, Triton-X-100 etc. (Figure 
2.10). Some surfactants which have been used for IONPs are discussed in this section. 
138-140 
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Figure 2.10: Selected surfactants used for INOP surface protection 
Filippousi et al evaluated three different surfactants, cationic cetyltrimethylammonium 
bromide (CTAB) surfactant, the nonionic polyvinylpyrrolidone, K30 (PVP) surfactant, 
and the anionic sodium cholate (S.C.) surfactant. These surfactants vary in terms of 
molecular weight, as well as polar head group and charge. He found that these distinctions 
between the surfactants had an impact on morphological, structural and magnetic 
properties of the resulting coated adduct.141 Li et al recently reported the synthesis of 
double-layered sodium alpha-olefin sulfonate SPIONPS. They were stable, maintained 
their original crystallinity and exhibited high water solubility and superparamagnetic 
properties.142 
Tietze et al developed IONPs stabilised with lauric acid and loaded with anti-cancer drug 
mitoxantrane. The delivery system efficiently delivered chemotherapeutic drug 
mitoxantrane to the tumour tissue of rabbits.143 
Oleic acid (OA) is a commonly used surfactant for modifying IONPs and consists of a 
non-polar hydrophobic tail and a polar carboxylic acid head group. It forms a very strong 
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bond between its carboxylic head group and the amorphous IONP surface. OA modified 
IONPs are biocompatible and OA has been reported to have anti-bacterial activity. Zhang 
et al. characterized OA modified NPs using Fourier transform infra-red and X-ray 
photoelectron spectroscopy and found that the OA molecules were adsorbed on the 
magnetic nanoparticles via chemisorption.144-145  
Coating with OA makes IONPs dispersible only in organic solvents and incompatible 
with an aqueous environment thus their use in the biological system is limited. In a recent 
study by Pawar et al, OA coated IONPs were further coated with chitosan to make them 
suitable for biological applications. The OA-chitosan coated IONPs showed 
superparamagnetic behavior at room temperature, high magnetization values, high 
colloidal stability and low cytotoxicity.146  
Ligand exchange of oleic acid with dopamine and tiron has been previously investigated. 
Ligand exchange is an approach based on the mixing of hydrophobic IONPs with a 
hydrophilic molecule. The hydrophilic ligand displaces the hydrophobic layer on the 
IONPs, due to its affinity towards IONPs surface resulting in aqueous-stable 
nanoparticles. Blum et al used ligand exchange of oleic acid for tiron (4,5-dihydroxy-1,3-
benzenedisulfonic acid disodium salt) and dopamine. Tiron is a cheap, commercially 
available capping agent that forms strong complexes with iron. Dopamine is also 
commercially available and can be further functionalized with acids through amide bonds. 
The IONPs retained their shape, size and superparamagnetic properties after ligand 
exchange.147 More recently, Blum et al used a single step mechanochemical approach to 
convert hydrophobic OA-coated SPIONPS to water compatible Tiron-capped.148 A 
separate study by Lee et al using dopamine capped SPIONPS confirmed the presence of 
dopamine quinone, a highly reactive compound that is believed to be neurotoxic. (Scheme 
2.4) 149, 150, 151 
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Scheme 2.4: Oxidation of dopamine to dopamine quinone 
2.4.3.4. Sugars 
There have also been reports on the use of sugars to stabilise IONPs, e.g. sucrose by 
Patsula et al.152 Herea et al reported a modified hydrothermal, single step reaction under 
alkaline conditions for MNPs coated with glucose-derived polymerization products using 
glucose and iron salts as starting materials. 153 
Several other reports have been published on using mannose, maltose, lactose and 
galactose to stabilize IONPs. 7 
2.5. Conjugation 
Iron oxide nanoparticles do not possess suitable surface properties for specific 
applications. Functionalisation with organic groups on their surface can allow them to be 
conjugated to other molecules. When conjugated with a drug payload, NPs can act as 
efficient, precise drug delivery systems. The conjugate should be able to carry a drug or 
multiple drugs without compromising its functionality once attached. Moreover, the drug 
loaded nanoparticles should release the drug at the target site at a desired rate. 
Drugs are usually associated with IONPs via direct binding to the iron oxide surface or 
by encapsulation of both the drug and IONP within a biodegradable polymer matrix. 
Direct binding can be achieved by covalent or non-covalent linkage.154 
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2.5.1. Covalent Linkage 
Covalent linkage involves linking the therapeutic agent to the nanoparticle via an amino 
or hydroxyl functional group already present on the surface of the nanoparticles. The 
covalent bond should be cleavable on demand, stable in the bloodstream and should not 
alter the drug’s structure. Iodoacetyls, maleimides and pyridyl disulfides have also been 
used as linkers. Figure 2.11 shows examples of functional groups that have been used for 
targeted delivery with IONPs.  
 
Figure 2.11: Functional groups used for covalent conjugation on targeted delivery154 
Covalent drug loading involves many synthetic procedures. However, by selecting an 
appropriate linker, it is possible to ensure drug release only occurs in specifically targeted 
areas. Covalent bonds which are pH sensitive have been exploited for controlled release.  
(Table 2.5) 
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Bond Notes Drug Loaded and 
release trigger 
Optimum 
Release 
Ref 
Amide  Very robust and can 
improve the thermal 
stability of anti-cancer 
drugs. Amide bond can be 
cleaved at low pH. 
Methotrexate/Citric 
acid 
pH 
70% (pH 4, 37 
°C, 48 h) 
155 
Hydrazone Most used pH sensitive 
bond.  
DOX/PEI 
pH 
33% (pH 4.5, 
37 °C, 24 h) 
156 
Schiff’s 
base 
(Imine) 
Stable at physiological pH, 
low pH facilitates 
hydrolysis of bond and high 
temperature accelerates 
hydrolysis 
DOX 
pH 
57.8% (pH 5.7, 
50 °C, 8 h) 
157 
Disulfide 
bridges 
Can be cleaved in the 
presence of reducing 
agents such as glutathione 
which is over expressed in 
cancer cells. 
O6 – 
benzylguanine 
Reduction 
100% (pH 5, 
37 °C, 100 
mM 
glutathione) 
158 
Table 2.5: Examples of covalent IONP-drug conjugates 
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2.5.2. Non-covalent  
Non-covalent interactions include electrostatic, absorption, coordination, 
hydrophobic/hydrophilic and affinity interactions (Table 2.6).  
Non-covalent  Notes Drug matrix Release kinetics  Ref 
Hydrophobic The hydrophobic zone 
created by coating  
acts as a reservoir and 
is destabilised in 
acidic environments 
DOX/Oleic 
acid 
70% (pH 6.5, 37 °C) 159 
Electrostatic 
and 
hydrophobic 
DOX absorbed 
through hydrophobic 
and electrostatic 
interactions.  
DOX/PEG 75%  (pH 5.5, RT, 25 
h) 
160 
Coordination  pH sensitive metal to 
ligand coordination  
DOX 67.2%  (pH 4, 37 °C, 
24 h) 
161 
Encapsulatio
n  
 DOX/PEG/li
posome 
 162 
Table 2.6: Non covalent drug interactions 
The choice of chemistry depends on the IONP surface and the ligand. Non-covalent binding 
has several synthetic advantages, i.e. no modification step required and therefore fewer 
synthetic steps, resulting in reduced potential for toxicity, and better cost effectiveness. 
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2.6. Release 
The release mechanism of a magnetically tagged drug further enhances its selective 
destruction of tumours. It has been observed in several studies that the drug payload is 
quickly released in vivo following administration before it reaches its target. This is 
referred to as the “burst effect”. Recently, stimuli responsive polymer coated SPIONs 
have become popular in the field of targeted delivery for cancer therapy. These polymers 
can undergo structural and physical transitions with change in the environmental 
conditions, e.g. pH, ionic strength, light, temperature, magnetic or electric properties.162 
2.6.1. pH triggered 
The slightly acidic pH in the tumour region and endosomes makes a pH responsive 
mechanism a good approach. Therefore, drug delivery systems that release the drug 
payload at low pH are preferred. 
Several polymers undergo rapid dissolution when the pH of the medium is less than 6.5 
and hence are expected to release their contents once within the acidic tumour 
microenvironment and endo/lysosome compartments of cells.163 Fang et al evaluated the 
drug release rate of SPIONPs with a biodegradable, pH sensitive poly (beta-amino ester), 
copolymer loaded with DOX. The model showed higher release rates at lower pH 
compared to physiological pH.164 Kievet et al conjugated DOX to PEI coated IONPs via 
the pH sensitive hydrazine bond. The highest Dox release was achieved at pH below 6.165 
Gautier et al studied the in vitro release of DOX from DOX loaded PEG-SPIONPs. The 
results demonstrated that the PEG layer delays drug release at physiological pH 7.4. 
However, lowering the pH to 4 accelerated the release of the drug by up to 85% in one 
hour.89  
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Recently Prabha et al developed β-cyclodextrin (β-CD) – polyethyleneglycol (PEG) – 
polyethyleneimine (PEI) coated IONPs with particle size range or 151-300 nm for drug 
delivery applications. The IONPs were loaded with 5-fluorouracil (5-FU), a low 
molecular weight antineoplastic used for solid tumours like stomach, colon, breast cancer 
etc. The loading capacity and in vitro release behaviour of 5-FU from the nanocomposites 
was evaluated in a phosphate buffer at pH 1.2 and 6.8 and at temperatures 37 °C and 45 
°C. Drug release was faster at pH 6.8 than at pH 1.2. This was attributed to a high polymer 
swelling effect which is a consequence of high pH. Increasing the temperature also 
resulted in faster release rate. The amount of drug encapsulated in this study ranged from 
10-50%. In this study, it was also noted that slowest release rate was observed where the 
least amount of drug was loaded onto the nanocomposites. This was attributed to the 
additional free void spaces that the drug molecules had to travel through.102 Peng et al 
developed dextran coated SPIONPs conjugated to DOX (Dox-DIONP). DOX release in 
vitro assays were carried out at pH 5, 6 and 7 to simulate lysosomal, endosomal and extra 
cellular components of the tumour microenvironment respectively. A high release rate 
was observed at pH 5 and the lowest release rate observed at physiological pH 7. The 
optimum release was at acidic pH, this was attributed to degradation of dextran at acidic 
pH.133  
Zhu et al reported the synthesis of IONPs attached to cystamine tert-acylhydrazine 
(CTA). The disulfide and acylhydrazine groups were attached onto the surface of 
SPIONPs through the coordination of CTA sulfur groups with Fe3O4 nanoparticles. DOX 
and PEG were conjugated onto the surface of IONPs nanoparticles via pH-sensitive 
acylhydrazone link. Accordingly, a multifunctional pH-sensitive SPIO nanocomposite 
system with long circulation, magnetic targeting and controlled release ability was 
successfully constructed. Under an acidic environment, the drug release of the nanocarrier 
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was accelerated greatly, attributed to the cleavage of pH-sensitive acylhydrazone 
linkages.166 
The findings from these studies suggest that the release of DOX under neutral conditions 
i.e. in blood plasma and normal tissue would be minimal, thereby reducing the systemic 
distribution of DOX during drug delivery. 
Nigam et al. developed citric acid functionalized (citrate-stabilized) IONPs (CA-IONPs) 
loaded with DOX (Figure 2.12) and evaluated the potential of the conjugate as a carrier 
system.167 
 
Figure 2.12: Structure of citrate stabilized IONP 
The positively charged DOX was bound to the surface of the negatively charged CA-
IONPs via electrostatic interactions. Drug release profiles were investigated at pH 5 and 
pH 7.3. The optimum release was obtained at pH 5. A sustained release of 60% of drug 
molecules was observed over 50 hours. At acidic pH, the carboxyl groups on the 
nanoparticle surface becomes partially neutralised due to the presence of protons. This 
leads to weakening of the electrostatic forces, resulting in the release of the drug. This is 
a slow process, which results in long, sustained release of the drug load.167  
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2.6.2. Hyperthermia 
Cancer cells are susceptible to heat, a change in temperature from 37 °C to 43 °C is 
sufficient to kill cancer cells provided this temperature be maintained for a sufficient 
period. Moreover, when the temperature is above 46 °C, tissues undergo thermal necrosis, 
also known as thermoablation.   
MNPs, in an alternating magnetic field, can be used to target a specific tumour location 
and deliver a toxic dose of heat. This heat has been proposed as a mechanism to trigger 
release of chemotherapeutic agents, a concept known as magnetic hyperthermia. By 
killing cancer cells and damaging proteins and structures within cells, hyperthermia may 
shrink tumours. To be efficient, magnetic hyperthermia requires that MNPs have a 
sufficiently high specific absorption rate (SAR), to deposit heat quickly onto cancer cells 
while minimizing damage on healthy tissue. SAR is dependent on physical properties 
such as size, saturation magnetization of the nanoparticles, particles structure and 
interparticle interactions.168  
As the size of IONPs decreases, the saturation magnetization also tends to decrease, 
thereby reducing heating efficiency. To overcome this, the use of core/shell IONPs has 
been proposed by several researchers. It has been reported that core/shell IONPs provide 
high saturation magnetization and increases hysteresis losses, enhancing its use for 
hyperthermia. 
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Figure 2.13: TEM Image of core-shell polymer-coated IONPs169  
 Nemati et al developed core/shell IONPs with average sizes of 8, 12, 14 nm and studied 
how size affected their heating properties for magnetic hyperthermia. Their results 
indicated that the bigger the core/shell IONPs had better heating efficiency and magnetic 
properties. Moreover, these IONPs retained their core/shell morphology for longer 
periods, making them more suited for biological applications.170  
Temperature responsive polymers have become popular for controlled drug release. The 
drug release is dependent upon the change in temperature. Below what is known as a 
critical solution temperature (CST), thermoresponsive polymers are soluble in water and, 
after heating, they become insoluble and form an emulsion. Much work has focused on 
raising the lower critical solution temperature (LCST), i.e. the critical temperature below 
which the components of a mixture are miscible for all compositions. Polymers which 
become insoluble upon heating, have a so-called lower LCST. Below the LCST, the 
polymer is hydrophilic. However, above this temperature the polymer becomes 
hydrophobic and cloudy. (Figure 2.14).162 
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Figure 2.14: Image of poly-SPIONs below and above LCST 162 
The thermos-responsive nature of the polymer means that upon reaching LCST, the 
polymer becomes hydrophobic and shrinks, releasing its aqueous content and expelling 
DOX at the same time. 
Kakwere et al developed thermo-responsive polymer-coated (N-isopropylacrylamide 
polymer), (Figure 2.15) cubic-IONPs loaded with DOX to obtain thermo-responsive, 
biocompatible nanohybrids.171 
 
 
Figure 2.15: IONPs functionalized with thermoresponsive polymer (PNIPAAM) 
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In this study, the LCST was 47 °C. The drug release was assessed at 25, 37 and 50 ° C 
(above the LCST). The DOX loaded IONPs exhibited a negligible drug release below 37 
°C. However, at higher temperatures (50 °C), they showed a consistent release of DOX 
by exploiting the capability of the IONPs to generate heat under an alternating magnetic 
field.171 Rastogi et al. also studied the drug release profile of PNIPAAM-PEGMA IONPs 
loaded with DOX, with an LCST of 44 °C.  The optimum release was observed at 
hyperthermia temperature (45 ° C) and a slightly acidic pH 5.5, with 72.42 ± 5.25 % of 
the drug released over 48 h.172  
2.6.3. Dual Responsive Release:  
Dual responsive release systems, where temperature and/or pH are used to trigger drug 
release have also been reported. They offer advanced features for the targeted delivery of 
drug molecules via the combination of magnetic targeting, and dual pH- and thermo-
responsive behaviour, which offers spatial and temporal control over the release of a drug 
load. 
Wadajkar et al. investigated the drug release of DOX loaded poly (N- 
isopropylacrylamide-chitosan) (PAC)-coated MNPs linked to DOX. The drug release was 
investigated by incubating the drug-loaded nanoparticles at different temperature (37 °C 
and 40 °C) and pH (6 and 7.4). Enhanced drug release was obtained at 40 °C and at pH 
6. This shows that a combination of external heat and low pH would result in enhanced 
drug release. In this case, the presence of chitosan further enhanced the pH 
responsiveness.169  
Hervault et al. developed magnetic, thermo sensitive nano-carriers conjugated to anti-
cancer drug DOX via acid-cleavable imine linker. A PEG based polymer P (DEGMA-co-
PEGMA-b-[TMSPMA-co-VBA]) consisting of two monomers di (ethylene glycol) 
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methyl ether methacrylate (DEGMA) and poly(ethylene glycol) methyl ether 
methacrylate (PEGMA) was used.  
The use of two PEG chains of different length provides temperature-responsive behaviour 
to the polymer, with the possibility to tune the LCST by varying the molar ratio PEGMA: 
DEGMA. 
DOX was conjugated to the nano-carriers through an imine bond, also called a Schiff base 
bond, between the primary amine group of DOX and the aldehyde group of P(DEGMA-
co-PEGMA-b-[TMSPMA-co-VBA]). The drug release studies were performed at 25 °C, 
37 °C (<LCST) and 50 °C (LCST). For each temperature, one sample was held at pH = 
7.4 and another at pH = 5.7. The optimal release was found at pH 5.7 and temperature of 
50 °C.  At physiological pH and temperature, the release of DOX was low. The acidic pH 
facilitated the hydrolysis of the imine bond. In this case the accelerated temperature has 
two effects, facilitating the burst effect upon reaching LCST and temperature-accelerated 
hydrolysis of the imine bond.157  
In this multi-stimulus system, the drug release could be triggered as a consequence of 
magnetic drug targeting, hyperthermia and tumour acidic pH.  
2.7. Limitations of the use of IONPs 
2.7.1. Toxicity 
The increasing applications of IONPs are accompanied by concerns about their 
toxicological properties and long term effect on human health and aquatic life. Over the 
last number of years, efforts have been made to investigate the potential effects of IONPs 
and address the safety issues associated with their use. Many studies have demonstrated 
that at concentrations of 100 µg/mL or higher, IONPs may cause low toxicity or 
cytotoxicity. Several in vitro studies have demonstrated that silver and zinc based 
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nanoparticles are more toxic than IONPs. The toxicity of IONPs cannot be properly 
established yet since results from in vitro studies are often contradictory; in vivo and 
human epidemiological studies are scarce. 
A study by Sundarraj et al on mice indicated that IONPs can cross the blood testes barrier 
causing testicular cytotoxicity due to oxidative stress and apoptosis.174 A study by Zhu et 
al on zebrafish demonstrated that IONPs caused serious delays in embryonic hatching; 
causing malformation in some zebrafish embryos and larvae and eventual mortality.175  
It has been suggested that most NP toxicity in vivo is a result of the production of reactive 
oxygen species (ROS) such as singlet oxygen, superoxide, hydrogen peroxide, and 
hydroxyl radicals. ROS are important in certain physiological processes such as 
respiration and cell signalling. However, an outburst of ROS results in what’s known as 
oxidative stress. Oxidative stress causes oxidative damage of biomolecules and disruption 
of cell signalling mechanisms.176-178 
Several studies have suggested that area and surface chemistry influence nanoparticle 
toxicity. Passivation of the IONPs by surface functionalization may enhance their 
resistance to lysosomal acidity, prevent agglomeration and also modulate dissolution 
kinetics, thereby reducing the overall toxicity.  Dextran, silica, and PEG coated IONPS 
have shown reduced cytotoxicity in in vitro tests. There have been reports of NP size, and 
shape-related toxicity. Nanoparticle size and shape can be controlled during synthesis. 
(See Section 2.3.).178 
Several techniques are used to assess the toxicity on nanoparticles in vitro and they are 
shown on Table 2.7. 
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Technique Notes 
In vitro assays  For cell viability, proliferation and differentiation 
Microscopy   Electron and atomic force microscopy for intracellular 
localization 
In vitro hemolysis assays  Effects of nanoparticle exposure on red blood cells,  
 Evaluates hemoglobin release in the plasma as an 
indicator of red blood cell lysis 
Genotoxicity assays  Evaluates the ability of NPs to damage chromosomes 
and/or DNA 
Table 2.7 : Currently used in vitro toxicity testing techniques 181 
These in vitro techniques are used for initial evaluation of NPs, to identify specific 
characteristics and as indicators of toxicity. They shed light on changes in membrane 
integrity, metabolic activity, and genetic material of cells upon reacting with IONPs. 
However, they have limitations such as their interaction with assay components and they 
cannot be used as a good prognostic indicator of long term physiological effects.180 Even 
though some IONPs are approved for use as MRI agents, translation to use in other in 
vivo applications such as drug delivery is limited due to concentration dependent toxicity. 
Very little correlation has been made between in vitro and in vivo studies due to the 
inability of in vitro studies to mimic the complex environment in vivo. Researchers have 
found that some toxic responses found in vitro are not reproduced in vivo.  This could be 
attributed to homeostasis which regulate the changes in pH, chemical composition and 
ionic strength in the blood.181 Before registration of any drug for FDA approval on clinical 
trials, in vivo studies explaining absorption, distribution, metabolism and elimination 
should be completed, and this remains a challenge.  
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 Table 2.8: Analytical tools currently used for analysis (adapted from Scown et al) 182 
The diverse potential applications of nanotechnology mean that it will inevitably yield 
considerable benefits to society. However, as the nano industry grows and the use of 
nanoparticles increase, so will the quantities released to the environment.  The aquatic 
environment is particularly at risk because it acts as a sink for most environmental 
contaminants.  Like in humans, NPs are likely to have different effects in aquatic life 
compared to their bulkier counterparts. Also, their small size means they can pass barriers 
that prohibit entry of bulkier particles.  
Analytical Tool Advantages Disadvantages 
Inductively 
Coupled Plasma  
Can determine nanoparticles 
composition, concentration, size, 
size distribution, and 
agglomeration 
Acid digestion during sample 
preparation means sample cannot be 
used further  
TEM Good resolution for visualisation 
of individual particles. 
Resolution is limited to two 
dimensions 
Extensive preparation is required 
which may alter cells 
Confocal Less invasive sample preparation May require fluorescent tags which 
alter particle behavior 
Coherent anti-
Stokes Raman 
Speectroscopy  
Three-dimensional visualisation of 
metal oxide nanoparticles in intact 
biological tissue  
Requires little sample preparation 
Limited in its ability to resolve sub-
cellular structure. 
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 One of the factors making it challenging to determine the toxicity in aquatic life and in 
vivo is the lack of techniques and equipment to trace, measure, visualise and quantify the 
nanoparticles. Table 2.8 shows equipment currently used and their limitations.  
Overall, the toxicity of nanoparticles is not fully understood. Current literature suggests 
that nanoparticles have potential adverse effects. More detailed studies in their 
physicochemistry and their interaction with other systems is required. Standardized 
approaches are also required in order to classify nanoparticles according to their hazard. 
Testing every nanoparticle type with every given size and coating, in every aquatic test 
media would not be time or cost effective and current efforts are focused on developing 
standard test methods and analytical tools for effective tracing and quantification of 
nanomaterials.182 
2.7.2. Other limitations 
Another limitation for using IONPs as nano-carriers for in vivo targeting is creating 
suitable magnetic field gradient is required for effective targeting and localization. The 
magnetic force should be strong enough to overcome resistance of blood flow from veins 
and arteries. Also, the magnetic field diminishes rapidly as a function of distance from 
the target tissue.  This limits the targeting ability in vivo, and means that only areas close 
to the surface of the skin can be targeted. Efforts are being made to engineer a magnetic 
field that penetrates to a greater depth.  
Lack of appropriate surface engineering on nanoparticles results in premature release of 
the drug load before it reaches its target site, known as the “burst effect”. The 
heterogeneous and complex structure of tumours make them very difficult to target. The 
EPR vary substantially between tumours and patients. Even parts of a tumour vary in 
terms of vascular permeability. This presents problems in specific targeting. 
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2.8. Conclusion 
This review has discussed cancer, the current treatment methods and their limitations. 
Several drug delivery mechanisms for specific targeting of anti-cancer drugs have been 
discussed and their current developments. IONPs in targeted drug delivery have been 
discussed in detail; their synthesis, surface modification and conjugation to 
chemotherapeutics. Targeted release is important as it ensures that the drug payload is 
released at a specific site and therefore enhancing drug selectivity. Different release 
mechanisms that ensure the drug payload is released at a specific site have been discussed.  
The use of IONPs for targeted delivery is a promising field, however there are still no 
FDA approved IONP drug delivery system on the market. Further research is required to 
understand how IONPs behave in vivo,and address toxicity in vivo and to aquatic life,  
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3 Synthesis of analogues of gymnastatins as potential anticancer agents 
To date, there has been little research in the literature reporting the synthesis and anti-
cancer activity of gymnastatins. This chapter describes synthetic work carried out towards 
the preparation of analogues of gymnastatin N. Two synthetic strategies were utilised and 
they are discussed in detail. 
3.1 Synthetic Strategy 1 
Two analogues of gymnastatins were prepared from octanal 1a using the methodology 
presented in Scheme 3.1. 
 
Figure 3.1: Retrosynthetic analysis of gymnastatin N analogue 
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Scheme 3.1: Overview of synthesis of synthesis of 6 and 6a 
The starting material is commercially available octanal 1a. The first step is a Wittig 
reaction which installs an alkene and extends the chain length. This is followed by a base 
catalysed hydrolysis to yield the corresponding acid 3. Coupling between the resulting 
acid and commercially available O-benzyl-L-tyrosine using HATU and DIEA to yield 
amide 4 is the key step. A reaction between the amide with N,N,dimethylformamide 
dimethyl acetal converts the acid moiety in the tyrosine unit to a methyl ester 5. The final 
step is the removal of the benzyl protecting group using boron trichloride dimethyl sulfide 
complex to yield the target compounds 6 and 6a. 
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3.1.1 The preparation of esters 
The first step in this synthetic strategy was a Wittig reaction using 
(carbethoxyethylidene)triphenylphosphorane (Scheme 3.2). Commercially available 
octanal 1a was used as a starting material.  
 
Scheme 3.2: Wittig reaction 
 (Carbethoxyethylidene)triphenylphosphorane was added to a solution of octanal 1a in 
THF and the mixture was left stirring for 6 hours under argon. The reaction was monitored 
by TLC and upon completion was quenched and the product was purified using column 
chromatography.   
The success of the Wittig reaction was confirmed by 1H NMR. The disappearance of the 
aldehyde proton at 9.50 ppm and an additional signal in the alkene region of the 1H NMR 
spectrum confirmed the installation of an alkene. The quartet at 4.10 ppm confirmed the 
presence of R-CH2 corresponding to the ethyl group of the ester. Furthermore, the 
presence of the methyl group α to the carbonyl was confirmed by the observed singlet at 
1.85 ppm in the 1H NMR.  
The mechanism for this reaction is illustrated in Scheme 3.3. The phosphorane attacks the 
carbonyl group of the octanal generating a negatively charged oxygen which attacks the 
positively charged phosphorus forming a very unstable 4-membered ring called an 
oxaphosphetane. The ring fragments to form an alkene as well as triphenylphosphine 
oxide (P=O) whose formation is the driving force of this reaction.1-2 
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Scheme 3.3: Wittig reaction mechanism involving octanal 1a 
3.1.2 Base catalysed hydrolysis 
The next step involved a base catalysed hydrolysis of 2 to form an acid. This reaction was 
initially attempted using KOH in methanol under reflux for 2 hours (Scheme 3.4) 
 
Scheme 3.4: Base catalysed hydrolysis using KOH in methanol 
This method afforded the product, however the high temperatures promoted isomerisation 
and formation of other side products which were difficult to remove and resulted in a low 
yield. LiOH in THF/methanol/water at room temperature represented a milder route to 
the target compounds (Scheme 3.5). However, this reaction typically involves longer 
reaction times of up to 24 hours.  
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Scheme 3.5: Base catalysed hydrolysis of ester 2 
The formation of the acid was confirmed by 1H NMR disappearance of the quartet at 4.16 
ppm corresponding to the R-CH2 group of the ethyl group of the ester. Furthermore, the 
identity of the product was confirmed by the broad peak at 12.05 ppm representing the 
OH of the carboxylic acid. The presence of the OH was further confirmed by a D2O shake 
and HSQC. 
The mechanism for the base-catalysed hydrolysis is presented in Scheme 3.6. The lithium 
hydroxide provides a nucleophilic hydroxide which attacks the carbonyl on the ester 
creating a tetrahedral intermediate. The intermediate collapses, reforming the carbonyl 
and the ethoxide leaves resulting in a carboxylic acid.1 
R O
O
OH
R O
O
OH
R O
O
H O
CH3
R O
O
H
R OH
O
 
Scheme 3.6: Base catalysed hydrolysis reaction mechanism  
3.1.3 Amide coupling 
Coupling between acid 3 and commercially available protected tyrosine thereby installing 
an amide bond was the key step. The amide functionality is a common feature in natural 
products. It is found in proteins which play a crucial role in most biological processes 
such as enzyme catalysis, transport (haemoglobin), immune protection (antibodies) and 
support (collagen).  Amide bond formation presents difficulties such as low yields, 
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racemisation, degradation and purification issues. This is overcome by using different 
coupling reagents which not only activate the acid but also reduce racemisation, optimise 
the reaction and reduce the formation of by-products.1, 3-4 
In this work, several procedures were attempted to form an amide link between the acid 
side chain and the tyrosine. Initially, cheap Boc protected O-benzyl-L-tyrosine was used 
as the reagent (Scheme 3.7).  
 
Scheme 3.7: Attempted amide coupling using N-Boc- O-benzyl-L-tyrosine 
Several coupling reagents, e.g. diphenylphosphinic acid, EDC and oxalyl chloride, in 
different reaction conditions were used to form an amide link but no product was formed 
or in the case of oxalyl chloride, (entries 1a-1c), a very low yield was achieved. (Table 
3.1) 
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Entry Coupling 
reagent 
Additive Base Reaction 
time/ 
hours 
Temp/ ° C Yield/% 
1a Oxalyl 
chloride 
-- Et3N 6 – 24 RT  50  < 10% 
1b Oxalyl 
chloride 
DMF, 
 
Et3N 6 – 24 50  < 10% 
1c Oxalyl 
chloride 
DMF Et3N 6 – 24 70  < 10% 
2a EDC -- DMAP 12 – 24 RT 0 
2b EDC -- DIEA 12 – 24 RT 0 
2c EDC HOBt, DMAP 12 – 24 RT 0 
Table 3.1: Attempted amide coupling reaction conditions 
It was postulated that NH was not sufficiently reactive. The next attempt involved the use 
of O-benzyl-L-tyrosine (Figure 3.2). This approach involves a primary amine which is 
more reactive. In addition, the need for a Boc deprotection will be avoided.  
 
Figure 3.2: O-benzyl-L-tyrosine 
The first approach towards amide formation using O-benzyl-L-tyrosine was using an acid 
chloride. There were two options for this, the use of thionyl chloride or oxalyl chloride. 
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Oxalyl chloride was used as it is milder, more selective and requires lower temperatures. 
Triethylamine was used as a base to maintain basic pH conditions during the reaction, 
CH2Cl2 was used as the solvent. The reaction (Scheme 3.8) was monitored by 
1H NMR. 
 
Scheme 3.8: Attempted amide coupling using oxalyl chloride 
The reaction shown in Scheme 3.8 using oxalyl chloride resulted in a poor yield (< 10%). 
Increasing the temperature to 50 °C resulted in isomerisation of the alkenes, and 
formation of side products and did not improve the yield. Adding catalytic DMF to 
accelerate the reaction did not improve yield.  We decided to explore other coupling 
reagents to improve yields and reduce isomerisation. 
The next approach was using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
(Scheme 3.9.) 
 
Scheme 3.9: Attempted amide coupling using EDC 
In this reaction, the carbodiimide reacts with the carboxylic acid to form the O-
acylisourea anhydride, which reacts with the amine to yield the desired amide. A urea by-
product which is water soluble and can be eliminated by aqueous work up is also formed. 
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4-Dimethylaminopyridine (DMAP) was used as a nucleophile to enhance selectivity.  The 
reaction did not go to completion even after 48 hours. 
3.1.4 Coupling with HATU 
The failure of EDC and oxalyl chloride meant considering alternative routes. HATU was 
the obvious choice. HATU is one of the most efficient coupling reagents and was first 
reported by Carpino et al in 1993.5 It has proven to be efficient in difficult sterically 
hindered couplings and gives minimal racemisation. The first test reaction with HATU 
gave 82% yield, with no side products or racemisation and the crude mixture was purified 
by column chromatography.4-6 (Scheme 3.10)  
 
 
Scheme 3.10: Amide coupling using HATU 
This reaction was carried out using DMF as a solvent and DIEA was used as a base. The 
product was purified using column chromatography. The identity of the product was 
confirmed by 1H NMR. A signal was present at 171 ppm in the 13C NMR assigned to the 
carbonyl of the amide group. A multiplet at 7.20 ppm and a singlet at 4.80 ppm 
corresponding to the benzyl protecting group were present. An NH stretch and an amide 
band were also present, at 1511 and 1611 cm-1, respectively in the IR spectrum.  
Furthermore, LRMS showed a signal at m/z = 438.2, calculated for C27H35NO4 [M+H]
 +: 
438.3 corresponding to the parent ion. 
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The mechanism for the amide bond formation using HATU is outlined below. The 
reaction is initiated by the removal of the proton of the acid to form a carboxylate anion 
(Scheme 3.11). 
R OH
O
R O
ODIEA
-H  
Scheme 3.11: Deprotonation of acid 
The carboxylate anion attacks the HATU forming an unstable isouronium salt. The OAt 
anion attacks the isouronium salt affording an active OAt active ester. Addition of an 
amine (nucleophile) to the OAt ester results in acylation.4 
 
Scheme 3.12: Proposed reaction mechanism for amide formation using HATU 
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3.1.5 Methylation of acid side group 
In this step the acid group on the tyrosine unit was converted to a methyl ester using 
N,N,dimethylformamide dimethyl acetal. The effect of the presence of a methyl ester 
rather than acid side group on the anti-cancer activity of the gymnastatin analogues was 
of interest. To this end, a reaction was set up as shown in Scheme 3.13 to convert the acid 
side group on the tyrosine unit to a methyl ester. 
 
Scheme 3.13: Methylation of acid moiety in tyrosine unit 
Amide 4 was dissolved in DMF and to the solution was added N,N-dimethylformamide 
dimethyl acetal and the reaction stirred at room temperature for 16 hours.  The identity of 
the product was confirmed by a 1H NMR CH3 signal at 3.1 ppm and a 
13C NMR signal at 
52.3 ppm. Furthermore, removal of the acid side group results in significant change in the 
polarity of the molecule. Therefore, TLC was also used to confirm that the acid group had 
been removed. Furthermore, LRMS showed a signal at m/z = 452.2 calculated for 
C28H37NO4 [M+H]
 +: 452.3. 
3.1.6 Benzyl deprotection 
3.1.6.1 Debenzylation using Pd/C H2 
The final step in this synthetic route was the removal of the benzyl ether protecting group. 
Benzyl ethers are usually removed by hydrogenation over a palladium catalyst which 
cleaves the benzylic C-O bond.  The presence of easily reducible functional groups makes 
hydrogenation difficult. Caine and Bindra et al however reported the selective removal 
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of a benzyl ether protecting group in the presence of alkenes.9-10 To this end, this reaction 
was attempted on a small scale (Scheme 3.14). This did not yield the desired product as 
the alkenes were also reduced during the reaction. 
 
Scheme 3.14: Attempted O-Benzyl deprotection using H2, Pd/C 
3.1.6.2 Pd (OAc)2 / Et3SiH 
When hydrogenation using Pd/C and H2 did not yield the desired compound, other 
methods for selectively removing the benzyl protecting group while leaving the alkene 
intact were explored. 
Coleman et al. reported the selective cleavage of benzyl protecting group in the presence 
of acyl chlorides, bromides, cyclopropanes and alkenes using triethyl silane catalysed 
with Pd(OAc)2.
11  
This reaction was attempted as illustrated in Scheme 3.15 below. 
 
Scheme 3.15: Attempted O-benzyl deprotection 
However, this procedure did not result in debenzylation or reduction of the alkene, only 
the starting material was recovered. 
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3.1.6.3 Debenzylation using BCl3 
Boron trichloride is a Lewis acid that can be used to cleave ethers, acetals, and in some 
cases, esters. Boron trichloride is toxic and difficult to handle. Its complex with dimethyl 
sulfide (BCl3.S(CH3)2), also used to cleave ethers, is solid, stable in air, and easier to 
handle. 
 
In this work, the deprotection of the benzyl ether was attempted using boron trichloride 
dimethyl sulfide (2 M in CH2Cl2). There have been several reports on the selective 
removal of benzyl ethers using (BCl3.S(CH3)2) in the presence of other functional groups, 
e.g. olefins, at temperatures as low as -83 °C in dry  CH2Cl2.
18 This reaction was attempted 
with a view to selectively remove the benzyl protecting group illustrated in Scheme 3.16.  
 
Scheme 3.16: Benzyl deprotection using boron trichloride dimethyl sulfide complex 
Initially the reaction was attempted using a procedure reported in the literature. 
BCl3.S(CH3)2 was added to a solution of amide 4 in dry  CH2Cl2 under argon at -78 °C. 
The reaction was maintained at this temperature for 3 hours. After three hours, the 
reaction was not complete. The unreacted starting material was recovered and the reaction 
attempted using several reaction conditions. (Table 3.2).  The reaction only went to 
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completion when 8 equivalents of BCl3.S(CH3)2 were used. The reaction mixture was 
initially left stirring at -15 °C for 1 hour and warmed to room temperature and left stirring 
overnight (entry 6).   
Entry Conditions Comments 
 Temperature Duration/h Eq. of 
BCl3.S(CH3)2 
*Yields 
1 -78 °C 3  5  <10% 
2 -78 °C for 1 h to 
RT 
3  5 < 20% 
3 -78 °C for 1 hour 
to RT 
16  5 < 40%  
4 -15 °C 
 
3  5 < 40% 
5 -15 °C for 1 hour 
to room 
temperature 
 
16  5  < 70% 
6 -15 °C for 1 hour 
to room 
temperature 
16  8 Complete 
Table 3.2: Debenzylation reaction conditions using BCl3.S(CH3)2. Yields reported are 
estimates calculated from NMR integration 
It was concluded that 8 eq. BCl3.S(CH3)2 was required for the complete debenzylation of 
amide 6a.  
When NMR indicated that the reaction had gone to completion, the reaction was 
quenched with ice cold methanol and CH2Cl2. The crude product was purified using 
column chromatography. NMR analysis revealed an unexpected singlet at 3.6 ppm 
integrating to 3 protons. This suggested the presence of a methyl group within the 
Chapter 3  Synthetic gymnastatin analogues 
 
96 
 
structure. LCMS analysis was used to determine the mass of the parent ion. The m/z 
confirmed that the compound had a molecular weight 15 g/mol greater than expected. 
There were two possibilities: methylation of the acid side group on the tyrosine unit or 
the methylation of the OH on the phenol (Scheme 3.17). 
 
Scheme 3.17: Possible sites of methylation highlighted in red 
After analysis using HMBC, it was confirmed that methylation at the acid group rather 
than the hydroxyl group at the phenol took place. A singlet was observed at 8.20 ppm and 
this was attributed to the phenolic OH. The OH was further confirmed by D2O shake and 
HSQC. 
When it was confirmed that the methylation occurred on the acid side group, we set out 
to determine if quenching the reaction with methanol was responsible for methylation. To 
this end, the reaction was repeated and quenched with ethanol rather than methanol. It 
was confirmed by NMR that ethylation had occurred at the acid side group. The singlet 
that was associated with the methyl group during methylation was absent.  NMR analysis 
showed signals at 4.04 ppm and 1.10 ppm corresponding the ethyl group of the ethyl ester. 
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Further analysis using HMBC confirmed the ethylation of the acid to form 6b. (Figure 
3.3) 
 
Figure 3.3: Assigned HMBC spectrum of 6b 
These findings suggested that an acid chloride intermediate is formed, by conversion of 
the acid side group to an acid chloride. Quenching the reaction with methanol and ethanol 
results in methylation and ethylation respectively. (Scheme 3.18) 
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Scheme 3.18: Debenzylation reactions using BCl3.S(CH3)2 
To preserve the acid side-group the reaction was quenched using brine to yield 6a. The 
successful synthesis of 6a was confirmed by 1H NMR analysis by the absence of a singlet 
around 3.5 ppm. The signal corresponding to the acid did not appear on the 1H NMR 
spectrum. HRMS was used to further confirm the structure of 6a.  
Further analysis of the compounds 6, 6a and 6b using HRMS confirmed this reaction 
pathway.  
Chapter 3  Synthetic gymnastatin analogues 
 
99 
 
Entry Reaction 
quenched with 
Chemical 
formula 
Calculated 
mass 
Found mass 
6 Methanol (C21H31NO4) [M+H]
 +: 
362.2331, 
 
Found: 
362.2345. 
6a Brine  (C20H29NO4) [M+Na]
+ : 
370.1994, 
 
Found:  
370.2001 
6b Ethanol  (C22H33NO4) [M+H]
 +: 
376.2488, 
Found:  
376.2475 
Table 3.3: HRMS analysis of 6, 6a and 6b (samples ran by Jimmy Muldoon in UCD 
Dublin) 
The general mechanism for the reaction between an acid chloride and an alcohol (ROH) 
is illustrated in Scheme 3.19. It involves a straightforward nucleophilic substitution at the 
carbonyl. 
 
Scheme 3.19: General mechanism of the reaction between an acid chloride and an 
alcohol 
The methylation of the acid group during this step meant that the methylation of the acid 
group step (section 3.1.5) could be eliminated. 
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3.2 Synthetic Strategy 2 
Scheme 3.20 shows an overview of the synthesis of gymnastatin analogues with varying 
chain lengths, and an additional alkene.  
 
Figure 3.4: Retrosynthetic analysis of gymnastatin analogues 
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Scheme 3.20: Overview of synthesis 
Herein, an eight step procedure towards the synthesis of analogues of gymnastatin N is 
discussed.  The starting materials and the reagents are commercially available and cheap. 
The first step is a Horner-Wadsworth-Emmons (HWE) reaction which extends the chain 
length by two carbons and installs an alkene. This is followed by a reduction to the 
corresponding alcohols using diisobutyl aluminium hydride. Oxidation of the alcohols 
using Dess-Martin periodinane yields the corresponding aldehydes. A Wittig reaction 
further extends the chain and installs a methyl alkene. This is followed by a base catalysed 
hydrolysis to yield the corresponding acids. Coupling between the resulting acids and 
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commercially available O-benzyl-L-tyrosine using HATU and DIEA installing an amide 
bond is the key step. The final step is the deprotection of the benzyl ether to form the 
target compounds. The details of each of the procedures are discussed below.  
3.2.1 The preparation of esters 
The first step was a Horner-Wadsworth-Emmons (HWE) reaction, which involved a 
reaction between aldehydes and a phosphonate to obtain an alkene.7 The aldehydes used 
were cheap and commercially available heptanal, octanal and nonanal. The aldehydes 
used in this step defined the R-group for each reaction.  Triethyl phosphonoacetate was 
the reagent of choice as it afforded the desired product with regioselectivity resulting in 
the formation of E- isomer (Scheme 3.21). 
 
Scheme 3.21: The synthesis of alkenes 
Triethyl phosphonoacetate was added to a solution of sodium hydride in THF and the 
mixture stirred under argon at 0 °C for 10 minutes. The appropriate aldehyde 1a-1c was 
added dropwise and the resulting mixture stirred for 4 hours. TLC and the disappearance 
of the aldehyde proton in 1H NMR analysis were used to monitor the reaction. The 
mixture was quenched with ammonium chloride solution and extracted with ether. The 
phosphorus containing side product is water soluble and therefore was easily removed in 
the quenching step. The product was then purified by column chromatography.  
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Entry R % Yield 
7a C5H11 92 
7b C6H13 89 
7c C7H15 88 
 
The formation of the ester was confirmed by 1H NMR by the disappearance of the doublet 
at 9.00 ppm corresponding to the aldehyde functional group of the starting material. The 
presence of 2 signals in the alkene region of 1H NMR confirmed the installation of an 
alkene. Furthermore, the quartet at 4.20 ppm confirmed the presence of R-CH2 
corresponding to the ethyl group of the ester. The formation of the E alkene was 
confirmed by measuring the coupling constants of the alkenyl protons. (J = 15-16 Hz). 
The reaction mechanism is outlined below. The reaction begins with deprotonation of 
triethyl phosphonoacetate using NaH (Scheme 3.22) to give a carbanion.  
 
Scheme 3.22: Deprotonation of triethyl phosphonoacetate 
Nucleophilic attack of the carbanion on to the carbonyl group generates a negatively 
charged oxygen which attacks the positively charged phosphorus forming a very unstable 
4-membered ring, an oxaphosphetane. The ring fragments to form an alkene and P=O. 
(Scheme 3.23) The P=O bond has a bond energy of 575 kJmol-1 and is one of the strongest 
bonds in chemistry. Its formation is the driving force of this reaction.1 
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Scheme 3.23: Proposed mechanism for Horner-Wadsworth-Emmons reaction 
3.2.2 The preparation of the alcohols 
There were two options for the reduction of the ester to an alcohol; lithium aluminium 
hydride (LiAlH4) and diisobutylaluminium hydride (DIBAL-H). LiAlH4 is a powerful 
reducing agent, however, it is difficult to handle. Lithium borohydride has been used as a 
milder alternative, however it reduces esters to alcohols very slowly. DIBAL-H was used 
for the preparation of alcohols 8a-8c as it is easy to handle and involves quicker reaction 
times (< 2 h). DIBAL-H reduces esters to aldehydes at low temperatures, however at 
higher temperatures the ester is further reduced to an alcohol.1,8 
The ester reduction was initially attempted using 1.2 equivalents of DIBAL-H in CH2Cl2 
at 0 °C and at room temperature. No product was formed and the starting material was 
recovered. Increasing the temperature and reaction times resulted in isomerisation. Using 
excess DIBAL-H resulted in partial reduction and an emulsion was formed which was 
very difficult to separate resulting in low yields. The reaction went to completion with 
good yields when the temperature was maintained at -4 °C and 2 equivalents DIBAL-H 
used (Scheme 3.24).  
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The successful reduction of the ester to the alcohol was confirmed by 1H NMR by the 
disappearance of the quartet at 4.16 ppm and the triplet at 1.45 ppm corresponding to the 
ethyl group of the ester. The loss of 1H NMR signal at 166.8 ppm and of the IR peak at 
1720 cm-1 corresponding to the carbonyl of the ester also confirmed the successful 
reduction. Furthermore, the presence of the hydroxyl group was confirmed by the broad 
peak at 3321 cm-1 on the IR spectrum.  
 
Scheme 3.24: The synthesis of alcohols 
The appropriate ester 7a-7c in CH2Cl2 was cooled to -4 °C and stirred under argon after 
which DIBAL-H in CH2Cl2was added and the resulting mixture stirred for 2 hours. The 
reaction mixture was quenched using 1M HCl and extracted using ethyl acetate.  
Although the reaction went to completion, the initial yields were very low. DIBAL-H is 
an aluminium hydride which when used in excess, results in the formation of an 
aluminium salt emulsion between the aqueous and organic layer. This makes the work-
up very difficult and results in very low yields. To overcome this, a saturated aqueous 
solution of Rochelle’s salt was prepared. This was added to the completed reaction 
mixture and the solution vigorously stirred in an ice bath for 5 minutes. This broke up the 
emulsion and the crude mixture was purified using flash chromatography. 
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Entry R % Yield 
8a C5H11 84 
8b C6H13 85 
8c C7H15 91 
 
The mechanism for DIBAL-H reduction is shown in Scheme 3.25. The reduction of the 
ester is initiated by the attack of the nucleophilic hydrogen on the carbonyl to give a 
tetrahedral intermediate. The tetrahedral intermediate collapses and loses an alkoxide to 
form an aldehyde. The aldehyde is further reduced to form another tetrahedral 
intermediate with negatively charged oxygen which is protonated during the work up to 
form the alcohol product. 
O
O
H R
O-
O
H R
O
H R
O-
HH3O
+
RHO
Al
H
Al
H
R
R = C7H15
 
Scheme 3.25: Reaction mechanism for DIBAL-H reduction 
3.2.3 The preparation of aldehydes 
Dess-Martin periodinane (DMP) was used to oxidise the alcohols to aldehydes 9a-9c. The 
use of DMP as an oxidising agent was first reported in 1983 by Martin et al.  It oxidises 
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primary alcohols to aldehydes and secondary alcohols to ketones. Despite its cost, DMP 
is an efficient oxidising agent compared to 2-iodoxybenzoic-acid (IBX), DMSO and 
chromium based oxidising agents (pyridinium chlorochromate or pyridinium 
dichromate).12 Its advantages include short reaction times of between 0.5 – 2 hours, mild 
reaction conditions, good solubility in most organic solvents and high yields. The iodo 
by-product is easily separated from the product via work up. DMP is commercially 
available, however it can be prepared from IBX. Dess et al reported the first synthesis of 
DMP in 1983. In 1993, Ireland and Liu reported an improved procedure for the 
preparation of DMP illustrated in Scheme 3.26. Due to the risks associated with its 
synthesis, commercially available DMP was used.13-14 
 
Scheme 3.26: Improved procedure for preparation of Dess-Martin Periodinane using 
iodobenzoic acid as reported by Ireland.14 
The oxidation of alcohols 8a-8c is outlined in Scheme 3.27. The reactions went to 
completion in less than 90 minutes in good yield. The aldehydes had to be used straight 
away or stored at -20 °C. When stored at higher temperatures for a few hours or 
purification attempted, the aldehydes degraded or hydrolysed to corresponding acids. 
 
Scheme 3.27: The synthesis of aldehydes 
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The appropriate alcohol 8a-8c in CH2Cl2 was cooled to 0 °C. Dess-Martin periodinane in 
CH2Cl2, also at 0 °C, was added and the reaction mixture stirred for 1.5 hours under argon. 
The reaction mixture was quenched using 1M NaOH and extracted using ether. The 
product was used immediately without further purification or stored at -20 °C under 
argon. 
The successful oxidation of the alcohol to the aldehyde was confirmed by 1H NMR by 
the loss of the doublet of doublets at 4.10 ppm corresponding to the CH2 α to the hydroxyl 
group. Furthermore, the presence of a doublet at 9.50 ppm in the 1H NMR confirmed the 
presence of an aldehyde.   
Entry R Yield 
9a C5H11 94 
9b C6H13 90 
9c C7H15 91 
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The proposed mechanism is illustrated in Scheme 3.28.  
 
Scheme 3.28: Proposed reaction mechanism for oxidation of alcohol to aldehyde using 
Dess-Martin periodinane 
The lone pair of electrons on the alcohol attacks the iodine on the periodinane resulting 
in a positively charged oxygen. The acetoxy group deprotonates the alcohol to form 
AcOH. Another molecule of AcOH is lost. The I-O bond breaks resulting in a neutral 
iodine species and an aldehyde is formed. The reaction is quenched using NaOH which 
hydrolyses the side product acetoxyiodinane into 2-iodosobenzoate which together with 
acetic acid are removed during the work-up.15 
3.2.4 The preparation of esters 
A Wittig reaction in the presence of (carbethoxyethylidene) triphenylphosphorane 
increased the chain length by addition of another alkene according to Scheme 3.29.  
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Scheme 3.29: The synthesis of alkenes 
The appropriate aldehyde 9a-c in CH2Cl2 and (carbethoxyethylidene) 
triphenylphosphorane   were stirred under argon for 6 h before being quenched with 
ammonium chloride and extracted with diethyl ether and the volatiles removed in vacuo. 
The crude product was purified using column chromatography. 
Entry R Yield 
10a C5H11 81 
10b C6H13 75 
10c C7H15 72 
 
The success of the Wittig reaction was confirmed by disappearance of the doublet at 9.50 
ppm in the 1H NMR corresponding to the proton of the aldehyde. The presence of an 
additional signal in the alkene region of 1H NMR confirmed the installation of an 
additional alkene. The quartet at 4.10 ppm confirmed the presence of R-CH2 
corresponding to the ethyl group of the ester. Furthermore, the presence of the methyl 
group α to the carbonyl was confirmed by the 1H NMR singlet at 1.85 ppm.  
The proposed mechanism for this reaction is similar to that presented in section 3.1.1. 
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3.2.5 The preparation of acids 
The next step involved a base catalysed hydrolysis of the esters to form an acid using 
LiOH in THF/methanol/water at room temperature. 
 
Scheme 3.30: The synthesis of acids 
The procedure in Scheme 3.30 was employed for the synthesis of acids. After 24 hours, 
1M HCl was added to the reaction mixture followed by extraction using ether. This 
reaction was difficult to reproduce as a salt was formed in most cases. The acid was 
instead obtained by flushing the salt through silica gel several times. This lowered the 
yield but gave a clean acid product. The formation of the acid was confirmed by 1H NMR. 
The quartet at 4.16 ppm corresponding to the R-CH2 of the ethyl group of the ester was 
no longer present. Furthermore, the identity of the product was confirmed by the broad 
peak at 12 ppm representing the OH proton. This was further confirmed by a D2O shake. 
The proposed mechanism for this reaction is similar to the one presented in section 3.1.2. 
Entry R % Yield 
11a C5H11 80 
11b C6H13 89 
11c C7H15 70 
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3.2.6 Amide coupling 
Coupling of acids 11a-11c with O-benzyl protected tyrosine was carried out as previously 
described in section 4.1.4 via amide coupling using HATU, DIEA and DMF. (Scheme 
3.31) 
 
Scheme 3.31: Amide coupling using HATU 
The reaction was monitored by NMR and was complete in 16 h. The identity of the 
product was confirmed by NMR. An NH signal (doublet) was observed at 6.8 ppm and 
confirmed by a D2O shake. LRMS was also used to confirm the identity of the product. 
(Table 3.4) 
Entry R % 
Yield 
Calc 
(M+H)+ 
Found 
m/z  
12a C5H11 80 450.3 450.2 
12b C6H13 85 464.6 464.2 
12c C7H15 72 478.3 478.2 
Table 3.4: Yields and LRMS results for amide products. 
The mechanism for this reaction is discussed in section 3.1.4. 
3.2.7 Benzyl deprotection 
The final step was the removal of the benzyl protecting group. This was carried out as 
previously described in section 3.1.6.2 using boron trichloride methyl sulfide complex in 
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CH2Cl2. The reaction was quenched using brine or methanol, to preserve the acid side 
group, or install a methyl ester side group, respectively.  
 
Scheme 3.32:  O-benzyl deprotection using boron trichloride dimethyl sulfide complex 
 
Entry R R' % Yield 
13a C5H11 -CO2H 95* 
13b C6H13 -CO2H 85* 
13c C7H15 -CO2H 73* 
14a C5H11 -CO2Me 80 
14b C6H13 -CO2Me 79 
14c C7H15 -CO2Me 72 
Table 3.5: Yields of final compounds. * not purified 
Difficulties were encountered in the purification of the target compounds containing the 
acid side group 13a–13c. The compounds degraded during purification. The yields and 
characterisation reported are of the crude product. 
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3.2.8 Methyl ester derivative compound characterisation 
The yields of the reactions are illustrated in Table 3.5. The spectrum of 14a is used in this 
section to characterise the final compound.  The 1H NMR and COSY spectra of 14a are 
shown in Figure 3.5.  
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Figure 3.5: Assigned 1H NMR and COSY of 14a in CD3CN 
The successful debenzylation was confirmed by 1H NMR. The characteristic protons of 
the benzyl protecting group at 7.30 and 4.90 ppm were no longer present. The distinctive 
splitting pattern of the para- disubstituted benzene ring is observed in the aromatic region. 
A doublet corresponding to the secondary amide was observed at 7.20 ppm. The NH was 
confirmed by disappearance on D2O shake, and by HSQC. Furthermore, the NH signal 
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coupled with the proton at position 13 was evident in the COSY (Figure 3.5.). The alkenyl 
protons were observed in the alkenyl region. The proton at position 13 was observed at 
4.60 ppm as a quartet. Furthermore, the presence of the OH resulting from debenzylation 
was confirmed by a broad peak observed at 8.2 ppm. HSQC and a D2O shake confirmed 
that this was an OH signal.  A diastereotopic splitting pattern was observed at 3.0 ppm 
corresponding to the –CH2 at position 15. The singlet at 3.70 ppm represents a methyl 
group corresponding to the methyl ester on the tyrosine unit. 
3.3 Conclusion 
A library of eight novel gymnastatin analogues were prepared with various chain lengths. 
The compounds consisted of an unsaturated side chain linked to a tyrosine unit using an 
amide bond. The side chain was prepared by a HWE, reduction, oxidation, Wittig and 
hydrolysis reactions. The resulting acid was coupled to a benzyl protected tyrosine using 
HATU.  Additional functionality was added to the tyrosine unit by methylation of the 
acid side group to prepare methyl ester derivatives. The final compounds were obtained 
by removal of the benzyl protecting group. The resulting final compounds were 
characterised using NMR, IR and HRMS. 
Prior to this work, there are few reports in the literature on the synthesis of compounds of 
this nature. While three compounds with an acid side group were isolated, they were very 
difficult to purify. Future work within the group will involve purification of these 
compounds using preparative HPLC.  
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4. Biological evaluation of gymnastatin analogues 
4.1. Introduction  
This chapter documents the biological evaluation of the library of synthesised 
gymnastatins. This includes cytotoxic evaluation in the A549 cancer cell line. It begins 
with the background of the cell line used and the techniques used for measuring 
cytotoxicity. This is followed by the results and discussion of the biological evaluation 
using two assays, the MTT and the alamar blue assay.  
The last section of this chapter details preliminary work carried out on the evaluation of 
some compounds as potential Plk1 inhibitors. This is followed by a discussion of the 
preliminary results obtained from an ELISA assay targeting Plk1. 
4.1.1. Cell lines  
The compounds prepared were evaluated in the A549 cancer cell line. The A549 cell line 
is a continuous cell line derived from a human pulmonary adenocarcinoma. It was isolated 
in 1973 from cancerous lung tissue in the tumour of a 58-year-old caucasian male. It was 
later characterised as a representative of the alveolar type II pneumocytes of the lung cell. 
The alveolar epithelium comprises two cell types: the alveolar type I (ATI) and alveolar 
type II (ATII) cell. ATI cells are squamous cells that cover around 95% of the alveolar 
surface. ATII cells cover the remaining 5%. ATII cells play an important role within the 
lung and have been described as defenders of the alveolus. The A549 cell line is a useful 
model for the isolated ATII pneumocyte. It was selected for this work because of its facile 
manipulation. A549 cells are also a robust cell line providing a good starting point for an 
inexperienced researcher in this area.1-3 
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4.1.2. Cytotoxicity assays 
As an initial screen for potential drug candidates it is common to establish whether the 
drug candidates exhibit a cytotoxic effect. Cell based assays are often used to screen 
compounds to determine if test molecules show direct cytotoxic effects that will lead to 
cell death. There are a variety of assays used to estimate the number of viable cells at the 
end of an experiment. Most cytotoxicity assays are based on colorimetric assays involving 
the use of an organic dye. Many assays employed are based on the metabolic activity of 
healthy cells. The results are determined using UV-vis or fluorescence spectroscopy. The 
absorbance or fluorescence intensity corresponds to the metabolic activity of the cells. 
Damaged or dead cells have lower metabolic activity and thus generate a lower signal 
compared to healthy, undamaged cells.4-7 
To evaluate the response of A549 cells to the synthesised analogues of gymnastatins, the 
alamarBlue ® (AB) and MTT assays were used. The AB and MTT assays were conducted 
on separate plates. Briefly, cells were seeded into 96 well plates and incubated for 24 
hours. The cells were exposed to varying drug concentrations at different time points from 
24 to 72 hours. The details of each of the assays are discussed below.  
4.1.3. MTT assay 
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), 1 is a yellow 
water soluble tetrazolium salt which is actively absorbed into cells. It is reduced to a 
purple formazan dye 2 in the mitochondria of viable cells by the cleavage of the 
tetrazolium ring by dehydrogenase enzymes. 1,2 The reaction is illustrated in Scheme 4.1. 
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Scheme 4.1: Reduction of MTT 1 by mitochondrial enzymes to give the formazan dye 2. 
Cells lose their ability to reduce tetrazolium compounds shortly after death. Therefore, 
the ability of cells to reduce MTT is used as an indicator of mitochondrial activity which 
is interpreted as a measure of cell viability. The absorbance of the treated sample at 570 
nm is proportional to the quantity of viable cells in the sample.8 
4.1.4. AlamarBlue®  
AB monitors the reducing environment of a living cell. Its active ingredient, resazurin (7-
hydroxy-10-oxidophenoxazin-10-ium-3-one) is a redox indicator. It is non-toxic, water 
soluble and stable in culture media. Viable cells with active metabolism reduce the blue, 
non-fluorescent, resazurin 3 into the resofurin product which is pink and fluorescent.9 
(Scheme 4.2) 
 
Scheme 4.2: Reduction of resozurin sodium salt (3) to strongly fluorescent resofurin 
sodium salt (4) in the presence of viable cells 
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The quantity of resofurin produced is proportional to the number of viable cells which 
can be quantified using a microplate reader at 560 nm excitation and 590 nm emission.10-
12 
4.1.5. Methodology  
The A549 cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplement, with 10% fetal bovine serum (FBS) and 5 mM L-glutamine in appropriate 
asceptic conditions, at 37 °C in 5% CO2 humidified incubator.  
Fig 4.1 shows the characteristic growth pattern of cells. The plot shows cell density versus 
the time spent in each phase by the cell in culture. 
 
Figure 4.1: Characteristic growth curve of cells 
The lag phase is the period just after the cells have been seeded. It is characterised by 
slow growth as the cells adapt to the media and the new environment. This is followed by 
the log phase. During the log phase, also called the logarithmic phase, the cells have 
adapted and proliferate exponentially. The cells enter stationary phase when all the media 
has been used up, or growing cells have occupied all of the available substrate.  At this 
stage, proliferation is greatly reduced and eventually stops entirely. Cells have to be 
subcultured/seeded/passaged before they reach the stationary phase.  
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A standard procedure available in the laboratory was used for cytotoxic evaluation. Cells 
were harvested for experiments when they were in the “log” phase of growth. The cells 
were then seeded into 96 well plates at densities ranging from 3*104 to 1.2*105 depending 
on the duration of exposure (24, 48 and 72 h). The cells were incubated for 24 hours to 
allow for attachment. Drug solutions were prepared in DMSO (up to 1% v/v). Final test 
solutions were prepared by serial dilution of a 700 μM working stock solution. Following 
attachment, the cells were exposed to five different drug concentrations in eight replica 
wells. The final concentration was achieved by addition of the drug solution to the 
medium containing cell suspensions in the wells. Three replica plates were used for each 
experiment.  
Following exposure, the cells were incubated in appropriate asceptic conditions at 37 °C 
in 5% CO2 humidified incubator for 24, 48 and 72 hours. At the appropriate times, the 
assays were terminated by discarding the test solutions from plates and rinsing each plate 
using PBS. This was followed by the addition of fresh unsupplemented media and MTT 
solution.  The cells were further incubated for 3 hours, during which time, the 
mitochondria in viable cells absorbed and metabolised MTT. The supernatant was then 
removed and each well was washed with PBS to remove any unmetabolised MTT. The 
water-insoluble formazan salt was solubilised using DMSO and shaken for 10 minutes. 
The well plate was subsequently placed in a Genios plate reader and absorbance 570 nm 
was recorded. Figure 4.2 summarises the steps involved in the MTT assay. 
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Figure 4.2: Summary of MTT assay procedure 
For the alamar blue® assay, a slight variation of this procedure was used. Following 
exposure for the appropriate time, the test chemical was removed and replaced with AB 
dye stock solution. The plates were incubated for three hours after which time the plates 
were placed in a microplate reader and read at 560 nm excitation and 590 nm emission. 
This experimental procedure was performed in triplicate for each drug at each time point. 
The percentage viability was calculated using the following equation:  
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠
 × 100 
The cell viability was used to generate a concentration-response curve which was used to 
calculate the EC50 at each time point. The EC50 is defined as the concentration at which 
50% of the cell population exhibited the desired response from the drugs, in this case, cell 
death. The % cell viability versus concentration plot and the dose response curve for 3b 
at 72 hours are outlined in Figure 4.3 below as a representative example.  
Absorbance read at 570 nm
Plate is shaken for 10 minutes
Wells are rinsed with PBS and the formazan salt is solubised with DMSO
Incubation in appropriate asceptic conditions at 37 °C in 5% CO2 for 3 
hours
Test solution is discarded and replaced with MTT stock solution 
Cells are incubated for the specified time period with test chemical
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Figure 4.3: A % viability of treated A549 cells versus the concentration of 3b. % 
Viability values are calculated from three independent experiments and are shown +/- 
the standard deviation. B Dose response curve for 3b in A549 cells at 72 hour exposure. 
 
Fig 4.3 shows the viability of A549 cells treated with 3b over a range of concentrations. 
It can be seen that the drug reduces cell viability in a dose-dependent manner. The 
sigmoidal dose-response curve is the average response over three independent 
experiments.  
All drug solutions were prepared in DMSO. DMSO is a widely used organic solvent due 
to its ampiphilic properties, high polarity and liquid state over a large temperature range. 
In cell culture, DMSO is widely used as a vehicle. It has been used as a solvent vector in 
many studies including the study of paclitaxel anticancer properties by Fujimoto.13 Most 
literature procedures recommend maintaining DMSO concentration below 1% v/v.  
To assess the cytotoxicity of DMSO, an MTT assay was performed for various 
concentrations of DMSO (0.5 to 10%) at two timepoints, 24 h and 72 h. The study 
demonstrated that at a concentration of 1% or lower, DMSO was non-toxic to A549 cells. 
(Figure 4.4). 
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Figure 4.4: % viability of A549 cells treated with increasing concentration of DMSO 
versus untreated cells 
4.1.6. Results of cytotoxic evaluation Gymnastatin analogues in A549 cells 
The analogues of gymnastatin 1a-4b (Figure 4.5) were assessed for cytotoxicity in A549 
cells at concentrations 21.9 µM to 350 µM. A negative and positive control were included 
in each plate. All compounds assessed had good solubility in DMSO.  
4.1.6.1. Statistics 
Cytotoxicity data are the average of at least three experiments expressed as a mean 
percentage viability relative to the control (100 % media) ± standard deviation (SD). The 
results have been statistically analysed using one-way analysis of variance (ANOVA) 
followed by a post-ANOVA Dunnett’s test using GraphPad Prism software ®. Test results 
are considered relevant when P < 0.05 (denoted with *) and very significant when P < 
0.01 (denoted with #) for the Dunnets analysis (see Appendix). Statistical data was 
calculated using Microsoft excel. EC50 values were calculated using GraphPad Prism 
software ®.  
4.1.6.2. MTT Assay 
Initially all compounds were evaluated for potential anticancer activity using the MTT 
assay. The results of the evaluation are reported as EC50 values calculated as described in 
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section 5.1.5. The results for the cytotoxic assessment of analogues synthesised are 
summarised in Table 4.1 followed by the discussion of the results. Figure 4.5 shows a 
legend of the compounds evaluated using MTT assay at three different time points.  
 
Figure 4.5: Legend for Table 4.2 
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Compound EC50 
μM 
(+/- s. d.) 
 24 h 48h 72h 
1a > 350 a > 350 a > 350 a 
1b > 350 a > 350 a 227.5 (1.2) 
2a > 350 a > 350 a > 350 a 
2b > 350 a > 350 a 216.7 (1.3) 
3a > 350 a > 350 a > 350 a 
3b > 350 a 218 (1.1) 123 (1.2) 
4a > 350 a > 350 a >350 a 
4b > 350 a 126.2(1.4) 91.4(1.3) 
a EC50 could not be determined due to little or no activity at the concentrations used 
Table 4.1: (MTT Assay) EC50 (μM) of compounds against A549 at three time points: 24, 
48 and 72 hours post exposure. EC50 values are expressed as mean +/- standard 
deviation (s.d.) of at least three experiments. 
It can be seen from the EC50 values presented in Table 4.1 that the compounds containing 
the methyl ester side group in the tyrosine moiety showed time and dose dependent 
activity against A549 cells. For all methyl ester containing compounds, the best activity 
was observed after 72 hours of exposure. It is interesting to note that increasing the chain 
length resulted in increased activity. Analogue 4b which exhibited the longest chain 
length showed the best activity (91.4 μM) after 72 hours of exposure. The compound with 
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the shortest chain length showed the least activity (227 µM) against the A549 cell line.  
Fig 4.6 compares the dose response of compounds containing a methyl ester on the 
tyrosine unit. 
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Figure 4.6: Comparison of the dose-response of compounds containing methyl ester 
side group (1b-4b) at three timepoints 24, 48 and 72 hours (A, B, C respectively) 
At 24 hours there was no significant activity for any of the compounds evaluated. After 
48 hours there was some activity at concentrations above 87.5 μM, most notably 3b and 
4b which showed a viability of less than 60%. After 72 hours of exposure, all compounds 
showed activity at 175 and 350 μM. Compound 4b, possessing the longest chain length 
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clearly showed the most activity (< 30% viability). This initial data seems to suggest that 
the activity is dependent on the chain length.  
To assess the importance of the additional alkene, a comparison between compounds 1b 
and 2b is shown below.  
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Figure 4.7: Comparison of the dose-response of compounds 1b and 2b (A and B 
respectively) at three time points 24, 48 and 72 hours. 
There was no significant difference in activity between the two compounds assessed.  
Compound 2b had a slightly lower EC50 (216.7 μM) compared to 1b (EC50 = 227.5 μM). 
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Both compounds only showed significant activity after 72 hours at a concentration of 175 
μM or above. While the activity of these compounds was disappointing, it did suggest 
that the additional alkene did not offer significant benefit to the activity in this assay. 
Figure 5.8 shows a comparison of compounds containing the acid side group in the 
tyrosine unit. These compounds were also evaluated at three different timepoints.  
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Figure 4.8: Comparison of the dose-response of compounds containing acid side group 
(1a-4a) at three timepoints 24, 48 and 72 hours (A, B, C respectively) 
It was disappointing to note that compounds 1a-4a did not show significant activity at 
concentrations tested (350 μM), even after 72 hours of exposure. While these results were 
Chapter 4  Biological Evaluation 
 
131 
 
disappointing, they suggested that the presence of an acid side group did not impact the 
cytotoxicity in this assay. 
Overall the results for the activity of synthetic gymnastatin analogues using the MTT 
assay were disappointing, with the exception of 4b. At this stage, it was decided to use a 
different assay to determine if the drugs targeted a different part of the cell.  
4.1.6.3. Alamar Blue® Assay 
The compound showing the best activity for MTT 4b as well as 1b and 4a were assessed 
using alamar blue. 4a was chosen to evaluate the potential effect of the acid group on 
activity. 1b was chosen in order to assess the effect of the chain length and presence of 
an additional alkene.  
AB does not necessarily specifically indicate a mitochondrial dysfunction like the MTT 
assay. There have been reports which have suggested that cytosolic and microsomal 
enzymes also contribute towards the reduction. AB remains a suitable indicator of the 
cellular health and viability.11-14 AB was used to examine if some of the compounds 
assessed using the MTT assay targeted other parts of the cell other than the mitochondria. 
A legend for the compounds evaluated using the AB assay is presented in Figure 4.9. 
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Figure 4.9:  Legend for compounds assessed using alamar blue assay 
Evaluation of compounds 1b, 4a and 4b gave a different outcome. A significant 
difference in activity between compounds assessed using MTT versus AB was observed. 
All compounds assessed performed better in the AB assay compared to the MTT assay. 
(Figure 4.10). 
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Figure 4.10: Comparison of the dose-response of compounds 1b, 4a, and 4b (A, B and 
C respectively) assessed using AB assay at two timepoints, 48 and 72 hours. 
As can be seen in Figure 4.10, the compounds assessed showed significant cytotoxicity 
at high concentrations. The compounds were evaluated at 48 and 72 hours. Compound 
1b showed significant activity at 350 μM, however at lower concentrations, lower activity 
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was observed. However, the activity was still higher than the activity observed when the 
MTT assay was used. Interestingly, compound 4a, which contains an acid side group 
showed a vast improvement in cytotoxicity in the AB assay. 4a showed moderate activity 
at lower concentrations and 48 hours exposure time. However, at 350 μM good activity 
was observed at 48 hours and at 72 hours.  Compound 4b showed the best activity of the 
compounds evaluated using the AB assay. Compound 4b exhibited significant 
cytotoxicity after 24 hours of exposure. The cytotoxicity observed was almost 50% better 
than that observed in the MTT assay. Table 4.2 shows a comparison of the EC50 values 
from AB and MTT assays for compounds 1b, 4a and 4b. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4  Biological Evaluation 
 
135 
 
Compound EC50 
μM 
(+/- s. d.) 
 AlamarBlue® MTT 
 48 h 72 h 48 h 72 h  
1b 160.5 
(1.5) 
71.4 (1.4) >350 227.5 
(1.2) 
4a 309.5 
(1.5) 
83.2 (1.6) >350 >350 
4b 51.8 (1.3) 49.1 (1.4) 126.2 
(1.4) 
91.4 (1.3) 
Table 4.2: (Alamar Blue Assay) EC50 (μM) of compounds against A549 at three time 
points: 48 and 72 hours post exposure. EC50 values are expressed as mean +/- standard 
error of at least three experiments. 
Overall, all three compounds performed better in the AB assay. The compounds 
containing the methyl ester were still more active than those containing the acid side 
group. From these results, it can be suggested that the methyl ester is responsible for the 
activity of these compounds. Increasing the chain length also resulted in increased 
activity.  
This structure activity relationship could be because of the hydrophilic/hydrophobic 
nature of the compounds. It is well known that in order to be transcellularly absorbed, a 
drug must possess a degree of lipophilicity.  This is a requirement in order for a drug to 
pass through the lipophilic environment of the cell membrane. There are several examples 
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where polar, ionisable groups of molecules have been masked with an ester to increase 
lipophilicity and promote membrane permeability.  The more hydrophobic a molecule is, 
the faster it crosses the cell membrane. The methyl ester containing compounds are 
hydrophobic and acid containing compounds hydrophilic. An increase in the chain length 
also adds to the hydrophobicity of the compounds.15-16 
4.2. ELISA Assay 
4.2.1. Gymnastatins and Plk1 
Gymnastatin N and a range of analogues were screened against Plk1 by Phoon et al. and 
their IC50 values measured. The same compounds were also tested against Cdk 2, another 
serine/threonine kinase to eliminate common inhibitors. Only the samples which had 5 
times more potency against Plk1 versus Cdk 2 were selected for further assessment. Table 
4.4 shows a selection of the IC50 values of the compounds assessed. The assays were 
performed in well plates using heparin as a sample.17 
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Entry  Structure Plk1 
IC50 
(µM) 
1 
N
H
O
CO2H
OH
 
13 
2 
N
H
O
CO2Me
OH
 
>208 
3 
 
82 
4 
 
2.2 
5 
 
Table 4.3: Plk1 study of Gymnastatin N (24) 
and its analogues 
> 268 
The natural product Gymnastatin N (entry 1) was identified as a Plk1 inhibitor. The 
methyl ester (entry 2) and fully saturated (entry 3) analogues showed a decrease in the 
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bioactivity compared to Gymnastatin N (entry 1). This structure activity relationship 
suggested the importance of the carboxylic acid group and conjugated diene 
functionalities in the bioactivity against Plk1. A shorter chain length analogue (Entry 4) 
which contained a tyrosine unit and a conjugated diene exhibited the highest potency. 17 
We set out to determine if the compounds prepared inhibited Plk1. Of particular interest 
were the compounds containing the acid side group which did not show significant 
activity in cytotoxicity assays. 
4.2.2. Methodology 
The details of sample preparation are detailed in Chapter 6. In summary, A549 cells were 
exposed to drug solutions at EC50 values calculated from the MTT assay. The cells were 
exposed to the drug concentration at 5 time points, 1, 2, 4, 6 and 18 hours, in 6 well plates. 
A control well was included for each experiment.  Following trypsinisation, the cell 
suspension was centrifuged and the resulting pellet washed with PBS three times. The 
pellet was lysed using a sonicator and the resulting suspension centrifuged further to pellet 
any debris. The supernatant was transferred to a micro centrifuge tube and stored at – 80 
°C until required for use.  
The Plk1 ELISA assay used in this work employs the quantitative sandwich enzyme 
immunoassay technique. The plates were pre-coated with an antibody specific for Plk1. 
Samples, controls and blanks were introduced into respective wells. The plate was 
incubated at 37 °C for 90 minutes. The samples were discarded and biotin-detection 
antibody was added followed by further incubation for 1 hour. A biotinylated detection 
antibody specific for Plk1 and Streptavidin horseradish peroxide (SABC) were added 
successively to each microplate well and incubated. The plate was then washed to remove 
any non-specific binding that may have occurred.  A substrate solution was then added. 
Only wells containing Plk1 exhibit a colour change. The assay was terminated by adding 
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a sulfuric acid solution and the change in optical density measured in a plate reader at a 
wavelength of 450 nm. The optical density value is proportional to the concentration of 
Plk1 in the sample. The percentage Plk1 inhibition of cells exposed to the drugs was 
calculated using the following equation: 
% 𝑃𝑙𝑘1 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  
𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑜𝑝𝑡𝑖𝑐𝑎𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 × 100 
4.2.3. Results 
To assess the activity of compounds prepared against Plk1, the compounds outlined in 
Table 4.4 were used. A549 cells were treated with drug concentrations equal to the 
calculated EC50 from Section 4.16 and assessed at different time points.  
Compound EC50 calculated from 
MTT/μM 
1a 350 
1b 227.5 
2a 350 
2b 216.7 
4a 350 
4b 91.4 
Table 4.4: Compounds and their EC50 values for Plk1 inhibition study. 
The experiments were done at time points shown in Table 4.5 to give an indication as to 
how long it took for the inhibition to occur. The different time points used could also be 
used to estimate the stages of the cell cycle where Plk1 inhibition is prominent. 
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Time/hours Stage of the cell cycle 
1 M Phase 
2 G2 – M phase 
4 G2 
6 S phase 
16 G1 
Table 4.5: Time spent in each phase of a 24 hour cell cycle.28 
1b 2b 4b
0
20
40
60
80
100
1h
2h
4h
6h
18h
A
Compound
%
 P
lk
 1
 i
n
h
ib
it
o
n
 v
s
. 
c
o
n
tr
o
l
1a 2a 4a
0
20
40
60
80
100
B
Compound
%
 P
lk
 1
 i
n
h
ib
it
o
n
 v
s
. 
c
o
n
tr
o
l
 
Figure 4.11: % Plk11 inhibition of A549 cell exposed to compounds (A): containing 
methyl ester side group (B): containing acid side group. 
As can be seen in Figure 4.14 (A), compounds containing the methyl ester inhibited Plk1 
at concentrations tested, with two exceptions (4b at 2 hours, 1b at 6 and 18 hours). Care 
should be taken when comparing the inhibition between samples as they were tested at 
different concentrations. It is interesting to note that compound 4b did not perform as 
well as it did in the MTT and AB assays.  
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It was disappointing to note that the compounds containing the acid side group did not 
perform as expected. According to a study by Phoon et al., discussed in Section 4.2.4, the 
conjugated diene and the free acid were responsible for the activity against Plk1. However 
in our study, compounds containing the free acid did not show significant inhibition 
against Plk1. Also, there was no significant difference in inhibition between compounds 
with a single alkene (1a and 2a) and compounds with a conjugated diene (4a, 4b). 
 In this assay, the drugs permeating the cell membrane should not have been an issue as 
the cells have been lysed and therefore the cell membrane removed.  
In summary, the results on the Plk1 inhibition were not illuminating. They did not show 
a clear pattern of inhibition at different time points. The results do however show that the 
compounds containing the acid side group do not inhibit Plk1, and compounds with the 
methyl ester side group inhibit Plk1.  
4.3. Conclusion 
A library of compounds was assessed for toxicity against the A549 lung cancer cell line. 
All compounds were assessed using the MTT assay. Compounds containing the methyl 
ester side group showed the best activity, while compounds containing the acid side group 
did not show any activity at concentrations and time points tested. Compounds 1b, 4a and 
4b were further evaluated using the AB assay. There was an improvement in cytotoxicity 
observed in all the three compounds. Of all compounds assessed, 4b showed the best 
activity. It was observed that compounds containing a methyl ester on the tyrosine side 
unit and longer chain compounds performed the best.  
Several compounds were screened against Plk1 at concentrations equal to their respective 
EC50 values calculated from the MTT assay (Section 4.1.6). The best activity was 
observed in compounds containing the methyl ester side group. Future work should 
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involve cell imaging using organelle specific dyes to identify the subcellular localisation 
of the compounds prepared. This, as well as flow cytometry will be carried out within the 
group as future work.  
The level of activity observed would suggest that the compounds and their analogues are 
worthy of further investigation. It is well known that cellular response may vary between 
cell lines. It would be interesting to evaluate these compounds against various cell lines 
e.g. Caco-2, HeLa and BEAS-2B. The different responses between different cell lines and 
different assays would increase the understanding of the mechanism of action of these 
compounds.  
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5. Conclusion and Future Work  
This chapter summarises the outcomes of this research and details suggestions for future 
work. 
The aim of this work was to prepare analogues of gymnastatin N and assess them for 
biological activity. Eight analogues of gymnastatin N were successfully prepared starting 
with commercially available aldehydes. The aldehyde used in the first step defined the 
chain length of the final product. To begin with, a side chain was prepared using a series 
of HWE, reduction, oxidation, Wittig and hydrolysis reactions. For the short chain 
analogues, the side chain was prepared by a Wittig followed by a hydrolysis reaction. The 
resulting acid was coupled with a commercially available benzyl protected tyrosine. 
Several difficulties were encountered during the amide coupling, however, successful 
coupling was achieved using HATU and DIEA. 
The selective removal of the benzyl protecting group presented difficulties, however, 
boron trichloride methyl sulfide complex successfully removed the benzyl protecting 
group while leaving the alkenes intact. Also, quenching the reaction with methanol 
resulted in methylation of the acid side group. This meant that the methylation step could 
be eliminated.  
Several difficulties were encountered in the purification of target compounds containing 
the acid side group. However, the compounds had 95% purity which was deemed 
sufficient for biological evaluation. Future work should be aimed at purification of the 
acid side group using preparative HPLC. 
The prepared gymnastatin analogues were evaluated for anti-cancer activity using MTT 
assay. A selection of the prepared compounds were further assessed using the AB assay. 
The compounds containing a methyl ester side group showed more activity than 
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compounds containing the acid side group.  It was also observed that increasing the chain 
length also resulted in increased activity against the cancer cells. The presence of an 
additional alkene did not result in significant improvement of activity. Furthermore, 
preliminary results of the activity of compounds using an ELISA assay showed that the 
compounds containing the methyl ester side group inhibited Plk1, where the compounds 
with the acid side group showed no inhibition. A more thorough biological evaluation of 
these compounds is required in order to evaluate their activity against other cell lines e.g. 
Caco-2 and HeLa cells which can be readily obtained in our laboratory.   
An investigation to assess the selectivity of these compounds should also be carried out. 
For example, evaluation against BEAS-2B, a healthy cell line isolated from normal 
human bronchial epithelium obtained from autopsy of non-cancerous individuals. 
To understand the subcellular localisation and drug distribution of these compounds, cell 
imaging experiments should be done. These should be done at times and concentrations 
when the drugs are known to display cytotoxicity. The mechanism of cell death induced 
by the prepared analogues can also be determined by flow cytometry.  
In this thesis, iron oxide nanoparticles and their use in targeted drug delivery for cancer 
treatment have been reviewed. Future work will include conjugation of the synthesised 
gymnastatin analogues to iron oxide nanoparticles at the phenol functionality. Work on 
conjugating iron oxide nanoparticles to organic compounds is already ongoing within the 
group.
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6 Experimental Procedures 
6.1 Part A: Synthetic Procedures 
6.1.1 General Experimental 
All reagents and dry solvents were purchased from Sigma-Aldrich and Apollo Scientific 
and were used without further purification. Argon and hydrogen were obtained from BOC 
gases and were used without further purification.  
1H NMR and 13C NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer 
at room temperature in deuterated solvents. Chemical shifts (σ) are given in parts per 
million (ppm) and coupling constants (J) are expressed in Hertz (Hz). An arbitrary 
numbering system is employed to aid assignment of NMR signals. High resolution mass 
spectrometry was carried out in University College Dublin by Dr Jimmy Muldoon on a 
Waters/Micromass LCT Mass Spectrometer with 40 % water (with ~1 % formic acid) 
and 60 % methanol. All samples were prepared in MeOH.  Infrared (IR) spectra were 
recorded on a Perkin Elmer Spotlight 400N FT-IR spectrometer with UATR accessory.  
Thin layer chromatography (TLC) was carried out on aluminium sheets pre-coated with 
silica gel 60 and visualised under a 254 nm UV lamp and stained with anisaldehyde 
solution (1.7 mL anisaldehyde, 0.7 mL glacial acetic acid, 2.3 mL concentrated sulfuric 
acid in 62.5 mL ethanol). Column chromatography separations were performed using 
Davisil silica gel LC60A (35-70 µm). 
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6.1.2 Synthesis of short chain gymnastatin analogues 
6.1.2.1 Wittig reaction 
 
(Ethyl- (E)-2-methyldec-2-enoate (2) To a solution of octanal 1a (7.8mmol, 1 g, 1 eq.) 
in CH2Cl2 (30 mL) at 0 °C was added a solution of 
(carbethoxyethylidene)triphenylphosphorane (8.6 mmol, 3.1 g, 1.1 eq.) in  CH2Cl2 (20 
mL), also at 0 °C. The reaction mixture was left stirring at room temperature under argon 
for 6 hours before being quenched with ammonium chloride. The reaction mixture was 
transferred to a separating funnel and diluted with diethyl ether (40 mL). The organic 
layer was collected and the aqueous layer was extracted two more times with ether. The 
organic layers were combined and dried over anhydrous magnesium sulfate. The volatiles 
were evaporated under vacuum using a rotary evaporator. The crude mixture was purified 
by flash chromatography using as the eluent, petroleum ether 9:1 ethyl acetate and the 
target compound 2 was isolated as a yellow oil. 
Ethyl (E) 2-methyldec-2-enoate (2) 
 
Yield = 79.8%, Rf = 0.5 (petroleum ether 9:1 ethyl acetate) 
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δH /ppm (400 MHz; CDCl3) 6.764 (1H, m, H8), 4.19 (2H, q, J = 7.2 Hz, H10), 2.15 (2H, 
q, J = 7.2 Hz, H7) , 1.75(3H, s, H9), 1.35 (13H, m, H2,3,4,5,6,11), 0.88 (3H, t, J = 7.2 Hz, 
H1). 
δC /ppm (100 MHz; CDCl3) 168.3 (C=O), 143.1 (C=C), 127.6 (C=CO), 60.3 (C-O), 31.8 
(CH2), 29.5(CH2), 29.3 (CH2), 29.1 (CH2), 28.7 (CH2), 28.6 (CH2), 22.6 (CH2), 14.3 
(CH2), 14.1 (CH), 12.3 (CH3). 
υmax/ cm-1 (neat) 2956, 2925, 2856, 1710, 1650, 1464, 1367, 1266, 1140, 1098 
6.1.2.2 Hydrolysis 
 
2-Methyl-(E)-dec-2-enoic acid (3) To a stirring solution of LiOH (24.5 mmol, 587 mg, 
15 eq.)  in ice-cold water (8 mL) was added a solution of 2 (1.63 mmol, 301 mg, 1 eq) in 
MeOH (4 mL) and THF (4 mL), also at 0 °C. The reaction mixture was warmed to RT 
and stirred for 16 hours. The reaction was then cooled to 0 °C and ice cold HCl (1M) 
added slowly to the rapidly stirring solution until pH 1. The reaction mixture was 
transferred to a separating funnel and diluted with diethyl ether (20 mL). The organic 
layer was collected and the aqueous layer extracted two more times with ether. The 
organic layers were combined and dried over anhydrous magnesium sulfate. The volatiles 
were evaporated under vacuum using a rotary evaporator. The target compound 3 was 
isolated as yellow solid and used without further purification. 
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Yield 94% yield.  
δH /ppm (400 MHz; CDCl3) 11.92 (1H, s, H10), 6.92 (1H, m, , H8), 2.19 (2H, q, J = 7.2 
Hz, H7), 1.83 (3H, s, H9), 1.37  (10H, m, H2-6), 0.89 (3H, t, J = 7.2 Hz, H1). 
δC /ppm (100 MHz; CDCl3) 169.2 (C=O), 142.7 (C=C), 126.0 (C-CO), 32.6 (CH2), 31.2 
(CH2), 28.6 (CH2), 28.4 (CH2), 22.1 (CH2), 17.6 (CH3), 12.4 (CH3). 
6.1.2.3 Amide Coupling 
 
[2-Methyl-(E)-dec-2-enamido]-3-[4-(benzyloxy) phenyl] propanoic acid (4) To a 
solution of acid 3 (2.35 mmol, 432 mg, 1 eq.) in dry DMF (10 mL) was added HATU 
(2.35 mmol, 823 mg, 1 eq.) and the resulting solution was stirred for 10 minutes at room 
temperature under argon. DIEA (7.10 mmol, 1.7 mL, 3 eq.) was added and the resulting 
solution was stirred for 20 minutes before O-benzyl-L-tyrosine (2.82 mmol, 874 g, 1.2 
eq.) was added. The reaction mixture was stirred at room temperature for 16 hours. The 
solvent was removed in vacuo and the crude mixture was purified by flash column 
chromatography using as the eluent petroleum ether 8.5:1.5 ethyl acetate. The product 
was isolated as a sticky, yellow oil in 86% yield. 
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δH /ppm (400 MHz; MeOD) 7.68 (5H, m, H1-5), 7.08 (2H, d, J = 8.4 Hz, H7-8) , 6.90 (2H, 
d, J = 8.4 Hz, H9-10), 6.33(1H, m, H16), 6.19 (1H,d , J = 7.2 Hz, H14) ,  5.02 (2H, s, H6), 
4.84 (1H, m, H12),  3.19 (2H, m, H11), 2.10 (2H, q, J = 7.2 Hz, H17), 1.77 (3H, s, H15),  
1.34 (10H, m, H18-22), 0.88 (3H, t, J = 6.8 Hz, H23). 
δC /ppm (100 MHz; MeOD) 174.0 (C=OOH), 171.4 (C=O), 158.0 (C-Ar), 138.4 (C=C), 
136.9 (C-Ar), 130.5 (C-Ar), 129.6 (C-Ar), 128.6(C-Ar), 128.1(C-Ar), 127.9 (C-Ar), 
127.4 (C-Ar), 115.0 (C=C), 70.1 (CH2), 53.5(CH), 36.3 (CH2), 32.5 (CH2), 31.8 (CH2), 
29.3 (CH2), 28.4 (CH2), 14.1 (CH3), 12.4 (CH3). 
υmax/cm-1 (CHCl3 film) 3427, 2926, 2856, 1884, 1723, 1660, 1612, 1511, 1455, 1384, 
1240, 1218, 1177, 1025. 
LRMS (ES+) calculated for C27H35NO4 [M+H]
 +: 438.3, found: 438.2. 
6.1.2.4 Methylation of acid side group 
 
To a stirring solution of 4 (0.27 mmol, 119 mg, 1 eq.) in dry DMF (5 mL) was added 
N,N,-dimethylformamide dimethyl acetal (1.36 mmol, 0.2 mL, 5 eq.) under argon. The 
reaction mixture was stirred at room temperature for 16 h. The solvent was removed in 
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vacuo and the crude mixture purified by flash chromatography using as the eluent 
petroleum ether 6: 4 ethyl acetate. The product was isolated as a yellow oil in 72% yield. 
[2-methyl-(E)-dec-2-enamido]-3-[4-(benzyloxy)phenyl]propanoate (5) 
 
δH /ppm (400 MHz; CDCl3) 7.33 (5H, m, H1-5), 6.94 (2H, d, J=8.8 Hz, H7-8), 6.82 (2H, 
d, J=8.8 Hz, H9-10), 6.26 (1H, td, J = 13.6, 6, 1.6 Hz, H16), 6.06 (1H, d, J=7.6 Hz , H14), 
4.96 (2H, s, H6), 4.82 (1H, m, H12), 3.66 (3H, s, H13),   3.03 (2H, m, H11), 2.06 (2H, q, J 
= 6.8 Hz, H17), 1.73 (3H, s, H15),  1.24 (10H, m, H18-22), 0.81 (3H, t, J=7.2 Hz, H23). 
δC /ppm (400 MHz; CDCl3) 172.4 (C=OCH3), 168.7 (C=O), 158.0 (C-Ar), 137.4 (C=C), 
136.9 (C=Ar), 130.3 (C=Ar), 130.3 (C=Ar), 130.1 (C=Ar), 128.6 (C=Ar), 128.2 (C-
CO), 128.0 (C=Ar), 127.9 (C=Ar), 127.5 (C=Ar), 114.9 (C=Ar), 70.0 (CH2-O), 53.4 
(CH-NH), 52.3 (O-CH3), 37.0 (CH2), 31.8(CH2), 29.3(CH2), 29.1(CH2), 28.7(CH2),  
28.4(CH2),  22.7(CH2), 14.1(CH3), 12.5(CH3). 
LRMS (ES+) calculated for C28H37NO4 [M+H]
 +: 452.3, found: 452.2. 
6.1.2.5 Debenzylation General procedure 1 
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To a solution of 4 (1 eq.) in dry CH2Cl2 at -15 °C, under argon, was added boron 
trichloride methyl sulfide complex (2 M in  CH2Cl2, 8 eq.), dropwise. The reaction was 
warmed to room temperature and left stirring overnight. The reaction mixture was 
quenched with the appropriate solvent and the solvent evaporated in vacuo. The product 
was purified by flash chromatography. 
 
6.1.2.5.1 Methanol Quench 
Methyl-(N-methyl (E)-dec-2-enoyl)tyrosinate (6) 
 
Methyl (N-methyl-(E)-dec-2-enoyl)tyrosinate (6) was prepared using general 
procedure 1 using 4 (0.09 mmol, 40 mg, 1 eq.) in dry  CH2Cl2(5 mL), boron trichloride 
methyl sulfide complex (2 M in  CH2Cl2, 0.73 mmol, 0.37 mL, 8 eq.) under argon. The 
crude mixture was quenched using methanol (10 mL) and the volatiles removed in vacuo. 
The product was purified using petroleum ether 3: 7 ethyl acetate and the target compound 
6 was isolated as a yellow oil in 80% yield. Rf = 0.39 (petroleum ether 6: 4 ethyl acetate). 
δH /ppm (400 MHz; (CD3)2CO) 8.234 (1H, s, H1), 7.07 (3H, m, H4,5,9), 6.76 (2H, d, H2-
3), 6.31 (1H, m, , H11), 4.65 (1H, m, H7), 3.66 (3H, s, H8), 3.10 (2H, m, H6), 2.14 (2H, q, 
H12), 1.77 (3H, s, H10),  1.34 (10H, m, H13-17), 0.88 (3H, t, H18). 
δC /ppm (100 MHz; (CD3)2CO)) 173.2 (C-OOMe), 169.3 (C=O), 157.2 (C-Ar), 136.5 
(C=C), 131.7 (C-Ar), 131.1(C-Ar), 128.8 (C-CO), 116.0 (C-Ar), 55.0(C-NH), 52.2 (O-
Chapter 6   Experimental Procedures 
 
153 
 
CH3), 37.3 (CH2-Ar), 32.6 (CH2), 30.4 (CH2), 30.3 (CH2), 29.5 (CH2), 29.3 (CH2), 28.8 
(CH2), 23.3 (CH2), 14.4 (CH3), 12.7 (CH3). 
υmax/ cm-1 (CHCl3 film) 3313, 3020, 2953, 2925, 2855, 1736, 1659, 1614, 1595, 1500, 
1438, 1363, 1267, 1216, 1173, 1124, 1105. 
HRMS (ES+) calculated for C21H31NO4 [M+H]
 +: 362.2331, found: 362.2345. 
6.1.2.5.2 BCl3 reaction quenched with Ethanol  
Ethyl--(N-methyl-(E)-dec-2-enoyl)tyrosinate (6b) 
 
Ethyl-(N-methyl-(E)-dec-2-enoyl)tyrosinate (6b) was prepared using general 
procedure 1 using 4  (0.10 mmol, 45 mg, 1eq.) and boron trichloride methyl sulfide 
complex (2 M in CH2Cl2, 0.82 mmol, 0.41 mL, 8 eq.) under argon. The reaction mixture 
was quenched using ethanol (10 mL) and the solvent removed in vacuo. The product was 
purified using petroleum ether 6: 4 ethyl acetate and the target compound 8a was isolated 
as a yellow oil in 75% yield. Rf = 0.44 (petroleum ether 6: 4 ethyl acetate). 
δH /ppm (400 MHz; CD3CN) 6.95 (2H, d, J = 8.8 Hz, H4,5,), 6.64 (2H, d, J = 8.8 Hz, H2-
3), (6.47 (2H, d, J = 7.6 Hz, H10), 6.12-6.16 (1H, m, H12), 4.45-4.50 (1H, m, H7), 4.03 
(2H, q, J = 7.2 Hz, H8), 2.94 (2H, m, H6), 2.04 (2H, m, J = 7.2 Hz, H13), 1.65 (3H, s, H11),  
1.20 (10H, m, H14-18), 1.11 (3H, t, J = 7.2 Hz, H9),  0.89 (3H, t, J = 6.8 Hz, H19). 
δC /ppm (100 MHz; CD3CN) 171.7 (C-OOEt), 168.7 (C=O), 155.6 (C-Ar), 136.3 (C=C), 
130.4 (C-Ar), 130.2 (C-Ar), 128.0 (C-CO), 114.9(C-Ar), 60.8 (CH2O-CH3), 54.0 (O-
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CH3), 36.0(CH2-Ar), 31.4 (CH2), 28.8 (CH2), 28.7 (CH2), 28.3 (CH2), 27.7 (CH2), 22.3 
(CH2), 13.3 (CH2), 13.2 (CH3), 11.7 (CH3). 
υmax/cm-1 (CHCl3 film) 3323, 2926, 2856, 1734, 1660, 1615, 1595, 1509, 1447, 1376, 
1349, 1269, 1215, 1126, 1028, 827, 756. 
HRMS (ES+) calculated for C22H33NO4 [M+H]
 +: 376.2488, found: 376.2475 
6.1.2.5.1 BCl3 reaction quenched with water  
 N-methyl-(E)-dec-2-enoyl tyrosine (6a) 
 
N-methyl-(E)-dec-2-enoyl tyrosine (6a) was prepared using general procedure 1 using 
4 (0.14 mmol, 62 mg, 1 eq.) and boron trichloride methyl sulfide complex (2 M in CH2Cl2, 
1.13 mmol, 0.57 mL, 8 eq.), dropwise, under argon. The reaction was quenched using 
water (10 mL) and the resulting mixture transferred to a separating funnel and diluted 
with dichloromethane (15 mL). The organic layer was collected and the aqueous layer 
extracted two more times with ether. The organic layers were combined and dried over 
anhydrous magnesium sulfate. The volatiles were evaporated under vacuum using a 
rotary evaporator. The crude mixture was purified by flash chromatography using 10% 
methanol in CH2Cl2. The product 11b was isolated as a yellow oil in 65% yield.  
δH /ppm (400 MHz; MeOD) 6.90 (2H, d, J = 8.4 Hz, H4-5), 6.55  (2H, d, J = 8.8 Hz, H2-
3), 6.13 (1H, t, J = 7 Hz, H11), 4.38 (1H, m, H7), 2.96 (2H, m, H6), 2.02 (2H, q, J = 7.2 
Hz, H12), 1.66 (3H, s, H10), 1.24 (10H, m, H13-17), 0.81 (3H, t, J = 6.8 Hz, H18). 
Chapter 6   Experimental Procedures 
 
155 
 
δC /ppm (100 MHz; MeOD) 175.3 (C-OOH), 172.2 (C=O), 157.3 (C=O), 138.2 (C-CO), 
131.3 (C-Ar), 129.9 (C-Ar), 129.2 (C-Ar), 124.8 (C-Ar), 116.2 (C-Ar), 57.9 (CH-NH), 
37.3 (CH2-NH), 33.0 (CH2), 29.6 (CH2), 30.7 (CH2), 31.8 (CH2), 23.8 (CH2), 14.5 (CH3), 
12.5 (CH3). 
υmax/cm-1 (CHCl3 film) 3373, 2926, 2856, 1590, 1509, 1412, 1245. 
HRMS (ES+) calculated for C20H29NO4 [M+Na]
+ : 370.1994, found: 370.2001. 
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6.1.3 Synthetic Strategy 2 
6.1.3.1 General procedure 2: HWE 
 
To a suspension of NaH (60% in mineral oil) (1.2 eq.) in dry THF at 0 °C was added 
triethyl  phosphonoacetate (1.2 eq.) dropwise under argon and the mixture left stirring for 
0.5 hours. The reaction temperature was brought to room temperature. The appropriate 
aldehyde 1a-c (1 eq.) was added slowly and the reaction mixture was left stirring for 4 
hours. The reaction mixture was quenched using ammonium chloride (30 mL), 
transferred to a separating funnel and diluted with diethyl ether (30 mL). The organic 
layer was collected and the aqueous layer extracted two more times with ether. The 
organic layers were combined and dried over anhydrous magnesium sulfate. The volatiles 
were evaporated under vacuum using a rotary evaporator. The crude mixture was purified 
by flash column chromatography using as the eluent, petroleum ether 9.5:0.5 ethyl 
acetate.  
Ethyl (E)-non-2-enoate (7a) 
 
Ethyl (E)-non-2-enoate (7a) was prepared using general procedure 2 using NaH (60% 
in mineral oil) (21 mmol, 0.84 g, 1.2 eq.) in dry THF (60 mL), triethyl phosphonoacetate 
(26.3 mmol, 5.6 mL, 1.5 eq.) and heptanal 1a (17.5 mmol, 2.5 mL, 1 eq.). The target 
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compound 7a was isolated as yellow oil (1.46 g) in 88% yield. Rf = 0.48 (petroleum ether 
9:1 ethyl acetate).  
δH /ppm (400 MHz; CDCl3) 6.96 (1H, dt, J = 15.0, 6.8 Hz. H7), 5.81 (1H, dt, J = 15.6, 
1.6 Hz, H8), 4.18 (2H, q, J = 6.8 Hz, H9), 2.16-2.22 (2H, m, H6), 1.37 (11H, m, H2-5, H10) 
0.88 (3H, t, J = 6.8 Hz, H1). 
 δC /ppm (100 MHz; CDCl3) 166.8 (C=O), 149.5 (C=C), 121.2 (C=C), 60.1 (CH2-O), 
32.2 (CH2), 31.6 (CH2), 29.7 (CH2), 29.0 (CH2), 28.0 (CH2), 22.5 (CH2), 14.2 (CH3), 14.0 
(CH3). 
υmax/ cm-1 (neat) 2957, 1720, 1654, 1465, 1367, 1263, 1123, 1096, 1028, 973, 845, 724. 
Ethyl (E) dec-2-enoate (7b) 
 
Ethyl (E) dec-2-enoate (7b) was prepared using general procedure 2 using NaH (60% in 
mineral oil) (10 mmol, 1 g, 1.2 eq.) in dry THF (40 mL), triethyl phosphonoacetate (10 
mmol, 1.95 mL, 1.2 eq.) and octanal 1b (8.3 mmol, 0.8 mL, 1 eq.). The target compound 
7b was isolated as yellow oil in 92% yield. Rf = 0.5 (petroleum ether 9:1 ethyl acetate).  
δH /ppm (400 MHz, CDCl3) 6.89 (1H, m, , H8), 5.74 (1H, m, H9), 4.11 (2H, m, , H10), 
2.12 (2H, q, J = 6.8, 1.6 Hz, H7),1.31 (13H, m, H2-6, H11) 0.81 (3H, t, J = 7.2 Hz, H1). 
δC /ppm (100 MHz, CDCl3) 165.8 (C=O), 148.5 (C=C), 120.16 (C=C), 59.1 (CH2-O), 
31.2 (CH2), 30.7 (CH2), 28.1 (CH2), 28.1 (CH2), 27.0 (CH2), 21.6 (CH2), 13.2 (CH3),13.3 
(CH3). 
υmax/ cm-1 (neat) 1721, 1654, 1463, 1367, 1264, 1166, 1126, 1095, 1042, 979, 855, 723. 
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ethyl (E)-undec-2-enoate (7c) 
 
ethyl (E)-undec-2-enoate  (7c) was prepared using general procedure 2 using NaH (60% 
in mineral oil) (16.8 mmol, 0.67 g, 1.2 eq.) in dry THF (60 mL), triethyl phosphonoacetate 
(21 mmol, 4.4 mL, 1.5 eq.) and nonanal 1c (14 mmol, 2.4 mL, 1 eq.). The target 
compound 7c was isolated as a yellow oil in 89% yield. Rf = 0.58 (petroleum ether 9:1 
ethyl acetate).  
δH /ppm (400 MHz; CDCl3) 6.96 (1H, m, H9), 5.82 (1H, m, H10), 4.19(2H, q, J = 7.2 Hz, 
H11), 2.18 (2H, m, , H8), 1.38 (2H, m, H7) 1.13 (13H, m, H2-6, H12) 0.88 (3H, t, J = 7.2 
Hz, H1). 
δC /ppm (100 MHz; CDCl3) 166.8 (C=O), 149.5 (C=C), 121.2 (C=C), 60.1 (CH2-O), 
32.2 (CH2), 31.8 (CH2), 29.4 (CH2), 29.2 (CH2), 29.2 (CH2), 28.0 (CH2), 22.7 (CH2), 14.3 
(CH3), 14.1 (CH3). 
υmax/ cm-1 (neat) 2925, 2855, 1721, 1655, 1465, 1367, 1264, 1179, 1126, 1042, 979, 722. 
6.1.3.2 General procedure 3: Reduction 
 
To a solution of the appropriate ester 7a-c (1 eq.) in dry THF at -4 °C, under argon, was 
added dropwise DIBAL-H (1M in CH2Cl2) (2 eq.). The mixture was maintained at this 
temperature and left stirring for 2 hours before being quenched by HCl (1M) until pH 1 
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at 0 °C. The reaction mixture was transferred to a separating funnel and diluted with 
diethyl ether (30 mL). The organic layer was collected and the aqueous layer extracted 
two more times with ether. The organic layers were combined and dried over anhydrous 
magnesium sulfate. The volatiles were evaporated under vacuum using a rotary 
evaporator. The crude mixture was purified by flash column chromatography using as the 
eluent petroleum ether 9: 1 ethyl acetate. 
(E)-Non-2-en-1-ol (8a) 
 
(E)-Non-2-en-1-ol (8a) was prepared using general procedure 3 using 7a (11 mmol, 2 g, 
1 eq.) in dry THF (60 mL) and DIBAL-H (1M in CH2Cl2) 13.2 mmol, 13.2 mL, 1.2 eq.). 
The target compound 8a was isolated as yellow oil in 91% yield. Rf = 0.32 (petroleum 
ether 9:1 ethyl acetate). 
 δH /ppm (400 MHz; CDCl3) 5.67 (2H, m, H7-8), 4.10 (2H, d, J = 6 Hz, H9), 2.04 (2H, q, 
J =6.7 Hz, H6), 1.34 (8H, m, H2-5), 0.89 (3H, t, J = 6.8 Hz, H1). 
δC /ppm (100 MHz; CDCl3) 133.6 (C=C), 128.7 (C=C), 63.8 (CH2-O), 32.2 (CH2), 30.8 
(CH2), 29.1 (CH2), 29.0 (CH2), 22.6 (CH3), 14.2 (CH3).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
υmax/cm-1 (neat) 3321, 2956, 2924, 2855, 1671, 1458, 1378, 1089, 1003, 723. 
(E)-Dec-2-en-1-ol (8b) 
 
(E)-Dec-2-en-1-ol (8b) was prepared using general procedure 3 using 7b (12.5 mmol, 
2.491 g, 1 eq.) in dry THF (60 mL) at -4 °C, under argon and DIBAL-H (15 mmol, 15 
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mL, 1.2 eq.). The target compound 8b was isolated as a yellow oil in 84% yield. Rf = 0.3 
(petroleum ether 9.5:0.5 ethyl acetate).  
δH /ppm (400 MHz; CDCl3) 5.66 (2H, m, H8-9), 4.08 (2H, d, J = 6.8 Hz, H10), 2.04 (2H, 
q, J = 6.8 Hz, H7), 1.26 (10H, m, H2-6), 0.88 (3H, t, J = 6.8 Hz, H1). 
δC /ppm (100 MHz; CDCl3) 133.5 (C=C), 128.8 (C=C), 63.8 (CH2-O), 32.2 (CH2), 31.8 
(CH2), 29.2 (CH2), 29.1 (CH2), 27.4 (CH2), 22.6 (CH3), 14.1 (CH3). 
υmax/cm-1 (neat) 1738, 1457, 1377, 1217, 1089, 1001, 968, 722. 
 
(E)-Undec-2-en-1-ol (8c) 
 
(E)-undec-2-en-1-ol (8c) was prepared using general procedure 3 using 7c (9.5 mmol, 2 
g, 1 eq.) in dry THF (60 mL) and DIBAL-H (11.4 mmol, 11.4 mL, 1.2 eq.) at -4 °C. The 
target compound 8c was isolated as a yellow oil in 85% yield. Rf = 0.34 (petroleum ether 
9:1 ethyl acetate).  
δH /ppm (400 MHz; CDCl3) δ ppm: 566 (2H, m, H9-10), 4.12 (2H, d, J = 6 Hz, H11), 2.03 
(2H, q, J = 6.4 Hz, H8), 1.43 (12H, m, H2-7), 0.88 (3H, t, J = 6.8 Hz, H1). 
δC /ppm (100 MHz; CDCl3) δ ppm: 133.6 (C=C), 128.8 (C=C), 63.9 8 (CH2-O), 32.2 
(CH2), 31.9 (CH2), 29.5 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 22.7 (CH3), 14.1 
(CH3). 
υmax/cm-1 (neat) 3500, 2924, 2854, 1654, 1463, 1368, 1266, 969, 722. 
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6.1.3.3 General procedure 4: Oxidation 
 
To a solution of appropriate alcohol 8a-c (1 eq.) in dry CH2Cl2 at 0 °C under argon was 
added a solution of Dess-Martin periodinane (1.1 eq.) in CH2Cl2 also at 0 °C. The reaction 
was warmed to RT and left stirring for 2 hours before being quenched using 1M NaOH 
solution. The reaction mixture was transferred to a separating funnel and diluted with 
diethyl ether (30 mL). The organic layer was collected and the aqueous layer extracted 
two more times. The organic layers were combined and dried over anhydrous magnesium 
sulfate. The volatiles were evaporated under vacuum using a rotary evaporator. The 
product was used without further purification. 
(E)-Non-2-enal (9a) 
 
(E)-Non-2-enal (9a) was prepared using general procedure 4 using 8a (4.93 mmol, 0.7 
g, 1 eq.) in dry CH2Cl2 (15 mL) and Dess-Martin periodinane (5.92 mmol, 2.5 g, 1.2 eq.) 
in CH2Cl2 (15 mL). The target compound 9a was isolated as a yellow oil and was used 
without further purification in 91 % yield Rf = 0.47 (petroleum ether 9.5:0.5 ethyl acetate).  
δH /ppm 1H NMR (400 MHz; CDCl3) 9.50 (1H, d, J = 8 Hz, H9), 6.86 (1H, dt, J = 15.6, 
6.8 Hz, H7), 6.09-6.15 (1H, m, H8), 2.35 (2H, m, H6), 1.39 (8H, m, H2-5), 0.89 (3H, t, J = 
6.8 Hz, H1). 
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(E)-Dec-2-enal (9b) 
 
(E)-Dec-2-enal (9b) was prepared using general procedure 4 using 8b (10 mmol, 1.65 g, 
1 eq.) in dry CH2Cl2 (20 mL) and Dess-Martin periodinane (11.6 mmol, 5 g, 1.1 eq.) in 
CH2Cl2 (20 mL). The target compound 9b was isolated as a yellow oil and was used 
without further purification in 94 % yield Rf = 0.5 (petroleum ether 9.5:0.5 ethyl acetate).  
δH /ppm (400 MHz; CDCl3) 9.4  (1H, d, J = 8 Hz, H10), 6.79 (1H, dt, J = 15.6, 6.8 Hz, 
H8), 6.02-6.08 (1 H, m, H9), 2.10-2.28 (2H, m,  H7), 1.21 (10H, m, H2-6), 0.81 (3H, t, J = 
7.2 Hz, H1). 
(E)-Undec-2-enal (9c) 
 
(E)-Undec-2-enal (9c) was prepared using general procedure 4 using 8c (5.9 mmol, 1 g, 
1 eq.) in dry CH2Cl2 (25 mL) and Dess-Martin periodinane (7.14 mmol, 3.1 g, 1.2 eq.) in 
CH2Cl2 (20 mL). The target compound 9c was isolated as a yellow oil and was used 
without further purification in 90 % yield Rf = 0.55 (petroleum ether 9.5:0.5 ethyl acetate).  
δH /ppm (400 MHz; CDCl3) 9.51 (1H, d, J = 7.6 Hz, H11), 6.86 (1H, dt, J = 15.6, 6.8 Hz, 
H10), 6.09-6.15 (1 H, m, H9), 2.31-2.37 (2H, m, H7), 1.36 (8H, m, H2-7), 0.89 (3H, t, J = 
6.4 Hz, H1). 
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6.1.3.4 General procedure 5: Wittig  
 
 
To a solution of appropriate aldehydes 9a-c (1 eq.) in CH2Cl2 at 0 °C under argon was 
added a solution of (arbethoxyethylidene)triphenylphosphorane (1.2 eq.) in CH2Cl2also 
at 0 °C. The reaction mixture was left stirring at room temperature for 6 hours before 
being quenched with ammonium chloride (20 mL). The reaction mixture was transferred 
to a separating funnel and diluted with diethyl ether (25 mL). The organic layer was 
collected and the aqueous layer extracted two more times. The organic layers were 
combined and dried over anhydrous magnesium sulfate. The volatiles were evaporated 
under vacuum using a rotary evaporator. The crude mixture was purified by flash 
chromatography using petroleum ether 9:1 ethyl acetate. 
Ethyl (2E,4E)- 2-methylundeca-2,4-dienoate (10a) 
 
Ethyl (2E, 4E)-2-methylundeca-2,4-dienoate (10a) was prepared using general 
procedure 5 using 9a (4.23 mmol, 0.6 g, 1 eq.) in CH2Cl2 (15 mL) and 
(carbethoxyethylidene)triphenylphosphorane (5.07 mmol, 1.8 g, 1.2 eq.) in CH2Cl2 (10 
mL). The target compound 10a was isolated as a yellow oil 72% yield, Rf = 0.6 (petroleum 
ether 9:1 ethyl acetate).  
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δH /ppm (400 MHz; CDCl3) 7.09 (1H, d, J = 11.6 Hz, H9), 6.26 (1H, m, H8), 6.02 (1H, 
quin, J = 7.3 Hz, H7), 4.13 (2H, q, J = 7.2 Hz, H11), 2.12 (2H, q, J = 7.2 Hz, H6), 1.86 
(3H, s, H10), 1.28 (11H, m, H2-5, 12), 0.81 (3H, t, J = 7.2 Hz, H1).  
δC /ppm (100 MHz; CDCl3) 167.8 (C=O), 143.3 (C=C), 138.6 (C=C), 125.9 (C=C), 122.0 
(C-CO), 60.4 (CH2-O), 33.3 (CH2), 31.9 (CH2), 29.7 (CH2), 29.4 (CH2), 22.7 (CH2), 14.3 
(CH2), 14.1 (CH3), 12.6 (CH3). 
υmax/cm-1 (neat) 2957, 2927, 2857, 1703, 1640, 1464, 1367, 1287, 1163, 1101, 970. 
Ethyl (2E,4E)-2-methyldodeca-2,4-dienoate (10b) 
 
Ethyl (2E,4E)-2-methyldodeca-2,4-dienoate (10b) was prepared using general 
procedure 5 using 9b (2.88 mmol, 450 mg, 1 eq.) in CH2Cl2 (30 mL) and 
(carbethoxyethylidene)triphenylphosphorane (5.75 mmol, 2 g, 2 eq.) in CH2Cl2 (20 mL). 
The target compound 14b was isolated as a yellow oil in 81% yield, Rf = 0.68 (petroleum 
ether 9:1 ethyl acetate).  
 δH /ppm (400 MHz; CDCl3) 7.08 (1H, d, J = 11.6 Hz, H10), 6.34 (1H, m, H9), 6.06 (1H, 
quin, J = 7.2 Hz, H8), 4.12 (2H, q, J = 7.2 Hz, H12), 2.11 (2H, q, J = 7.2 Hz, H7), 1.9 (3H, 
s, H11), 1.22 (13H, m, H2-6, 13), 0.85 (3H, t, J = 6.8 Hz, H1). 
δC /ppm (100 MHz; CDCl3): 166.3 (C=O), 144.1 (C=C), 143.8 (C=C), 127.3 (C=C), 
124.9 (C-CO), 59.1 (CH2-O), 31.9 (CH2), 30.8 (CH2), 28.7 (CH2), 28.1 (CH2), 28.0 (CH2), 
27.7 (CH2), 21.6 (CH2), 13.3 (CH3), 13.1 (CH3). 
υmax/cm-1 (neat) 2956, 2926, 2855, 1704, 1639, 1464, 1367, 1229, 1176, 1101, 748. 
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ethyl (2E,4E)-2-methyltrideca-2,4-dienoate (10c) 
 
ethyl (2E,4E)-2-methyltrideca-2,4-dienoate(10c) was prepared using general procedure 
5 using 9c (4.3 mmol, 0.72 g, 1 eq.) in CH2Cl2 (10 mL) and 
(carbethoxyethylidene)triphenylphosphorane (5.14 mmol, 1.86 g, 1.2 eq.) in CH2Cl2 (15 
mL). The target compound 10c was isolated as a yellow oil in 75% yield, Rf = 0.71 
(petroleum ether 9:1 ethyl acetate).  
δH /ppm (400 MHz; CDCl3) 7.01 (1H, d, J = 11.2 Hz, H11), 6.32 (1H, m, H10), 6.01 (1H, 
quin, J = 7.2 Hz, H9), 4.03 (2H, q, J = 7.2 Hz, H13), 2.68 (2H, q, J = 7.2 Hz, H8), 1.77 
(3H, s, H12), 1.24 (15H, m, H2-7, H14), 0.74 (3H, t, J = 7.2 Hz, H1). 
δC /ppm (100 MHz; CDCl3) 165.3 (C=O), 143.9 (C=C), 139.1 (C=C), 128.7 (C=C), 
126.9 (C-CO), 60.8 (CH2-O), 33.8 (CH2), 33.5 (CH2), 30.5 (CH2), 30.1 (CH2), 30.0 (CH2), 
29.9 (CH2), 29.7 (CH2), 23.3 (CH2), 14.4 (CH3), 12.7 (CH3). 
υmax/cm-1 (neat) 2924, 2854, 1705, 1640, 1463, 1367, 1232, 1174, 1103, 1032, 970, 748. 
6.1.3.5 General procedure 6 Hydrolysis 
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To a stirring solution of LiOH cooled in ice-cold water was added a solution of the 
appropriate ester 10a-c in MeOH and THF, also at 0 °C. The reaction mixture was 
warmed to RT and stirred for 16 hours. The reaction was then cooled to 0 °C and ice cold 
HCl (1M) added slowly to the rapidly stirring solution until pH 1. The reaction mixture 
was transferred to a separating funnel and diluted with diethyl ether (20 mL). The organic 
layer was collected and the aqueous layer extracted two more times. The organic layers 
were combined and dried over anhydrous magnesium sulfate. The volatiles were 
evaporated under vacuum using a rotary evaporator.  
(2E,4E)-2-Methylundeca-2,4-dienoic acid (11a) 
 
(2E,4E)-2-Methylundeca-2,4-dienoic acid (11a) was prepared using general procedure 
6 using 10a (14.4 mmol, 345 mg, 1 eq.) in MeOH (2 mL) and THF (2 mL), LiOH (14.4 
mmol, 345 mg, 15 eq.) in ice-cold water (5 mL). The target compound 11a was isolated 
as white crystals and used without further purification in 70% yield.  
δH /ppm (400 MHz; CDCl3) 11.03 (1H, s, H11), 7.22 (1H, d, J = 12.4 Hz, H9), 6.28 (1H, 
m, H8), 6.05 (1H, quin, J = 7.2 Hz, H7), 2.13 (2H, q, J = 7.2 Hz, H6), 1.85 (3H, s, H10), 
1.26  (8H, m, H2-5), 0.80 (3H, t, J = 7.2 Hz, H1). 
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(2E,4E)-2-Methyldodeca-2,4-dienoic acid (11b) 
 
(2E,4E)-2-methyldodeca-2,4-dienoic acid (11b) was prepared using general procedure 
6 using 10b (4.18 mmol, 1 g, 1 eq.) in MeOH (5 mL) and THF (5 mL), LiOH (63 mmol, 
1.5 g, 15 eq.) in ice-cold water (3 mL)   The target compound 11b was isolated as a yellow 
solid and was used without further purification in 80% yield.  
δH /ppm (400 MHz; CDCl3) 12.32 (1H, s, H12), 7.07 (1H, d, J = 11.2 Hz, H10), 6.39 (1H, 
q, J = 7.2 Hz, H9), 6.12 (1H, q, J = 7.2 Hz, H8), 2.17(2H, q, J = 7.2 Hz, H7), 1.83 (3H, s, 
H11), 1.22 (10H, m, H2-6), 0.86 (3H, t, J = 7.2 Hz, H1). 
(2E,4E)-2-Methyltrideca-2,4-dienoic acid (11c) 
 
(2E,4E)-2-Methyltrideca-2,4-dienoic acid (11c) was prepared using general procedure 
6 using 10c (0.95 mmol, 225 mg, 1 eq.) in MeOH (2 mL) and THF (2 mL), LiOH (14.2 
mmol, 342 mg, 15 eq.) in ice-cold water (4 mL).  The target compound 11c was isolated 
as a yellow solid and was used without further purification in 89% yield.  
 
δH /ppm (400 MHz; CDCl3) 11.83 (1H, s, H13), 7.19 (1H, d, J = 13.6 Hz, H11), 6.28 (1H, 
m, H10), 6.06 (1H, q, J = 7.2 Hz, H9), 2.12 (2H, q, J = 7.4 Hz, H8), 1.76 (3H, s, H12), 1.28 
(12H, m, H2-7), 0.81 (3H, t, J = 7.2 Hz, H1). 
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6.1.3.6 General procedure 7: Amide Coupling 
To a solution of the appropriate acid 11a-c, in dry DMF, was added HATU and the 
resulting solution was stirred for 10 minutes at room temperature under argon. O-Benzyl-
L-tyrosine was added and the resulting solution was stirred for 20 minutes before DIEA 
was added. The reaction mixture was stirred at room temperature for 16 hours. The 
solvent was removed in vacuo and the crude mixture was purified by flash column 
chromatography using as the eluent petroleum ether 8.5:1.5 ethyl acetate. 
3-[4-(benzyloxy)phenyl]-2-[(2E,4E)-2-methylundeca-2,4-dienamido]propanoic acid 
(12a) 
 
3-[4-(benzyloxy)phenyl]-2-[(2E,4E)-2-methylundeca-2,4-dienamido]propanoic acid 
(12a) was prepared using general procedure 7 using 11a (1.12 mmol, 220 mg, 1 eq.), 
HATU (1.2 mmol, 420 mg, 1.1 eq.), DIEA (3.36 mmol, 1 mL, 3 eq.) and O-Benzyl-L-
Tyrosine (1.34 mmol, 498 mg, 1.2 eq.). The target compound 12a was isolated as a sticky, 
yellow oil in 80% yield.  
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δC /ppm (400 MHz; MeOD) 7.23 (5H, m, H1-5, 14), 7.01 (2H, d, J = 8.8 Hz, H7-8), 6.76 
(2H, d, J = 8.8 Hz, H9-10), 6.64 (1H, d, J = 10.8 Hz, H16), 6.23 (1H, m, H17), 5.87 (1H, m, 
H18),  4.89 (2H, s, H6), 4.48 (1H, m, H12), 3.00 (2H, m, H11), 2.05 (2H, q, J = 7.2 Hz, H19), 
1.73 (3H, s, H15),  1.21 (8H, m, H20-23), 0.79 (3H, t, J = 7.2 Hz, H24). 
δC /ppm (100 MHz; MeOD) 171.4 (C-OOH), 159.0 (C-Ar), 142.8 (C=C), 138.9 (C-Ar), 
135.6(C=C), 131.6 (C-Ar), 131.5(C-Ar), 129.5 (C-Ar), 129.0(C-Ar), 128.8 (C-Ar), 128.6 
(C-Ar), 127.0 (C=C), 115.7 (C-Ar), 71.0 (OCH2-Ar), 57.0 (CH-NH), 37.8 (CHCH2-Ar), 
34.2 (CH2), 32.9 (CH2), 30.2 (CH2), 30.0 (CH2), 23.7 (CH2), 14.5 (CH3), 12.9 (CH3). 
υmax/cm-1 (neat) 3424, 2929, 2858, 1660, 1510, 1439, 1386, 1255, 1092, 1063, 841. 
LRMS (ES+) calculated for C28H35NO4 [M+H]
 +: 450.3, found: 450.2. 
3-[4-(benzyloxy)phenyl]-2-[(2E,4E)-2-methyldodeca-2,4-dienamido]propanoic acid 
(12b) 
 
3-[4-(benzyloxy)phenyl]-2-[(2E,4E)-2-methyldodeca-2,4-dienamido]propanoic acid 
(12b) was prepared using general procedure 7 using 11b (0.63 mmol, 132 mg ,1 eq.), 
HATU (0.69 mmol, 242 mg, 1.1 eq.), DIEA (1.89 mmol, 0.6 mL, 3 eq.), O-Benzyl-L-
Tyrosine (0.76 mmol, 283 mg, 1.2 eq.) and dry DMF (5 mL). The target compound 12b 
was isolated as a sticky, yellow oil in 85% yield.  
δH /ppm (400 MHz; CD3CN) 7.31 (5H, m, H1-5), 7.07 (2H, d, J = 8.4 Hz, H7-8), 6.83 (2H, 
d, J = 8.4 Hz, H9-10), 6.65 (1H, d, J = 11.2 Hz, H16), 6.55 (1H, d, J = 7.6 Hz, H14), 6.29 
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(1H, m, H17), 5.95 (1H, m, H18),  4.97 (2H, s, H6), 4.50 (1H, m, H12), 3.00 (2H, m, H11), 
2.08 (2H, q, J = 7.6 Hz, H19), 1.73 (3H, s, H15),  1.25 (10H, m, H20-24), 0.79 (3H, t, J = 
7.2 Hz, H25). 
δC /ppm (100 MHz; CD3CN); CD3CN 172.0 (C-OOH), 168.9 (C=O), 157.3 (C-Ar), 141.6 
(C-Ar), 137.1 (C-Ar), 134.0 (C=C), 130.0 (C-Ar), 129.2 (C-Ar), 128.1 (C-Ar), 127.5 (C-
Ar), 127.3 (C-Ar), 127.2 (C-Ar), 125.3(C=C), 117.0 (C-Ar), 114.3 (C-Ar), 69.2 (OCH2-
Ar) , 53.9 O (CH-NH), 35.3 (CH2), 32.4 (CH2), 31.2 (CH2), 29.0 (CH2), 28.5 (CH2), 28.5 
(CH2), 22.0 (CH2), 3.1(CH3), 11.6 (CH3). 
υmax/cm-1 (neat) 3484, 2929, 2859, 1657, 1505, 1386, 1256, 1091, 1063, 843. 
LRMS (ES+) calculated for C29H37NO4 [M+H]
 +: 463.6, found: 464.2. 
3-[4-(benzyloxy)phenyl]-2-[(2E,4E)-2-methyltrideca-2,4-dienamido]propanoic acid 
(12c) 
 
3-[4-(benzyloxy)phenyl]-2-[(2E,4E)-2-methyltrideca-2,4-dienamido]propanoic acid 
(12c) was prepared using general procedure 7 using 11c (0.7 mmol, 147 mg, 1 eq.), 
HATU (0.72 mmol, 252 mg, 1.1 eq.), DIEA (2.1 mmol, 0.6 mL, 3 eq.), O-Benzyl-L-
Tyrosine (0.84 mmol, 313 mg, 1.2 eq.) and dry DMF (5 mL) . The target compound 12c 
was isolated as a sticky, yellow oil in 72% yield. 
δH /ppm (400 MHz;) MeOD) 7.25(5H, m, H1-5), 7.00 (2H, d, J = 8.8 Hz, H7-8), 6.76 (2H, 
d, J = 8.8 Hz, H9-10), 6.64 (1H, d, J = 10.8 Hz, H16), 6.22 (1H, m, H17), 5.86 (1H, m, H18),  
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4.91 (2H, s, H6), 4.41 (1H, m, H12), 3.07  (2H, m, H11), 2.07 (2H, q, J = 6.8 Hz, H19), 1.74 
(3H, s, H15),  1.16 (12H, m, H20-25), 0.79 (3H, t, J = 6.8 Hz, H26). 
υmax/cm-1 (neat) 3329, 2925, 2855, 2487, 1609, 1512, 1381, 1240, 1177, 1026, 975. 
LRMS (ES+) calculated for C30H39NO4 [M+H]
 +: 478.3, found: 478.2. 
6.1.3.7 General procedure 8: Debenzylation using boron trichloride 
To a solution of (E)-3-(4-(benzyloxy) phenyl)-2-(2-methylundec-3-enamido) propanoic 
acid (12a) (1 eq.) in dry CH2Cl2 at -15 °C was added boron trichloride methyl sulfide 
complex (2 M in CH2Cl2, 8 eq.), dropwise. The reaction was warmed to room temperature 
and left stirring overnight. The reaction mixture was quenched with CH2Cl2/MeOH 
mixture and the solvent evaporated in vacuo.  
methyl [(2E,4E)-2-methylundeca-2,4-dienoyl]tyrosinate (14a) 
 
methyl [(2E,4E)-2-methylundeca-2,4-dienoyl]tyrosinate (14a) was synthesised 
according to general procedure 8 using 12a (0.222 mmol, 100 mg, 1 eq.), boron trichloride 
methyl sulfide complex (1.776 mmol, 0.888 mL, 8 eq.). The product was purified using 
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purified using petroleum ether 4: 6 ethyl acetate and the target compound 14a was isolated 
as a yellow oil in 80% yield. Rf = 0.54 (petroleum ether 4:6 ethyl acetate). 
δH /ppm (400 MHz; (CD3)2CO) 7.13 (1H, d, J = 8.8 Hz, H9), 7.08 (2H, d, J = 8.8 Hz, H4-
5), 6.83 (1H, d, J = 11.2 Hz, H11), (6.76 (2H, d, J = 8.8 Hz, H2-3), 6.39 (1H, m, H12) 5.99 
(1H, quin, J = 7.2 Hz, H13), 4.68 (1H, m, H8), 3.68 (3H, s, H7), 3.02 (2H, m, H6), 2.09 
(2H, m , H14), 1.86 (3H, s, H10),  1.36 (12H, m, H15-18), 0.88 (3H, t, J = 6.8 Hz, H19). 
δC /ppm (100 MHz; CD3CN) 173.1 (C-OOMe), 169.3 (C=O), 157.2 (C-Ar), 141.2 (C=C), 
134.5 (C=C), 131.1 (C-Ar), 129.1 (C-Ar), 128.8 (C-Ar), 126.8 (C=C), 116.1 (C-Ar), 53.9 
(CH-NH), 51.4 (O-CH3), 35.8 (CHCH2-Ar), 32.4 (CH2), 31.1 (CH2), 28.4 (CH2), 28.3 
(CH2), 23.3 (CH2), 14.4 (CH3), 12.9 (CH3). 
υmax/cm-1 3324, 2956, 2925, 2855, 1740, 1651, 1615, 1595, 1515, 1445, 1364, 1260, 1216, 
1173, 1087, 1087, 1020, 971, 801, 751. 
HRMS (ES+) calculated for C22H31NO4 [M+H]
 +: 374.2331, found: 374.2340. 
methyl [(2E,4E)-2-methyldodeca-2,4-dienoyl]-L-tyrosinate (14b) 
 
methyl [(2E,4E)-2-methyldodeca-2,4-dienoyl]-L-tyrosinate (14b) was synthesised 
according to general procedure 8 using 12b (0.323 mmol, 150 mg, 1 eq.), boron 
trichloride methyl sulfide complex (2.584mmol, 1.292 mL, 8 eq.). The product was 
purified using petroleum ether 3:7 ethyl acetate and the target compound 14b was isolated 
as a yellow oil in 79% yield. Rf = 0.46 (petroleum ether 4: 6 ethyl acetate). 
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δH /ppm (400 MHz; CDCl3) 6.94 (2H, d, J = 8.4 Hz, H4-5), 6.63 (3H, m, H2-3, 11), 6.28(2H, 
m, H12), 5.93 (1H,quin, J = 7.6 Hz, H13), 4.54 (1H, m, H8), 3.62 (3H, s, H7), 2.91 (2H, m, 
H6), 2.09 (2H, q, J = 7.2 Hz, H14), 1.85 (3H, s, H10),  1.30 (10H, m, H15-19), 0.90 (3H, t, J 
= 7.2 Hz, H20). 
δC /ppm (100 MHz; CDCl3) 174.9 (C-OOMe), 172.2 (C=O), 157.4 (C-Ar), 143.0 (C=C), 
135.9 (C=C), 131.2 (C-Ar), 129 (C-Ar), 129.0 (C-Ar), 128.7 (C-Ar), 126.9 (C=C), 116.3 
(C-Ar), 55.9 (CH-NH), 52.7 (O-CH3), 37.3 (CHCH2-Ar), 33.0 (CH2), 30.3 (CH2), 30.3 
(CH2), 30.2 (CH2), 23.7 (CH2), 14.5 (CH3), 12.7 (CH3). 
υmax/ cm-1 (CH3Cl film) 3302, 3028, 2954, 2925, 2855, 1740, 1647, 1615, 1514, 1445, 
1365, 1222, 1106, 1085, 971. 
HRMS (ES+) calculated for C23H33NO4 [M+H]
 +:388.2488, found: 388.2499. 
Methyl [(2E,4E)-2-methyltrideca-2,4-dienoyl] tyrosinate (14c) 
 
Methyl [(2E,4E)-2-methyltrideca-2,4-dienoyl] tyrosinate (14c) was synthesised 
according to general procedure 8 using 12c (0.167 mmol, 80 mg, 1 eq.), boron trichloride 
methyl sulfide complex (1.336 mmol, 0.668 mL, 8 eq.). The product was purified using 
petroleum ether 3: 7 ethyl acetate. The target compound 14c was isolated as a yellow oil 
in 72% yield. Rf = 0.35 (petroleum ether 6: 4 ethyl acetate). 
δH /ppm (400 MHz; CD3CN) 7.18 (1H, s, H1),  7.05 (2H, d, J =7.6 Hz, H4-5), 6.76 (3H, 
m, H2-3, 11), 6.68 (1H, d, J = 7.6 Hz, H9), 6.38 (2H, m, H12), 6.06 (1H, quin, J = 7.6 Hz, 
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H13), 4.64 (1H, m, H8), 3.68 (3H, s, H7), 3.02 (2H, m, H6), 2.13 (2H, q, J = 7.2 Hz, H14), 
1.86 (3H, s, H10),  1.37 (12H, m, H15-20), 0.91 (3H, t, J = 7.2 Hz, H21). 
δC /ppm (100 MHz; CD3CN) 171.9 (C-OOMe), 168.4 (C=O), 155.5 (C-Ar), 141.4 (C=C), 
133.7 (C=C), 129.9 (C-Ar), 127.7 (C-Ar), 127.3 (C=C), 125.3 (C-Ar), 114.8 (C-Ar), 53.9 
(CH-NH), 51.4 (O-CH3), 35.9 (CHCH2-Ar), 32.4 (CH2), 31.3 (CH2), 28.8 (CH2), 28.7 
(CH2), 28.6 (CH2), 28.4 (CH2), 22.1 (CH2), 13.1 (CH3), 11.7 (CH3). 
υmax/cm-1 (CH3Cl film) 3306, 2955, 2926, 2856, 1740, 1648, 1615, 1595, 1515, 1445, 
1366, 1261, 1216, 1086, 1023, 803, 750. 
HRMS (ES+) calculated for C24H35NO4 [M+H]
 +: 402.2644, found: 402.2631. 
6.1.3.8 General procedure 9: Debenzylation using boron trichloride 
 
To a solution of (E)-3-(4-(benzyloxy) phenyl)-2-(2-methylundec-3-enamido) propanoic 
acid (12a) (1 eq.) in dry CH2Cl2 at -15 °C was added boron trichloride methyl sulfide 
complex (2 M in CH2Cl2, 8 eq.), dropwise. The reaction was warmed to room temperature 
and left stirring overnight. The reaction mixture was quenched with water. The mixture 
was transferred to a separating funnel and diluted with dichloromethane. The organic 
layer was collected and the aqueous layer extracted three times using dichloromethane. 
The organic layers were combined and dried over magnesium sulfate. The volatiles were 
evaporated under vacuum using a rotary evaporator.   
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Methyl [(2E,4E)-2-methylundeca-2,4-dienoyl]tyrosinate (13a) 
 
Methyl [(2E,4E)-2-methylundeca-2,4-dienoyl]tyrosinate (13a) was synthesised 
according to general procedure 9 using 12a (0.222 mmol, 100 mg, 1 eq.), boron trichloride 
methyl sulfide complex (1.776 mmol, 0.888 mL, 8 eq.). The product was purified using 
10% MeOH in CH2Cl2 and the target compound 13a was isolated as a yellow oil.  
δH /ppm (400 MHz; MeOD) 6.91 (2H, d, J =8 Hz, H4-5), 6.67 (2H, d, J =11.2 Hz, H11), 
6.56 (1H, d, J =8 Hz, H2-3), 6.24 (1H, m, H12), 5.90 (1H, m, H13), 4.39 (1H, s, H8), 2.87 
(2H, m, H6), 2.09 (2H, q, J = 7.2 Hz, H14), 1.76 (3H, s, H10),  1.27 (8H, m, H15-18), 0.79 
(3H, t, H19). 
υmax/cm-1 3290, 3015, 2956, 2925, 2854, 1707, 1614, 1591, 1514, 1446, 1386, 1234, 1106, 
969, 806, 753. 
HRMS (ES+) calculated for C21H29NO4 [M+H]
 +: 360.2175, found: 360.2186. 
[(2E,4E)-2-methyldodeca-2,4-dienoyl]tyrosine (13b) 
 
[(2E,4E)-2-methyldodeca-2,4-dienoyl]tyrosine (13b) was synthesised according to 
general procedure 9 using 12b (0.323 mmol, 150 mg, 1 eq.), boron trichloride methyl 
sulfide complex (2.584 mmol, 1.292 mL, 8 eq.). The product was purified using purified 
using 10% MeOH in CH2Cl2 and the target compound 13b was isolated as a yellow oil. 
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δH /ppm (400 MHz; MeOD) 6.94 (2H, m, H4-5), 6.61 (2H, m, H11, 2-3), 6.26 (1H, m, H12), 
5.92 (1H, m, H13), 4.54 (1H, m, H8), 2.98 (2H, m, H6), 2.10 (2H, m H14), 1.76 (3H, s, 
H10),  1.20 (H15-19), 0.80 (3H, t, H20). 
υmax/cm-1 3336, 2970, 2927, 2858, 1595, 1516, 1466, 1380, 1303, 1261, 1161, 1128, 1106, 
1026, 816. 
HRMS (ES+) calculated for C22H31NO4 [M+H]
 +: 374.2331, found: 374.2338. 
[(2E,4E)-2-methyltrideca-2,4-dienoyl]tyrosine (13c) 
 
[(2E, 4E)-2-methyltrideca-2, 4-dienoyl]tyrosine (13c) was synthesised according to 
general procedure 9 using 12c (0.167 mmol, 80 mg, 1 eq.), boron trichloride methyl 
sulfide complex (1.336 mmol, 0.668 mL, 8 eq.). The product was purified using 10% 
MeOH in CH2Cl2 and the target compound 13c was isolated as a yellow oil. 
δH /ppm (400 MHz; MeOD) 6.90 (2H, d, J =12 Hz, H4-5), 6.67 (2H, d, J =12 Hz, H11), 
6.55 (2H, d, J =8.4 Hz, H2-3), 6.26 (1H, m, H12), 5.89 (1H, m, H13), 4.41 (1H, s-broad, 
H8), 2.97 (2H, m, H6), 2.09 (2H, q, J = 7.2 Hz, H14), 1.76 (3H, s, H10),  1.27 (broad), 0.77-
0.82 (3H, t, H21). 
υmax/cm-1 3336, 2970, 2929, 1595, 1466, 1379, 1305, 1161, 1128, 1107, 817. 
HRMS (ES+) calculated for C23H33NO4 [M+H]
 +: 388.2488, found: 388.2491.  
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6.1.4 Attempted amide coupling 
 
Amide coupling was attempted using the following procedures.  
Entry Coupling 
reagent 
Additive Base Reaction 
 time 
Temp  
1 Oxalyl 
chloride 
DMF 
No DMF 
Et3N 6 – 24 h RT, 50 ° C, 
70 ° C 
2 EDC HOBt 
No HOBt 
DMAP 
DIEA 
12 – 24 h RT 
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6.1.5 Attempted Debenzylation 
6.1.5.1 Debenzylation using H2  
 
A mixture of methyl 2-((E)-2-methyldec-2-enamido)-3-(4-(benzyloxy) phenyl) 
propanoate (4) (0.45 mmol, 200 mg, 1 eq.), triethylamine, Pd/C (20 mg) and methanol (3 
mL) was stirred under hydrogen atmosphere (balloon) at room temperature. The desired 
product was not formed.  
6.1.5.2 Debenzylation using Et3SiH 
 
A solution of Pd (OAc) 2 (0.048 mmol, 1.07 mg, 0.04 eq.), Et3SiH (0.16 mmol, 0.03 mL, 
1.4 eq.) and Et3N (0.02 mmol, 0.02 mL, 0.14 eq.) in anhydrous CH2Cl2 (4 mL) was stirred 
at room temperature under argon for 15 minutes. A solution of 4 (0.12 mmol, 50 mg, 1 
eq.) in CH2Cl2 (2 mL) also under argon was added dropwise. The resulting mixture was 
stirred at room temperature under argon overnight before quenching using ammonium 
chloride (15 mL). The aqueous layer was extracted with CH2Cl22 (2 x 10 mL) and the 
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combined organic extracts were washed with brine (15 mL), dried under magnesium 
sulfate and the volatiles removed in vacuo. No product was formed.
 
6.2 Part B: Cytotoxicity assays using MTT and Alamar blue 
6.2.1 Materials and instrumentation 
The A549 cell line was obtained from the lab stock. Dulbecco’s modified Eagles medium, 
foetal bovine serum (FBS), 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT), resazurin sodium salt (Alamar Blue® (AB)) were purchased from Sigma 
Aldrich. All consumables were purchased from VWR. Cell counting was performed using 
a Beckmann Counter. Absorbance was measured using TECAN GENios multi plate 
reader.  
6.2.1.1 Preparation of PBS solution  
PBS solution was prepared by dissolving potassium phosphate monobasic (1.065 g, 7.5 
mmol), sodium phosphate monobasic dihydrate (0.389 g, 2.5 mmol) and sodium chloride 
(8.498 g, 145 mmol) in ultra-pure water. The solution was made up to the mark using 
ultra-pure water and autoclaved for 20 minutes @ 121.5 °C and 15 psi. 
6.2.1.2 Preparation of PBS-EDTA solution  
PBS-EDTA solution was prepared by adding ethylenediaminetetraacetic acid (0.1 g, 0.34 
mmol) to 500 mL of PBS solution prepared in section 7.1.6.1. The solution was 
autoclaved for 20 minutes @ 121.5 °C and 15 psi. 
6.2.2 Procedures  
Cells were maintained in Dulbecco’s modified Eagles’ media supplemented with FBS 
(10% v/v). Cells were sub cultured every 3-4 days. All cells were incubated at 37 °C in a 
Chapter 6   Experimental Procedures 
 
180 
 
humidified atmosphere with 5% CO2. Cells were harvested when they were in exponential 
or log phase. The cells were evaluated to ensure health and correct confluence by 
visualisation using a light microscope.  The cells were then trypsinised and suspended in 
fresh media. Working solutions were prepared before use by preparing a stock solution 
in DMSO and dilution of the stock using medium (maximum concentration of DMSO 
used was 1%). Control assays were carried out on all experiments with 100% media 
(positive control) and 10% v/v DMSO (negative control). Stock solutions of MTT and 
AB were prepared up to 6 hours in advance and stored in darkness for up to three days. 
Trypsin was prepared in advance and stored for up to two weeks at 4 °C. Working 
solutions for MTT and AB were made immediately before use by diluting the stock 
solution with appropriate medium. 
6.2.3 Procedure for trypsinising (splitting) cells 
The cells were visually assessed under a light microscope. Old media was decanted from 
the flask into a waste beaker. The flask was rinsed with PBS to remove any dead cells. 
To the flask was added trypsin-EDTA solution (3 mL) and the cells were incubated at 37 
°C for 5 -10 minutes. Trypsin-EDTA solution was prepared by asceptically adding 10 mL 
Vercene (EDTA) to an aliquot of trypsin (10 mL).  The cells were returned to the laminar 
hood and sterile media (15 mL) added to neutralise the trypsin. The cell suspension was 
asceptically decanted into sterilin (25 mL). To a new flask, was added fresh media (15 
mL). Cell suspension (500 μL) was added to the flask containing fresh media and the 
flask sealed. The cells were then incubated at 37 ° C in a humidified atmosphere with 5% 
CO2. The health of the cells was assessed every 24 hours and trypsinisation carried out 
every 3 – 4 days. Only cells showing normal health were used for experiments.  
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6.2.4 Cytotoxicity Assays 
6.2.4.1 Procedure for MTT assay 
Part A: All experiments were carried out in triplicate. Cell count was performed using a 
haemocytometer. Stock solutions of cell suspensions were prepared depending on the 
length of exposure as shown in Table 6.1 below.  
Exposure duration Cell suspension concentration 
24 h 1.2 × 105 
48 h 5 × 104 
72 h 3 × 104 
Table 6.1: Cell suspension concentrations for various exposure duration. 
The desired cells were seeded into 96-well microtitre plates with 100 µL of the 
appropriate cell concentration. The cells were incubated for 24 h in order to attach to the 
plate. Drug stock solutions were prepared in DMSO (1%). Final test concentrations were 
prepared by diluting the stock solution with medium. The cells were exposed to 5 drug 
concentrations, including a positive and negative control in 8 replicate wells per plate. 
Following exposure, the plates were incubated for the desired time; 24, 48 or 72 hours.  
Part B: The assay was terminated by discarding supernatant media and rinsing with 
sterile PBS. MTT stock solution was prepared by adding MTT (20 mg) to sterile PBS (10 
mL) followed by filter sterilisation. To each well, was added MTT (100 µL) (10% in 
unsupplemented fresh media) and the plates further incubated for 3 hours. During this 
time, viable cells absorbed and metabolised the MTT. After the three hours, the 
supernatant was removed and the cells washed with PBS to remove unmetabolised MTT. 
The remaining formazan was solubilised in DMSO (100 μL) and the plates shaken at 240 
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RPM for 10 minutes. The plates were placed in a plate reader and the absorbance of each 
solution read and recorded at 570nm. The percentage viability was calculated using 
corrected absorbance readings as follows: 
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 t𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
  × 100 
6.2.4.2 Procedure for AB assay 
Following part A from procedure for MTT assay, the assay was terminated by discarding 
supernatant media and rinsing with sterile PBS. AB stock solution was prepared by 
adding 0.5 mL sterile AB dye to 10 mL unsupplemented media. To each well, was added 
100 µL of the AB solution and the plates further incubated for 3 hours. The plates were 
placed in a plate reader and each solution read and recorded using 540 nm excitation and 
650 nm emission. The percentage viability was calculated using corrected absorbance 
readings as follows: 
% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 t𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
  × 100 
6.2.5 Preparation of cell suspensions and control and drug solutions 
6.2.5.1 Working cell suspensions 
Each cell suspension was diluted in supplemented media to give the appropriate cell 
density, dependent on period of exposure. The cell densities used were 1.2 x 105 cells/well 
for 24 h timepoint, 5 x 104 for 48 h timepoint and 3 x 104 for 72 h timepoint. 
6.2.5.2 Preparation of drug solutions (700 μM) 
Drug stock solutions were prepared in DMSO. All final drug solutions contained DMSO 
at a concentration no greater than 1%. The range of solutions were created by serial 
dilutions within the plates.  
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6.2.6 Plate seeding procedure 
a) 100 μL of the appropriate cell suspension was added to lanes 1 to 12 of each 
plate, with 8 replicates per lane. 
b) The plates were incubated at 37 °C in a humidified 5% CO2 atmosphere for 24 
hours to allow for attachment. 
c) After 24 h, the media was discarded and each well rinsed with 100 μL sterile PBS 
d) To lanes 1 - 11 of the plate was added 100 μL supplemented media 
e) To lane 12 was added 100 μL of 1% DMSO in supplemented media. 
f) To lane 11 was added 100μL of 350 μM drug solution, followed by serial 
dilutions to lanes 10 – 7. 
g) To lane 6 was added 100μL of 700 μM of a different drug solution, followed by 
serial dilutions to lanes 5 – 2. 
h) Contents of each well were mixed by carefully pipetting up and down gently up 
to three times. 
i) The plates were incubated at 37 °C in a humidified 5% CO2 atmosphere for the 
desired times (24, 48 or 72 hours). 
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Figure 6.1: 96-Well plate set up for MTT assay with suspension cells, A549. 2 
compounds at 5 drug concentrations were assessed per plate 
6.2.7 MTT Exposure and absorbance reading 
A stock solution of MTT in sterile PBS (10 mg/5 mL) was prepared and filter sterilised. 
MTT stock solution was diluted in unsupplemented media (10% v/v). Following exposure 
for the appropriate time, the test solutions were discarded from plates and each plate was 
rinsed with 100 μL sterile PBS. 100 μL of the MTT solution was added to each well and 
the plates were incubated at 37 ° C for 3 hours. The supernatant was carefully discarded 
and the plates rinsed with PBS. 100 μL DMSO was carefully added to each well and the 
plates shaken at 240 RPM for 10 minutes. The plates were placed in a plate reader and 
the absorbance of each solution read and recorded at 570 nm.  
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6.2.8 AB Exposure and absorbance reading 
A stock solution of AB in sterile unsupplemented medium (0.5 mL/10 mL) was prepared. 
Following exposure for the appropriate time, the test solutions were discarded from plates 
and each plate rinsed with 100 μL sterile PBS. 100 μL of the AB solution was added to 
each well and the plates were incubated at 37 ° C for 3 hours. The plates were placed in 
a plate reader and each solution read and recorded using 540 nm excitation and 650 nm 
emission.  
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6.3 Part C: ELISA Assay 
6.3.1 Materials and instrumentation 
A FIRELISA Human PLK-1 ELISA Kit Assay purchased from Medical Supply Co. Ltd 
was used. The A549 cell line used was obtained from the lab stock. Dulbecco’s modified 
Eagles medium, foetal bovine serum (FBS) were purchased from Sigma Aldrich. All 
consumables were purchased from VWR. Cell counting was performed using a 
Beckmann Counter. Absorbance was measured using TECAN GENios multi plate reader.  
6.3.2 Preparation of samples and standards 
6.3.2.1 Preparation of cell suspensions and seeding procedure 
Cell suspension was diluted in supplemented media to give the appropriate cell density. 
The cell densities used were 5 x 105 cells/well. The desired cells were seeded into 6-well 
microtitre plates with 2 mL of the appropriate cell concentration. The cells were incubated 
for 24 h in order to attach to the plate. Drug stock solutions were prepared in DMSO (1%). 
Final test concentrations were prepared by diluting the stock solution with medium. The 
cells were exposed to drug concentrations, including a positive control for 5 different time 
points. Following exposure, the plates were incubated for the desired times.  
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Figure 6.2: 6 well plate design for preparation of cell culture supernatant for ELISA 
assay. 
6.3.2.2 Plate seeding procedure 
a) 2 mL of the cell suspension was added to each well of each plate. 
b) The plates were incubated at 37 o C in a humidified 5% CO2 atmosphere for 24 
hours to allow for attachment. 
c) After 24 h, the media was discarded and each well rinsed with 2 mL sterile PBS 
d) To well  A1, A3, B1, B2, B3 of the plate was added 2 mL supplemented media 
e) To well A2 was added the appropriate drug solution in supplemented media and 
the plate incubated. 
f) After 12 hours, media was taken out of well A3 and replaced with the appropriate 
drug concentration 
g) After 2 hours, media was taken out of well B3 and replaced with the appropriate 
drug concentration 
h) After 2 hours, media was taken out of well B2 and replaced with the appropriate 
drug concentration 
i) After 1 hour, media was taken out of well B1 and replaced with the appropriate 
drug concentration 
j) After 1 hour, the plate was removed from the incubator and the media discarded 
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k) Each well was rinsed using sterile PBS and the cells trypsinised according to 
procedure 7.2.3. using 1 mL trypsin- EDTA and 5mL media. 
l) The supernatant was collected for lysis. 
6.3.2.3 Preparation of cell culture supernatant 
The cell supernatant collected in section 7.3.2.2 was centrifuged @ 4 °C for 20 minutes 
at 2500 rpm. The supernatant was discarded and the cells rinsed using sterile PBS (2 * 2 
mLs). The cell pellet was diluted in 2 mL PBS and lysis performed using a sonicator. (10 
seconds blast and 10 seconds rest). The sonication was repeated three times. The cells 
were further centrifuged @ 4 °C for 20 minutes at 2500rpm to pellet the debris. The clear 
supernatant was transferred to a cryogenic vial and stored at -78 °C until required for use.  
6.3.2.4 Preparation of drug solutions 
Drug stock solutions were prepared in DMSO. All final drug solutions contained DMSO 
at a concentration no greater than 1%. The range of solutions were created by serial 
dilutions within the plates. Final test concentrations were prepared by diluting the stock 
solution with medium. 
6.3.2.5 Preparation of standard and Assay Procedure  
The standards and assay procedure were carried out as per manufacturers manual. The 96 
well plate design is shown in Figure 6.3. Lanes 11 and 12 were removed and stored at -
80 °C for future work. 
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Figure 6.3: 96 well plate design for ELISA assay showing different drug solutions (C1-
C6) and different time exposures (1, 2, 4, 6 and 18 hours), controls, calibration 
standards and blank wells.  
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A. Appendix 
Results of the biological evaluation 
Cytotoxicity data are the average of at least three experiments expressed as mean 
percentage viability relative to control (100 %) ± standard deviation (SD). The results 
have been statistically analysed using one-way analysis of variance (ANOVA) followed 
by a post-ANOVA Dunnett’s test using GraphPad Prism software ®. Test results are 
considered relevant when P < 0.05(denoted with *) and very significant when P < 0.01 
(denoted with #) for the Dunnets analysis. Statistical data were calculated using Microsoft 
excel. EC50 values were calculated using GraphPad Prism software ®.  
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Figure A.1: Legend for Appendices 
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MTT Assay 
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Figure A.2: Viability of A549 versus concentration of 1a 
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Figure A.3: Viability of A549 versus concentration of 1b 
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Figure A.4: Viability of A549 versus concentration of 2a 
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Figure A.5: Viability of A549 versus concentration of 2b 
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Figure A.6: Viability of A549 versus concentration of 3a 
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Figure A.7: Viability of A549 versus concentration of 3b 
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Figure A.8: Viability of A549 versus concentration of 4a 
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Figure A.9: Viability of A549 versus concentration of 4b 
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Alamar Blue Assay 
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Figure A.10: Viability of A549 versus concentration of 1b 
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Figure A.11: Viability of A549 versus concentration of 4a 
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Figure A.12: Viability of A549 versus concentration of 4b 
 
 
